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Zusammenfassung 
Lissenzephaly ist eine kortikale Entwicklungsstörung, die durch ein glattes Gehirn und einen 
unstrukturierten Cortex charakterisiert ist. Mutationen im LIS1 Gen wurden als häufigste 
Ursache für diese Erkrankung identifiziert. LIS1-Lissenzephaly zeichnet sich dadurch aus, dass 
Betroffene unterschiedlich schwer erkrankt sind. Einige haben verbreitete kortikale 
Einfaltungen, sogenannte Gyri und zeigen milde Krankheitsverläufe, andere wiederum sind 
schwer betroffen und haben ein glattes Gehirn ohne Gyri. Analysen in murinen Systemen 
konnten bislang nicht die Gesamtheit der Erkrankung widerspiegeln, zeigten jedoch, dass die 
Dosierung von LIS1 für die Schwere der Erkrankung relevant ist. Dennoch konnte die Frage, 
warum eine spezifische Mutation im LIS1 Gen, wie sie bei den Erkrankten identifiziert wurden, 
zu unterschiedlichen Ausprägung der Erkrankungen führt, durch das Fehlen von adäquaten 
Modellsystem, bisher nicht beantwortet werden. Das gleiche gilt für die Frage, ob die 
unterschiedlichen Mutationen human-spezifische Entwicklungsprozesse differenziert 
beeinflussen. Aus diesem Grund habe ich zusammen mit meinen Kollegen ein Protokoll für die 
Generierung von zerebralen Organoiden entwickelt und dessen Fähigkeit untersucht, 
verschiedene Schweregrade von LIS1-Lisenzephaly widerzuspiegeln. Hierfür wurden 7 
unterschiedlich schwer erkrankte (mild, moderate und schwer) Lissenzephaly Patienten aus 
einer 63 Patienten Kohorte ausgewählt, bei welchen die Erkrankung durch eine molekular 
charakterisierte heterozygote Mutation im LIS1 Gen hervorgerufen wird. Um die 
Konsequenzen der einzelnen Patienten-spezifischen Mutationen auf die humane 
Gehirnentwicklung zu untersuchen, wurden von jedem Patienten somatische Zellen zu 
Stammzellen zurückprogrammiert, um 3D zerebrale Organoide zu generieren. Diese in vitro 
Gewebe zeigten krankheits-assoziierte phänotypische Veränderungen, die in ihrer 
Ausprägungsstärke mit den Schweregrad der Patienten korrelierten. Entwickelte 
Quantifizierungsprotokolle zeigten mit zunehmenden Schweregrad eine progressive 
Veränderung der kortikalen Ventrikular-Struktur-Dimensionen sowie verfrühte Neurogenese. 
Um die direkte Konsequenz der Patienten-spezifischen Mutationen auf die LIS1 Mikrotubuli-
stabilisierende Funktion zu untersuchen, wurde das astrale Zytoarchitekutur-stabilisierende 
Zytoskelett analysiert und ein progressiver Zusammenbruch mit zunehmender Schwere der 
Erkrankung festgestellt, was zu einer zellulären Unordnung innerhalb des in vitro Gewebes 
führte. Die Behandlung der zerebralen Organoide mit EpothiloneD, ein Mikrotubuli-
stabilisierendes FDA-genehmigtes Medikament, konnte die Zytoarchitektur stabilisieren und 
somit partiell die zelluläre Ordnung wiederherstellen. Darüber hinaus zeigte die Untersuchung 
                                                       Unraveling the pathology of different disease severities  
 
 
 
7 
der Teilungsorientierung von apikalen Radialgliazellen, dass es in Organoiden, die von Zellen 
von schwer (weniger von moderat und mild) Erkrankten generiert wurden, eine spezifische 
Umorientierung von proliferativer zu neurogener Zellteilung gibt, was zu verfrühter 
Neurogenese und kleineren Ventrikular-Strukturen führte. Bei mild und moderat Erkrankten 
zeigten die Zellen dagegen überwiegend eine unspezifische Fehlorientierung der 
Zellteilungsebene, die ebenfalls, jedoch weniger stark ausgeprägt, im Vergleich zu schweren 
Bedingungen, zu verfrühter Neurogenese führte.  Als molekulare Ursache für die spezifische 
Umorientierung der Zellteilungsebene konnte eine Störung der WNT Signalübertragung 
ermittelt werden, so dass der Zellteilungsstörung mit GSK3ß Inhibierung (WNT 
Signalübermittlungsaktivierung) entgegengewirkt werden konnte.  
Meine Forschung zeigt, dass zerebrale Organoide sensitiv genug sind, um unterschiedliche 
Schweregrade einer Erkrankung widerzuspiegeln, eine zuvor nicht bewiesene große 
Herausforderung des in vitro Systems. Die Daten zeigen, dass die verschiedenen Patienten-
spezifischen Mutationen im LIS1 Gen die Mikrotubuli-stabilisierende Funktion von LIS1 direkt 
unterschiedlich beeinflussen, was direkt (zelluläre Unordnung) oder indirekt (WNT-
Signalübermittlungsstörungen) zu einer gestörten Entwicklung des Gehirn führt. Damit konnte 
diese Arbeit den bisher fehlenden Zusammenhang zwischen Patienten-spezifischen Mutationen 
und klinischen Schweregrad aufklären. Des Weiteren konnten involvierte Pathomechanismen 
spezifisch für den Schweregrad aufgedeckt und therapeutische Substanzen identifiziert werden, 
die den Krankheitsverläufen in vitro entgegenwirkten. Der zukünftige Einsatz von Organoiden 
für die Untersuchung von individuellen Krankheitsverläufen könnte personalisierte Medizin 
verbessern und zu einem tieferen Verständnis von Patienten-spezifischen Pathologien für 
personalisierte Therapien führen. 
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HCl hydrochloric acid 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
hiPS cell human induced pluripotent stem cell 
HOPX hop homeobox 
IP intermediate progenitor 
iPS cell induced pluripotent stem cell 
KO knockout 
LIS1-patient LIS1-lissencephaly patient 
mild LIS1-patient LIS1-lissencephaly patient with a mild reduction of gyrification 
moderate LIS1-patient LIS1-lissencephaly patient with an anterior-posterior gradient of malformation 
severe LIS1-patient LIS1-lissencephaly patient with a smooth brain 
LRP LDL-receptor-related protein 
M molar 
MCD malformation of cortical development 
Min minutes 
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MOI multiplicity of infection 
MPTP 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine  
MZ marginal zone 
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N-Cad N-cadherin 
NMD non-sense mediated decay 
NSC neural stem cell 
OCT 3/4 octamer-binding transcription factor 3/4  
P phosphorylation 
PBMC peripheral blood mononuclear cell 
PP Pluripro medium 
PAFAH1B1 platelet-activating factor acetylhydrolase IB subunit alpha 
PBS phosphate-buffered saline 
PCR polymerase chain reaction 
Pen/Strep penicillin-streptomycin 
PFA paraformaldehyde 
rcf relative centrifugal force 
RG cell radial glia cell 
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RNAi RNA interference 
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rpm revolutions per minute 
RT reverse transcriptase 
RT-PCR reverse transcriptase polymerase chain reaction 
S.d. standard deviation 
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SEM standard error of the mean 
SG stress granular 
SMA smooth muscle actin 
Snp single nucleotide polymorphism 
SOX 2 SRY (sex determining region Y)-box 2 
SSEA 3 stage-specific embryonic antigen 3  
SG stress granules  
TAE tris base, acetic acid and EDTA. 
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TGFβ transforming growth factor ß 
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Figure Legends 
Figure 1: Illustration of the developing cortex. The developing cortex consists of distinctive 
developmental regions including the proliferative ventricular zone (VZ) containing the apical 
radial glia cells (aRG cell), the in primates highly expanded subventricular zone (SVZ) defined 
by intermediate progenitors (IP) and basal radial glia cells (bRG), the cell-poor intermediate 
zone (IZ) as wells as the cortical plate, which is migrated by differentiating neurons forming 
the developing 6-layered cortex. .............................................................................................. 28 
Figure 2: Illustration of the canonical WNT-signaling cascade. (A) In the absence of WNTs 
the destruction complex composed of AXIN, ADENOMATOSIS POLYPOSIS COLI (APC), 
GLYCOGEN SYNTHASE KINASE 3ß (GSK 3ß) and CASEIN KINASE 1a (CK 1a) primes 
the phosphorylation of ß-CATENIN (ß-CAT) by GSK 3ß and CK 1a leading to the 
ubiquitination and subsequent proteolytic destruction by the proteasomal machinery. (B) In the 
presence of WNTs FRIZZLED (FZD) and LOW-DENSITY LIPOPROTEIN RECEPTOR-
RELATED PROTEIN (LRP 5/6) are forming a complex, which induces the membrane 
translocation of AXIN. GSK 3ß and CK 1a leading to the phosphorylation of LRP 5/6, which 
promotes the binding of AXIN together with the destruction complex to the co-receptor. 
Furthermore, WNT activation leads to the recruitment of DISHEVELLED (DSH), which is 
also known to bind to AXIN and FZD to inhibit GSK 3ß. This complex formed at the membrane 
at FZD/ LRP 6 prevents the degradation of ß-CAT and consequently leads to the stabilization 
and accumulation in the cytoplasm enabling a translocation into the nucleus to active WNT 
target genes including TRANSCRIPTIONFACTOR (TCF)/ LYMPHOID ENHANCER-
BINDING FACTOR (LEF). ß-CAT is also positive regulated by AKT signaling through direct 
phosphorylation at residue Serine 552 or through the inhibition of the negative regulator GSK 
3ß, by phosphorylation at Serine 9. In addition, there is recent evidence that N-CADHERIN 
(N-CAD) is involved in the canonical WNT-signaling pathway. ............................................ 31 
Figure 3: Scheme of maturing organoid and timepoint depend cytoarchitecture. At the 
timepoint of matrix embedding and differentiation the organoid mainly consists of apical radial 
glia (aRG) cells. In the next 10 days aRG cells divide symmetrically and increase their 
progenitor pool, so that the organoid ventricular zone structures expand and consist at day 20 
mainly of aRG cells. Between day 20 and day 50 aRG cells start to divide asymmetrically, 
leading to the generation of intermediate progenitors (IP) and neurons, which form the 
subventricular-like zone (SVZ) and the cortical plate-like structure (CP). The human-specific 
basal radial glia (bRG) cells start to emerge around day 50 within the SVZ. Prolonged 
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differentiation leads to organoid ventricular structures containing deep and upper layer neurons.
 .................................................................................................................................................. 34 
Figure 4: Scheme of the wildtype LIS1 protein dimer conformation. The N-terminal 
homology motif is important for dimerization and the C-terminal 7 blade 𝛽-propeller structure 
is indispensable for protein interactions. .................................................................................. 36 
Figure 5: Scheme of the lissencephalic severity spectrum. The healthy primate brain is 
characterized by multiple folds, so called gyri and sulci. This gyrification developed evolutive 
by the expansion of the neocortex. One of the main phenotypes of lissencephalic brains is a 
reduction of gyrification, which occurs in different severities. The milder phenotypes are 
characterized by broader gyri. Moderate lissencephalic brains show often a gradient of severity 
from anterior to posterior with anterior pachygyria and posterior agyria. The most severe 
lissencephalic phenotypes are characterized by the complete absents of gyrification (smooth 
brain). ....................................................................................................................................... 39 
Figure 6: Protocol outline for cortical forebrain-type organoid generation. The organoid 
generation is initiated by embryoid body formation, which are restricted to the ectodermal fate 
by neural induction through dual SMAD and WNT inhibition. The outgrowth of neuroepithelial 
ventricular structures is supported by extracellular matrix proteins and mechanical scaffold 
provided by Geltrex (GT) embedding. To ensure good nutrient delivery into the tissue, 
organoids are cultured on a shaker. For further maturation growth factors including Ascorbic 
acid (AA), LM 22 A, LM 22 B and GT are added into the differentiation medium (maturation 
medium) from day 35 on. ......................................................................................................... 74 
Figure 7: Immunocytochemical analysis of iPS cell pluripotency. All generated iPS cell 
lines (2 clones per line) were quality controlled for pluripotency including 
immunocytochemical staining`s for the pluripotency markers SOX 2 and OCT 3/4, which a 
transcription factors crucial for self-renewal of undifferentiated stem cells, NANOG, a 
transcription factor important for the maintenance of pluripotency through the suppression of 
cell determination factors, and SSEA 3, a glycosphingolipid, which is specifically on the cell 
surface of pluripotent stem cells. Scale bars, 50 µm. ............................................................... 87 
Figure 8: Assessment of tripotente differentiation capacity into the 3 germ layers 
endoderm, mesoderm and ectoderm. (A-C) Representative brightfield recordings of 4 weeks 
differentiated iPS cells without morphogenic cues from 1 mild LIS1-patient patient line (P2.1) 
(A), 1 moderate LIS1-patient patient line (P4.2) (B) as well as from 1 severe LIS1-patient line 
(P5.2) (C). (D-F) Representative immunocytochemical recordings for the mesoderm marker 
                                                       Unraveling the pathology of different disease severities  
 
 
 
19 
smooth muscle actin (SMA) (D), the endoderm marker α-fetoprotein (AFP) (E) and the 
ectoderm marker ß-III-tubulin (TUBB3) (F). Scale bars 20 µm. ............................................. 88 
Figure 9: Validation of karyotypic integrity. All generated iPS cell lines were high resolution 
single-nucleotide polymorphism (snp) analyzed for chromosomal integrity. The graphs 
illustrate the B allele frequents (BAF) and the Log R ratio (LRT) for every chromosome. BAF 
is an allelic intensity ratio, the value should be around 0,5. When a deletion chromosomal copy 
number variation (CNV) occurred the value clusters around 0 or 1. When a duplication is 
present the values are around 0, 0,33, 0,67 and 1. The LRR is a normalized measurement of 
total signal intensity. When a deletion CNV happened the LRR values for snp markers in this 
region decrease and when a duplication is present the values increase. .................................. 91 
Figure 10: Validation of the respective patient-specific LIS1 mutation in the generated 
iPS cell lines. (A-G) Electropherograms generated by sanger sequencing. The mild LIS1-
patient lines P1 and P2 carry a point mutation at c.569-10 T>C (A,B), the moderate LIS1-patient 
P3 have a deletion at position 13 in the coding sequencing causing a frameshift in the following 
sequence (C), the moderate LIS1-patient P4 has a deletion of exon 11 (D), the severe LIS1-
patient P5 a point mutation at c.1002+1G>A (E), the severe LIS1-patient P6 a point mutation 
at c.531 G>C (F) and severe LIS1-patient P7 a point mutation at c.445 C>T (G). The sequencing 
for mild 1, 2 and moderate 1, 2 was done by Camille Maillard at the hospital Neckar Enfants 
Malades in France explaining the different illustration when comparing A-D with E-G (Sanger 
sequencing method was performed in the same way, except the exon 11 deletion of 732 was 
validated by whole exome sequencing).................................................................................... 92 
Figure 11: Schematic overview of the organoid protocol and illustration of 'go' and 'no-
go' criteria. (A) Schematic overview of the protocol. CI medium: cortical induction medium; 
CD: cortical differentiation medium. (B-C) Image of an optimal 90% confluent iPS cells 
monolayer culture (B) and a non-suitable iPS cell culture exhibiting differentiation (C). (D-E) 
An iPS cells aggregate optimal in size, cell density, and surface appearance (D) and two 'no-go' 
cell aggregates exhibiting either cell spares cavities (E, upper aggregate) or irregular edges (E, 
lower aggregate) 2 days following cell aggregation. (F-G) Cell aggregates exhibiting 
translucent and smooth edges (F) and cell aggregates lacking optical clearing (G). The yellow 
line is visualizing the area of interest. (H-K) An optimal organoid with continuous 
neuroepithelial ventricular zone structures (H, J) and an organoid that failed to develop radially 
organized neuroectoderm (I, K) imaged at day 15 and day 20, respectively. Scale bars, (B-C) 
500 μm; (D-K) 200 μm. Figure published in JoVE (Krefft et al., 2018). ................................ 94 
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Figure 12: Homogeneity and reproducibility of the forebrain-type organoid protocol. (A-
B) Representative bright-field images of organoids from 1 batch at day 15 (A) and day 26 (B). 
(C) Quantitative analyzes of organoids at day 20. Organoids which display at the outer surface 
a neuroepithelium, recognizable in bright-field as optically clear superficial tissue with a clear 
border and evidence of radial cellular architecture were quantified (n = 3 per iPS cell line with 
at least 16 organoids per experiment). Scale bars, A, B 500 μm. Error bars ± SD. Figure 
published in JoVE (Krefft et al., 2018). ................................................................................... 95 
Figure 13: Validation of forebrain-type organoids at day 20. (A-F) Immunocytochemical 
characterization of organoids. Organoids organize in multiple neuroepithelial ventricular zone 
structures (A, counterstained with DAPI). Stratified organized cells within the neuroepithelial 
ventricular zone structures express the neural stem cell marker SOX 2 (B, D), the forebrain 
markers PAX6 (C, D) and Otx2 (E), as well as the dorsal forebrain marker Emx1 (F). (K) RT-
PCR analysis for the region-specific transcription factors at day 20 of 2 independent sets of 
organoids derived from 2 different iPS cell lines, performed by Ammar Jabali. FB: fetal brain 
control; AB: adult brain control. Scale bars, A-D 200 μm; E-I 10 μm. Figure published in JoVE 
(Krefft et al., 2018). .................................................................................................................. 96 
Figure 14: Schematic illustration of ventricular zone structure parameters. (A-F) Each 
ventricular zone (VZ) structure contains important information about the cytoarchitectural 
development of each neural tube-like structure. The VZ structure diameter is determinant by 3 
length measurements (µm) forming a right-angle fan area pointing to the nearest pial surface, 
at 0, 45 and 90 degree (A). The apical (B) and basal (C) membrane length are determined by 
the diameter of VZ structure and ventricle-like structure. The other 3 parameters are area 
measurements (µm2) for the VZ structures including the ventricle-like area (D), the VZ 
structure tissue area (E) and the total VZ structure (F). All parameters taken together enable a 
reliable assessment of VZ structure dimensions and consequently a detailed comparison 
between organoid batches, patients and severities. .................................................................. 98 
Figure 15: Quantification protocol of acetylated -TUBULIN strand density. Organoid 
slices are stained for ACETYLATED -TUBULIN (AC-TUB) and the signal plot profile is 
drawn into the apical and basal ventricular zone (VZ) region using FIJI. The Plot profile is 
pasted into a self-designed Excel file, which contains mathematical formulas to calculate the 
mean strand density. In the first step the measurements of every second pixel are considered, 
because every strand is about 2 pixels wide. Then the background signal is determined and the 
file automatically gives the number of signals on the plot profile line, which are above the 
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background signal. The number is normalized by the total length of the plot profile resulting in 
a mean density of strands crossing the line (*100=%). Scale bar, 20 μm. ............................... 99 
Figure 16: Apical membrane diameter quantification. Organoid slices are stained for DAPI 
for ventricular zone structure tissue visualization and N-CADHERIN (N-CAD) to analyze the 
apical membrane. The membrane thickness is measured at 90°, 180°, 270° and 360° to the 
ventricular zone structure center using FIJI. Scale bar, 20 μm. ............................................... 99 
Figure 17: Organoid morphology is specific for LIS1-patient`s severity. (A) LIS1-patient 
MRI recordings provided from Dr. Nadja Bahi-Buisson from the hospital Neckar Enfants 
Malades (mild LIS1-patient patient 1, moderate LIS1-patient patient 1 and severe LIS1-patient 
3). (B) Representative brightfield field (BF) recordings of control C1.2, mild LIS1-patient P1.1, 
moderate LIS1-patient P3.1 and severe LIS1-patient P5.1 patient derived organoids at day 20. 
(C) Representative light sheet microcopy (LSM) recordings of whole-tissue cleared control 2.1, 
mild LIS1-patient P1.1, moderate LIS1-patient P3.2 and severe LIS1-patient P5.1 derived 
organoids at day 20 stained for ß-III Tubulin (TUBB3). (D) Representative TUBB3 recordings 
of control C4.1, mild LIS1-patient P2.1, moderate LIS1-patient P4.1 and severe LIS1-patient 
P5.2 patient derived organoids at day 20. (E) Representative DAPI recordings of ventricular 
zone structures of control C1.2, mild LIS1-patient P1.1, moderate LIS1-patient P3.1 and severe 
LIS1-patient P5.1 patient derived organoids at day 20. Scale bars, (A) 5 cm, (B, C) 200 µm (D, 
E) 50 µm. ................................................................................................................................ 102 
Figure 18: Ventricular zone parameter quantification reveals a gradually decrease of 
tissue dimensions with increasing LIS1-patient severity. (A-F) Quantification of ventricular 
zone (VZ) structure diameter, ventricle area, length of apical membrane, length of basal 
membrane, VZ structure tissue and total VZ structure area in control- and LIS1-patient derived 
organoids at day 20. control C1.2 N=38, control C4.2 N=33, mild P1.1 N=33, mild P1.2 N=19, 
mild P2.1 N=13, mild P2.2 N=17, moderate P3.1 N=20, moderate P3.2 N=19, moderate P4.1 
N=20, moderate P4.2 N=18, severe P5.1 N=61, severe P5.2 N=49, severe P6.1 N=23, severe 
P6.2 N=48, severe P7.1 N=58. Error bars, ±SD. *p < 0.05, **p < 0.01, ***p < 0.001. ........ 103 
Figure 19: Gradually breakdown of cell stabilizing astral tubulin with increasing LIS1-
patient severity. (A, B) Representative recordings of cleared and cryo-sectioned organoids 
from control C4.1, mild P1.1, moderate P3.2 and severe P5.2 LIS1-patient derived organoids 
stained for acetylated-α tubulin (AC-TUB) at day 20. (C) Representative recordings of ARl13b, 
a cilia marker, in control C4.1, mild P1.1, moderate P3.2 and severe P5.2 LIS1-patient derived 
organoids at day 20. (D) High magnification recordings of AC-TUB stained VZ structures in 
control C4.1, mild P1.1, moderate P3.2 and severe P5.2 LIS1-patient derived organoids at day 
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20. (E) Quantification of apical and basal AC-TUB strand density in control, mild-, moderate- 
and severe LIS1-patient derived organoids. control C1.2 N=12, control C2.1 N=12, control 
C4.2 N=20, mild P1.1 N=13, mild P1.2 N=13, mild P2.1 N=13, mild P2.2 N=15, moderate P3.1 
N=13, moderate P3.2 N=12, moderate P4.1 N=12, moderate P4.2 N=14, severe P5.1 N=22, 
severe P5.2 N=20, severe P6.1 N=13, severe P6.2 N=13, severe P7.1 N=12). (F) Western blot 
analyzes of AC-TUB protein level in controls (C1.2, C2.1, C4.1, C4.2 and C5.2), mild- (P1.1, 
P2.1, and P2.2), moderate- (P3.1) and severe (P5.1, P5.2 and P7.1) LIS1-patient derived cortical 
progenitor cells. Scale bars, (A) 200 µm, (B) 20 µm. Error bars, ±SD. *p < 0.05, **p < 0.01, 
***p < 0.001. .......................................................................................................................... 106 
Figure 20: Progressive disruption of cellular organization with LIS1-patient severity. (A) 
Representative recordings of hematoxylin-eosin (HE) recordings of control C4.1, mild LIS1-
patient P1.2, moderate LIS1-patient P3.1 and severe LIS1-patient P5.1 derived organoids. (B) 
Representative recordings of cryo-cut organoids from control 3.1, mild LIS1-patient P2.1, 
moderate LIS1-patient P3.2 and severe LIS1-patient P5.1 derived organoids stained for N-
CADHERIN (N-CAD) at day 20. (C) Quantification of apical disruption diameter in control, 
mild, moderate and severe LIS1-patient derived organoids at day 20. Schematic illustration of 
how the disruption diameter was quantified is illustrated on the right side of the diagram. control 
C1.2 N=12, control 2.1 N=12, control 4.2 N=20, mild P1.1 N=13, mild P1.2 N=13, mild P2.1 
N=13, mild P2.2 N=15, moderate P3.1 N=13, moderate P3.2 N=12, moderate P4.1 N=12, 
moderate P4.2 N=14, severe P5.1 N=22, severe P5.2 N=20, severe P6.1 N=13, severe P6.2 
N=13, severe P7.1 N=12. Scale bars 20 µm. Error bars, ±SD. *p < 0.05, **p < 0.01, ***p < 
0.001. ...................................................................................................................................... 108 
Figure 21: Epothilone D treatment in part rescues LIS1-associated microtubule 
instabilities stabilizing ventricular zone structure architecture. (A) Representative 
acetylated ALPHA-TUBULIN (AC-TUB) recordings of control C3.1, mild- P1.1, moderate- 
P1.2 and severe P5.1 patient derived organoids treated with DMSO or 1nM EpothiloneD. (B) 
Quantification of apical and basal AC-TUB strand density in DMSO and EpothiloneD treated 
control C3.1 (N=9), control C4.1 (N=9), mild P1.1 (N=9), mild P2.2 (N=9), moderate P3.2 
(N=9), severe P5.1 (N=9), severe P6.1 (N=9) and severe P7.1 (N=9) LIS1-patient derived 
organoids at day 15. (C) Representative N-CADHERIN (N-CAD) recordings of control C3.1, 
mild P1.1, moderate P3.2 and severe P5.1 LIS1-patient derived organoids treated with DMSO 
or 1nM EpothiloneD. (D) Quantification of N-CAD diameter expansion in DMSO and 
EpothiloneD treated control C3.1 (N=10), control C4.1 (N=10), mild LIS1-patient P1.1 (N=10), 
mild LIS1-patient P2.2 (N=10), moderate LIS1-patient P3.2 (n=6), severe LIS1-patient P5.1 
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(N=6), severe LIS1-patient P6.1 (N=6) and severe LIS1-patient P7.1 (N=6) patient derived 
organoids at day 15. Scale bars (A) 200 µm, (A, C) 20 µm. Error bars, ±SD. *p < 0.05, **p < 
0.01, ***p < 0.001. ................................................................................................................. 111 
Figure 22: Microtubule array stabilization by Epothilone D partially rescues ventricular 
zone structure dimensions in LIS1-pateint derived organoids. (A) Representative DAPI 
recordings of control C3.1, mild- P1.1, moderate- P1.2 and severe- P1.1 LIS1-patient derived 
organoids treated with 1nM Epothilone D (EpothiloneD) and DMSO control. (B) Ventricular 
structure (VZ) parameter quantification of EpothiloneD and DMSO control treated control- 
C3.1, control- C4.1, mild- P1.1, mild- P2.2, moderate- P3.2, severe- P5.1, severe- P6.1 and 
severe- P7.1 LIS1-patient- derived organoids at day 15. control C3.1 DMSO N=16, control 
C3.1 CHIR N=21, control C4.1 DMSO N=10, control C4.1 CHIR N=18, mild P1.1 DMSO 
N=16, mild P1.1 CHIR N=24, mild P2.2 DMSO N=12, mild P2.2 CHIR N=11, moderate P3.2 
DMSO N=14, moderate P3.2 CHIR N=12, severe P5.1 DMSO N=14, severe P5.1 CHIR N=11, 
severe P5.2 DMSO N=16, severe LIS1-patient P5.2 CHIR N=11, severe P6.1 DMSO N=10, 
severe P6.1 CHIR N=10, severe P7.1 DMSO N=11, severe P7.1 CHIR N=11. Scale bars (A) 
200 µm. Error bars, ±SD. *p < 0.05, **p < 0.01, ***p < 0.001. ........................................... 113 
Figure 23: Organoids derived from LIS1-patients display niche-dependent WNT-
signaling disruption leading to altered aRG cell division specific for the disease condition. 
(A) Representative WNT-GFP recordings of WNT-GFP reporter control C3.1, P1.1 mild- and 
P5.1 severe LIS1-patient derived organoids at day 20. (B) Quantification of mean grey value 
of WNT-GFP signal in VZ structures (control C3.1 N=10, control C4.1 N=10, mild P1.1 N=10, 
mild P2.2 N=10, moderate P3.2 N=10, severe P5.1 N=10). (C) Representative recordings of 
vertical-, horizontal and oblique division planes by marking dividing cells with p-VIMENTIN 
(p-VIMENTIN) and the mitotic spindle by TPX 2 in control- (C4.1) and severe LIS1-patient 
(P1.1) patient-derived organoids. (D) Quantification of orientation of plane of cell division in 
control and mild LIS1-patient, moderate LIS1-patient and LIS1- severe patient-derived 
organoids. (control C1.1 N=20, control C2.2 N=20, control C4.2 N=14, mild P1.1 N=15, mild 
P1.2 N=15, mild P2.1 N=15, mild P2.2 N=11, moderate P1.1 N=11, moderate P1.2 N=9, 
moderate P2.1 N=10, moderate P2.2 N=13, severe P1.1 N=17, severe P1.2 N=14, severe P2.1 
N=9, severe P2.2 N=10, severe P3.1 N=11). Scale bars (A) 50 µm, (B) 10 µm, (C) 20 µm. Error 
bars, ±SD. *p < 0.05, **p < 0.01, ***p < 0.001. ................................................................... 116 
Figure 24: WNT activation changes aRG cell division pattern in iPS cell derived organoids 
from severe disease. Quantification of vertical, horizontal and oblique division planes of 
dividing aRG cells in control C3.1 (N=9), mild P1.1 (N=9), moderate P1.2 (N=9) and severe 
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P1.1 (N=9) patient derived organoids in the absence (DMSO) and presence of GSK 3ß inhibitor 
CHIR at day 15. ...................................................................................................................... 117 
Figure 25: CHIR treatment-related rescue of aRG cell division orientation improves 
organoid ventricular zone structure dimensions. (A, B) Representative DAPI recordings of 
control C3.1, mild P1.1, moderate P4.2 and severe P6.1 LIS1-patient derived organoids treated 
with DMSO or 1 µM CHIR. (C-H) Loop parameter quantification of CHIR and DMSO control 
treated organoids (control C3.1 DMSO N=16, control C3.1 CHIR N=21, control C4.1 DMSO 
N=10,control C4.1 CHIR N=18, mild P1.1 DMSO N=16, mild P1.1 CHIR N=24, mild  2.2 
DMSO N=12, mild P2.2 CHIR N=11, moderate P3.2 DMSO N=14, moderate P3.2 CHIR 
N=12, severe P5.1 DMSO N=14, severe P5.1 CHIR N=11, severe P5.2 DMSO N=16,severe 
P5.2 CHIR N=11, severe  2.1 DMSO N=10, severe P6.1 CHIR N=10, severe P7.1 DMSO 
N=11, severe P7.1 CHIR N=11. Scale bars 200 µm. Error bars, ±SD. *p < 0.05, **p < 0.01, 
***p < 0.001. .......................................................................................................................... 119 
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Abstract 
The human neocortex is greatly expanded and exhibits a highly organized and extensively 
folded (gyrencephalic) structure. Model systems gave a fundamental understanding about 
how the cortex is generated although the applied models often involve species with a smooth 
(lissencephalic) brain surface, such as mice. Thus, key cellular events that impact human-
specific brain expansion and our understanding of how disease-linked mutations disrupt 
human cortical development remains elusive. Lissencephaly is a malformation of cortical 
development which is characterized by a smooth brain and a disorganized cortex. Heterozygous 
deletions or mutations in the LIS1 gene, encoding a microtubule-associated protein in humans, 
were identified to cause lissencephaly with diverse clinical phenotypic variations ranging from 
mild pachygyria (broad gyri) to severe agyria (no gyri) resulting in epilepsy and intellectual 
disabilities. While the clinical severity generally correlates with the degree of agyria, the 
location and type of mutation in the LIS1 gene does not. From LIS1 mouse models we know 
that LIS1 regulates the microtubule motor cytoplasmic dynein and by that dynein-dependent 
processes such as neuronal migration, nucleokinesis, interkinetic nuclear migration and 
mitotic spindle orientation. Even though the observed LIS1-deficiency-associated phenotypes 
appeared drastically milder in murine systems compared to humans these studies suggest that 
LIS1 gene dosage is relevant for the phenotypic severities. However, why a specific mutation 
within the LIS1 gene as identified in LIS1-lissencephalic patients (LIS1-patients) leads to 
different disease severities and whether human-specific processes during cortical 
development are differentially affected by the specific mutations could, due to a lack of 
adequate model systems, so far not been investigated. Here, I explore the ability to 
recapitulate different disease severities of LIS1-lissencephaly using LIS1-patient-specific 
iPS cells and thereof derived forebrain-type cerebral organoids. To do so, I selected from a 
LIS1-patient cohort comprising 63 cases 7 patients who cover the whole spectrum of 
gyrification alterations of LIS1-lissencephaly ranging from Dobyns grade 5 (mild) to 1 
(severe). Each patient harbors a different molecular characterized heterozygous mutation in the 
LIS1 gene. To analyze the consequences of each LIS1 mutation on human brain development 
a 3D cell culture forebrain-organoid protocol was developed. Following reprogramming of 
patient-derived somatic cells and basic characterization (2 clones each) the iPS cells were 
applied to the organoid protocol. Organoids reproduced, in correlation with the patient’s 
severity, alterations in organoid cytoarchitecture and premature neurogenesis. To assess the 
direct consequences of the patient-specific mutations on LIS1 microtubule stabilizing function 
I investigated the stability of the cytoskeleton of apical (a) RG cells within the cortical 
                                                       Unraveling the pathology of different disease severities  
 
 
 
26 
ventricular-like zone (VZ) structures and found a progressive collapse of tubulin strand stability 
with increasing patient disease severity leading to a disruption of cellular organization. These 
phenotypic alterations could in part be reversed by stabilizing the microtubule array using the 
FDA-approved drug EpothiloneD. In addition, organoids from individuals with severe but not 
mild disease showed a non-random aRG cell division switch from proliferative to neurogenic 
division. As an underlying molecular cause, WNT-signaling alterations were identified, most 
prominently in severe conditions. To test to what extend perturbed WNT-signaling contributes 
to the observed patient-specific alterations, organoids were exposed to the GSK3ß inhibitor 
CHIR99021 leading to a significant rescue of non-random aRG cell division switch in severe 
organoids and to enlarged VZ diameters as well as reduced neurogenesis in all patient derived 
organoids.  
The here demonstrated research underlines the capability of cerebral organoids to sensitively 
model individual disease severities, a so far not addressed major challenge of the system. My 
data show that different patient-specific mutations in the LIS1 gene have divergent direct 
impact on microtubule stability, which directly and/or indirectly lead to perturbed human 
corticogenesis providing the missing link between the patient-specific LIS1 mutation and the 
clinical severity grade. Future applications analyzing individual diseases have the potential to 
advance personalize medicine and improve the understanding of individual pathology for 
personalized therapy. 
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1. Unraveling the pathology of different disease severities in human cortical organoid 
models of LIS1-lissencephaly 
To follow the here presented research, this chapter provides detailed information about the 
development of the human neocortex, including cytoarchitectural aspects as well as 
fundamental cell identities forming the 6-layered cortex. Furthermore, information about the 
essential WNT-signaling pathway, the cutting-edge organoid technology, the LIS1 protein and 
lissencephaly are given. Additionally, an overview of existing studies elucidating the question 
why a specific mutation within the LIS1 gene as identified in LIS1-patients leads to different 
disease severities is provided. At the end, the aims and objectives of this thesis are postulated 
in summary. 
1.1. The developing cortex – cytoarchitecture and cell types 
A precise choreography of progenitor proliferation, neurogenesis, neuronal migration and 
synaptogenesis forms the basis of human cortical development. The performance starts with a 
thin sheet of neural stem cells (NSC) founding the neuroepithelium. In the process of 
neuroepithelial thickening due to cell proliferation, the NSCs exceedingly elongate and transit 
to so called aRG cells (Bystron, Blakemore, and Rakic 2008). The next chorographical step 
comprises the formation of defined developmental zones distinctive by their cell types (Figure 
1). Adjacent to the ventricle-forming lumen is the proliferative ventricular zone containing the 
bipolar aRG cells, which undergo internuclear migration (INM). The apical processes are 
anchored in the apical membrane and form adherent junctions, which are crucial for transducing 
morphogen signals from the cerebrospinal fluid. The basal processes of aRG cells are send to 
the pial surface to stabilize the radial organization of the developing cortex. Early in 
development aRG cells self-renew by symmetric cell division at the apical membrane, therefore 
increasing the aRG cells progenitor pool causing the expansion of the VZ. Later in development 
these progenitors start to divide asymmetrically, which can result in the direct generation of 
neurons or the production of intermediate cell populations including intermediate progenitors 
(IP) or bRG cells (also called outer RG cells) (Fietz et al. 2010; Hansen et al. 2010; Johnson et 
al. 2017). This precise orchestration of proliferation leads to the formation of the subventricular 
zone (SVZ), the intermediate zone (IZ) and the cortical plate (CP) (Figure 1). The SVZ contains 
the IPs and primate-specific bRG cells and is striking elaborated in primate cortical 
development (De Juan Romero and Borrell 2015; Borrell 2019). In contrast to aRG cells, bRG 
cells lack apical processes and are therefore not important for signal transduction at the apical 
membrane. These RG cell types may generate the majority of cortical neurons having a 
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tremendous proliferative potential (Lewitus, Kelava, and Huttner 2013). The IZ is a cell-poor 
region, which needs to be traversed by migrating neurons on their way to the CP to build up the 
6-layered cortex in an inside-outer manner. This choreography of cortical development is choir 
mastered by distinctive signaling pathways, which regulate the self-renewal and differentiation 
of neuronal progenitors specifying their cell fates. One major signaling event is the evolutionary 
highly conserved WNT pathway.  
 
Figure 1: Illustration of the developing cortex. The developing cortex consists of distinctive developmental 
regions including the proliferative ventricular zone (VZ) containing the apical radial glia cells (aRG cell), the in 
primates highly expanded subventricular zone (SVZ) defined by intermediate progenitors (IP) and basal radial glia 
cells (bRG), the cell-poor intermediate zone (IZ) as wells as the cortical plate, which is migrated by differentiating 
neurons forming the developing 6-layered cortex. 
1.2. WNT-signaling – a major choirmaster during embryogenesis 
The WNT pathway is a major choirmaster in orchestrating embryogenesis including cell fate 
determination, cell migration, cell polarity, neural patterning, organogenesis and stem cell 
renewal (Komiya and Habas 2008). Discrete signaling centers release in a tightly regulated and 
spatially specific manner morphogens establishing regional identities. During forebrain 
development WNT-signaling from the cortical hem regulates the expansion and cell type 
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specification of the aRG cells and controls dorsal-ventral forebrain patterning in conjunction 
with BMP, FGF and SHH signaling (Harrison-Uy and Pleasure 2012). Subsequently, WNTs 
are crucial determinants for aRG cells division mode switch from self-renewing symmetric cell 
division to asymmetric cell proliferation leading to neurogenesis. Several signaling branches 
downstream of the WNT receptors have been identified including the canonical ß-CATENIN 
(ß-CAT) dependent) pathway as well as the non-canonical (ß-CAT independent) pathway. This 
project is focused on the canonical WNT pathway, where the secreted WNT ligands bind to the 
FRIZZLED (FZD)/ LOW-DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN 
(LRP 5/6) leading to the accumulation and translocation of adherents-junction associated-
protein ß-CAT into the nucleus (Figure 2). In the absence of WNT morphogens, a so-called 
destruction complex composed of AXIN, ADENOMATOSIS POLYPOSIS COLI (APC), 
GLYCOGEN SYNTHASE KINASE (GSK 3) and CASEIN KINASE 1a (CK 1a) leads to the 
degradation of ß-CAT (Gordon and Nusse 2006). The phosphorylation of ß-CAT by GSK 3ß 
and CK 1a leads to the ubiquitination and subsequent proteolytic destruction by the proteasomal 
machinery (He et al. 2004; Aberle et al. 1997). The presence of WNTs leads to FZD and LRP 
5/6 complex formation, which induces the membrane translocation of AXIN, a key negative 
regulator of WNT-signaling. GSK 3ß and CK 1a phosphorylate LRP 5/6 promoting the binding 
of AXIN to the co-receptor. Furthermore, WNT activation leads to the recruitment of another 
negative regulator, the phosphoprotein DISHEVELLED (DSH), which is also known to bind 
to AXIN and FZD to inhibit GSK 3ß. It is still unresolved how DSH is activated (Kishida et al. 
1999).  This complex formed at the membrane at FZD/ LRP 5/6 prevents the degradation of ß-
CAT and consequently leads to the stabilization and accumulation in the cytoplasm enabling a 
translocation in the nucleus to activate WNT target genes (Figure 2). ß-CAT signaling leads for 
example to the expansion of the cerebral precursor population and cortical surface area 
enlargement (Woodhead G., Mutch C. A., Olson E. C 2006). Additionally, to remark is that 
there is recent evidence that cell adherent-junctions protein N-CADHERIN (N-CAD) impacts 
WNT/ß-CAT signaling. Adherent junctions have an important role in signal transduction from 
the cerebrospinal fluid into the aRG cells during cortical development. It has been shown that 
N-CAD interacts with AXIN and LRP 5/6 to negatively regulate WNT/ß-CAT signaling in 
osteoblasts by decreasing the soluble cytoplasmic tool through binding ß-CAT at the membrane 
(Hay et al. 2009; Marie and Hay 2013). In addition, cadherins are also required for augmented 
activation of the WNT/ß-CAT pathway during epithelial-mesenchymal transition (Howard et 
al. 2011). Furthermore, Zhang et al. showed that AKT activation by N-CAD impacts ß-CAT 
and neuronal differentiation during cortical development in a cell-autonomous fashion (J. 
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Zhang et al. 2013). AKT signaling is crucial for multiple organ developmental processes. How 
N-CAD promotes the phosphorylation of AKT remains largely unknown, there is evidence that 
N-CAD adhesion cause phosphatidylinositol 3-kinase (PI3K)-mediated activation of AKT 
(Tran et al. 2002). Downstream signaling of AKT includes direct phosphorylation of ß-CAT at 
residue Serine 552, which stabilize the soluble cytosolic form. Moreover, AKT inhibits the 
negative regulator of ß-CAT, GSK 3ß, by phosphorylation at Serine 9 leading also to 
stabilization and nuclear accumulation of ß-CAT. How exactly AKT and WNT-signaling are 
regulated during neural development and the underlying mechanisms through which AKT and 
WNT mediate cortex development remains elusive. To shed more lights on the complex 
signaling choreography during corticogenesis further intensive research needs to be done. To 
face such human developmental questions the young field of 3D organoid cell culture has 
emerged as very promising tool. 
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Figure 2: Illustration of the canonical WNT-signaling cascade. (A) In the absence of WNTs the destruction 
complex composed of AXIN, ADENOMATOSIS POLYPOSIS COLI (APC), GLYCOGEN SYNTHASE 
KINASE 3ß (GSK 3ß) and CASEIN KINASE 1a (CK 1a) primes the phosphorylation of ß-CATENIN (ß-CAT) 
by GSK 3ß and CK 1a leading to the ubiquitination and subsequent proteolytic destruction by the proteasomal 
machinery. (B) In the presence of WNTs FRIZZLED (FZD) and LOW-DENSITY LIPOPROTEIN RECEPTOR-
RELATED PROTEIN (LRP 5/6) are forming a complex, which induces the membrane translocation of AXIN. 
GSK 3ß and CK 1a leading to the phosphorylation of LRP 5/6, which promotes the binding of AXIN together with 
the destruction complex to the co-receptor. Furthermore, WNT activation leads to the recruitment of 
DISHEVELLED (DSH), which is also known to bind to AXIN and FZD to inhibit GSK 3ß. This complex formed 
at the membrane at FZD/ LRP 6 prevents the degradation of ß-CAT and consequently leads to the stabilization 
and accumulation in the cytoplasm enabling a translocation into the nucleus to active WNT target genes including 
TRANSCRIPTIONFACTOR (TCF)/ LYMPHOID ENHANCER-BINDING FACTOR (LEF). ß-CAT is also 
positive regulated by AKT signaling through direct phosphorylation at residue Serine 552 or through the inhibition 
of the negative regulator GSK 3ß, by phosphorylation at Serine 9. In addition, there is recent evidence that N-
CADHERIN (N-CAD) is involved in the canonical WNT-signaling pathway. 
1.3. Cerebral organoids – cutting edge technology 
Human developmental processes have always been most challenging to understand due to 
fetal tissue inaccessibility and the lack of in vitro model systems. Early human corticogenesis 
and its precise choreography remains largely elusive. Within the last decade the field of 3D 
cell cultures have emerged as a promising tool to model organ development in vitro 
facilitating completely new perspectives in understanding embryogenesis. Since the pioneer 
work from Yoshiki Sasai (Eiraku et al. 2008) paved the way, organoid technology has made 
one of the most rapid advances in the field of cell biology. Potential applications can not 
only include embryogenesis, the field of tissue regeneration as well as drug screening can 
also be covered by organoid research. Here, I focus on brain organoids of cortical identity to 
analyze malformation of cortical development (MCD). Cortical organoid development 
started in 2008 when Eiraku et al. (Eiraku et al. 2008) differentiated iPS cells aggregates 
under serum free conditions, so called SFEBq (short for: serum-free floating cultures of 
embryoid body-like aggregate with quick reaggregation) showing apico-basally polarized 
cortical tissue with spatially organization including VZ, SVZ and a CP-like regions. The real 
organoid hysteria started in 2013, when Madeline Lancaster and coworkers from the 
Knoblich laboratory (M. Lancaster et al. 2013) described cerebral organoids containing 
multiple brain regions like retina, choroid plexus, midbrain, hindbrain and forebrain tissue. 
At the same time also the Saisai laboratory (Kadoshima et al. 2013) contributed to the 
organoid publicity by further improving the SFEBq approach and introducing the rolling 
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morphogenesis of region-specific cortical organoids. From that time on various of 
publications aimed to improve organoid culture protocols to faithfully recapitulate specific 
aspects of human brain development, all using the self-organizing capacity of iPS cells 
(Paşca et al. 2015; Camp et al. 2015; X. Qian et al. 2016; Watanabe et al. 2016; Iefremova 
et al. 2017; Renner et al. 2017; Karzbrun et al. 2018). My coworkers and me also developed 
a reproductible forebrain-type organoid protocol leading to highly homogenous cultures 
within and across organoid batches (Krefft et al. 2018; Iefremova et al. 2017) (outlined in 
Figure 6). Like most of the cortical region-specific organoid protocols, it is based on an iPS 
cell aggregation phase, followed by a cortical induction phase by small molecule pathway 
modulators including SMAD signaling inhibitors to counteract mesoderm and endoderm 
differentiation and WNT-signaling inhibitors to evade posterization (Chambers SM, Fasano 
CA, Papapetrou EP, Tomishima M, Sadelain M 2009). Further differentiation includes 
stabilization and enhancement of the organoids cortical VZ structure architecture by 
extracellular matrix (ECM) embedding. The nutritive support and the oxygen exchange are 
enriched through constant agitation on a shaker. Additionally, at later timepoints, further 
molecules and growth factors are implanted to promote the formation of the developmental 
zones distinctive by their cell types over a time course up to 100 days (Figure 3). After 20 
days of differentiation, organoids show remarkable similarities in cell composition and 
cytoarchitecture to its in vivo counterparts including an aRG cell pool with apico-basal 
polarity and few IPs representing early gestation period (Figure 3). Prolonged differentiation 
leads to cortical structures including a VZ with aRG cells, SVZ containing IPs and bRG cells 
as well as a cortical-plate like regions showing diverse layer-specific neurons denoting the 
first to second gestation trimester (Figure 3). Important to consider is that organoids are still 
an artificial system missing for example cells form other germ layers such as endothelia cells 
or microglia. It still needs to be addressed to what extend organoids have the same degree of 
complexity as their in vivo organs. Impressively, single-cell transcriptomics revealed 
significant resemblances in cell composition in accordance to different developmental stages 
with impressive intersection of their transcription profile comparing to in vivo brain cells 
(Camp et al. 2015; Kanton et al. 2019). In the future, the innovative single-cell sequencing 
technique will hopefully provide a depth understanding of spatiotemporal gene expression 
trajectories in cortical organoids shedding more light on the degree of correlation between 
organoids and in vivo organs (Marsoner, Koch, and Ladewig 2018). It is undeniable that 
organoids already enormously improved in vitro research. The advantage of in vivo-like cell-
cell interactions as well as human-specific cell populations such as bRG cells already 
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elevates in vitro research in terms of mimicking physiological cell behavior on a completely 
different level compared to 2D cell culture. Previously inaccessible aspects of human 
corticogenesis can be elucidated in vitro without the need of fetal tissue. Not only in health 
but also in disease. The complexity of the human brain has made it difficult to study many 
MCDs in model organisms like mice. MCD-associated phenotypes often show a reduction 
or absence of gyrification limiting the use of natural lissencephalic brains  and suggesting 
that MCD causing human genes might have gained new functions compared to their mouse 
orthologs. We, and also the Kriegstein laboratory modeled the Miller-Dieker Syndrome 
(MDS), a severe lissencephaly, in cortical organoids to address pathophysiological changes 
(Bershteyn et al. 2016; Iefremova et al. 2017). We could identify human-specific non-cell 
autonomous disruption in WNT-signaling, leading to perturbations in aRG cells division 
modes (Iefremova et al. 2017). The Kriegstein laboratory (Bershteyn et al. 2016) showed 
MDS pathophysiological defects in bRG cells in the SVZ. Moreover, cortical organoids 
displayed a useful tool to model the impact of infectious disease on cortical development 
like the relatively recent outbreak of the ZIKA virus leading to microcephaly (X. Qian et al. 
2016; Cugola et al. 2016; H. et al. 2018; Janssens et al. 2018; Dang et al. 2016; Garcez et al. 
2016; Wells et al. 2016).  The sensitivity of cortical organoids to model different disease 
severities and analyze individual pathologies has not been examined yet. This project 
explored the ability to recapitulate different disease severities of LIS1-lissencephaly using 
mild, moderate and severe affected LIS1-patient specific iPS cells and thereof derived 
forebrain-type cerebral organoids. 
                                                       Unraveling the pathology of different disease severities  
 
 
 
34 
 
Figure 3: Scheme of maturing organoid and timepoint depend cytoarchitecture. At the timepoint of matrix 
embedding and differentiation the organoid mainly consists of apical radial glia (aRG) cells. In the next 10 days 
aRG cells divide symmetrically and increase their progenitor pool, so that the organoid ventricular zone structures 
expand and consist at day 20 mainly of aRG cells. Between day 20 and day 50 aRG cells start to divide 
asymmetrically, leading to the generation of intermediate progenitors (IP) and neurons, which form the 
subventricular-like zone (SVZ) and the cortical plate-like structure (CP). The human-specific basal radial glia 
(bRG) cells start to emerge around day 50 within the SVZ. Prolonged differentiation leads to organoid ventricular 
structures containing deep and upper layer neurons. 
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1.4. Lissencephaly – a rare second group MCD 
MCDs were first grouped in 1996 as disorders resulting from disturbance of the normal 
developmental processes of the human cerebral cortex causing a wide range of developmental 
disorders (Barkovich A.J., Kuzniecky R.I., Dobyns W.B., Jackson G. D. 1996). Depending on 
the appearance of the first developmental abnormalities, these disorders were classified into 3 
major classes (Barkovich et al. 2005, 2012a; Desikan and Barkovich 2016). The first group 
includes those disorders thought to be caused by abnormal progenitor cell proliferation or 
apoptosis such as microcephaly (reduced brain size) and macrocephaly (abnormal large brain), 
while the second group is compost of those cases believed to be largely caused by alterations 
in neuronal migration including lissencephaly (smooth brain) as well as heterotopia (abnormal 
displaced neurons leading to cytoarchitecture alterations). The third described group includes 
malformations secondary to abnormal postmigrational development, such as polymicrogyria 
(overfolding and abnormal lamination of the cortex). This project focuses on lissencephaly, a 
heterogenous spectrum of MCDs associated with a smooth brain and a disorganized 
thickened cortex (Francis et al. 2006; Barkovich et al. 2012b). Patients suffer from mental 
retardation and untreatable epilepsy (Aronica, Becker, and Spreafico 2012; Guerrini and 
Dobyns 2017). Continuous advancement of molecular genetics has led to the identification 
of many lissencephaly-related genes, most are related to microtubule structural proteins 
(tubulin) or microtubule-associated proteins (MAPs). LIS1 was the first gen associated with 
this MCD (Dobyns et al. 1993; Reiner et al. 1993). 
1.4.1. LIS1 – an indispensable protein  
Sporadic heterozygous mutations in the human LIS1 gene, also called PAFAH1B1 (short for: 
platelet-activating factor acetylhydrolase isoform1B, α subunit) cause lissencephalic brains 
with different severe gyrification alterations. The protein is a homodimer, made of a N-terminal 
dimerization domain and a C-terminal ß-propeller structure, which is important for protein 
interactions (Figure 4). 
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Figure 4: Scheme of the wildtype LIS1 protein dimer conformation. The N-terminal homology motif is 
important for dimerization and the C-terminal 7 blade 𝛽-propeller structure is indispensable for protein 
interactions. 
LIS1 is assigned to 2 main cellular functions. Originally, it was identified as a stoichiometric 
component of PAFAH1b functioning as enzyme in the deactivation of the lipid messenger 
platelet-activating factor. However, mice null for the catalytic subunit of PAFAH1b showed 
normal brain development (Koizumi et al. 2003; Yan et al. 2003). Consequently, there had to 
be an additional function of LIS1 causing lissencephaly. Because of the lethality of LIS1 null 
mice, it became precipitously clear that LIS1 is an essential gene during brain development 
(Hirotsune, Gambello, et al. 1998; Cahana et al. 2001). The reduction of LIS1 dosage led to 
migration defects in mice causing dosage-depended cellular disorganization of cortical layers, 
hippocampus, cerebellum and olfactory bulb (Hirotsune, Fleck, et al. 1998; Gambello, Darling, 
Yingling, Tanaka, Gleeson, and Wynshaw-boris 2003; Tanaka et al. 2004). The necessity of 
LIS1 for correct neuronal migration has been also shown by direct examination of neuronal 
migration in mouse embryonic brain slice cultures, which were in utero transfected with green 
fluorescent protein to label migrating neurons (Shu et al. 2004). Using RNAi knockdown of 
LIS1 undoubtfully demonstrated that LIS1 is required of neuronal migration and that LIS1 
deficiency leads to neuronal migration defects associated with lissencephaly (Shu et al. 2004; 
Tsai J, Chen Y, Kriegstein A 2005; Youn et al. 2009). Consequently, LIS1-lissencephaly was 
long time considered to be a neuronal migration disorder. However, to date it is known that the 
underlying disease triggers are characterized by a broader spectrum of disease-causing 
pathology also including progenitor abnormalities like mitotic spindle formation as well as 
perturbed radial glial cell proliferation (Tsai J, Chen Y, Kriegstein A 2005; Tanaka et al. 2004; 
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N. E. Faulkner et al. 2000; Yingling et al. 2008). Extended mouse studies showed an additional 
role of LIS1 in cell proliferation during neurogenesis as well as for neuronal survival 
(Gambello, Darling, Yingling, Tanaka, Gleeson, and Wynshaw-Boris 2003). LIS1 knock-down 
was associated with impaired neural stem cell division (Tsai J, Chen Y, Kriegstein A 2005). 
Already Tanaka et al. (Tanaka et al. 2004) showed that LIS1 is required for nuclear movement 
during neuronal migration by coupling the nucleus to the centrosome. In fact, to date there are 
multiple publications confirming the function of LIS1 as  important DYNEIN regulator (Nicole 
E Faulkner et al. 2000; Smith et al. 2000; Huang et al. 2012; Toropova et al. 2014; Mi Moon 
and Wynshaw-boris 2013; DeSantis et al. 2017; Sasaki et al. 2000). Tai and colleagues (Tai et 
al. 2002) showed that the interaction is substoichiometric and occurs through 3 distinct sites 
within DYNEIN’s cargo binding domain and the motor domain. Moreover, Faulkner et al. 
found (N. E. Faulkner et al. 2000) that LIS1 is co-localized with cytoplasmic DYNEIN at the 
mitotic kinetochores indicating a role of LIS1 in chromosomal behavior. Microinjections of 
anti-LIS1 antibody caused delay in mitotic progression as well as chromosomal defects at the 
metaphase during mitosis (N. E. Faulkner et al. 2000; Moon et al. 2014). Additionally, it was 
shown that LIS1 is also localized at the marginal area of the developing cortex in NES cells. 
The overexpression led to mitotic spindle disorganization potentially caused by reduction of 
DYNEIN distribution pointing out the importance of DYNEIN/ LIS1 interactions for the 
regulation of spindle orientation (N. E. Faulkner et al. 2000). It was also shown that LIS1 
deficient mice had 80 % thinner and severely disorganized cortices due to reduced numbers of 
progenitors, potentially caused by a failure of mitotic spindle function (Pawlisz et al. 2008). 
This was further shown by Yingling et al. (Yingling et al. 2008) by using a Cre-loxP strategy 
to induce a complete loss of LIS1 in defined spatial-temporal patterns in NES- and RG cells. 
The loss of LIS1 in NES cells completely diminished those cell population, whereas loss of 
LIS1 in RG cells resulted in depletion of progenitors without catastrophic loss. They proposed 
a model to explain these findings, saying, that the cleavage planes early in development in the 
NES cells are tightly controlled to a vertical (symmetric) division to produce daughter cells 
both becoming progenitor cells. Explaining the massive cell loss when LIS1 deficiency leads 
to incorrect spindle orientation. Whereas in RG cells later in development, when more spindle 
planes are orientated horizontally (asymmetric) LIS1 deficiency leads to the reduction of 
progenitors and the decrease of neuron production resulting in a smaller brain size, but without 
catastrophic consequences (Yingling et al. 2008). Moreover, they postulated that due to the 
LIS1 function of cortical microtubule capture and stability resulting from its function in 
DYNEIN regulation, LIS1 stabilizes microtubules by plus-end capture at the cell cortex via 
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localization of DYNEIN components, providing an explanation for the spindle orientation 
defects in LIS1 deficient NES and RG cells (Yingling 2008). It is also to add that LIS1-
lissencephlic mouse models also helped to elucidate the question how LIS1 deficiency results 
in defects of cortical DYNEIN localization. It is postulated, that LIS1 mediates anterograde 
transport of cytoplasmic DYNEIN to the plus-end of cytoskeletal microtubules as a complex 
on transportable microtubules (Masami Yamada et al. 2013). Consequently, LIS1 deficiency 
would lead to impaired plus-end directed DYNEIN transport and accumulation around the 
centrosome associated with peripheral depletion leading to nucleokinesis defects displayed by 
migrating neurons  (Tanaka et al. 2004). In addition, one mouse study rescued cortical DYNEIN 
localization and phenotypic LIS1 mutant defects by inhibiting LIS1 degradation by intra-
peritoneal injection of ALLN, a calpain inhibitor, rescuing apoptotic neuronal cell death, 
reduction of brain weight as well as neuronal migration defects (M. Yamada et al. 2009). 
Important interaction partners of LIS1 to regulate cytoplasmic Dynein are NUDE (also known 
as NDE1) and its isoform NUDEL (also known as NDEL1) (Kitagawa et al. 2000; Niethammer 
et al. 2000; Morris et al. 1998) also found in Aspergillus through the ortholog interaction of 
NUDF (Efimov and Morris 2000). The physiological necessity for such a complex interaction 
network is poorly understood. It can be assumed that the complexity in interactions relates to a 
precise control of DYNEIN activity, which plays a role in all microtubule-depend processes, 
but how exactly LIS1 regulates DYNEIN is not known yet. Mesngon and colleagues (Mesngon 
et al. 2006) reported that LIS1 causes some stimulation of DYNEIN ATPase activity. 
Concluded it is to say that LIS1-lissencephaly is not just, as traditionally considered, an 
isolated neuronal migration disorder (Mi Moon and Wynshaw-boris 2013). LIS1 is 
imperative for microtubule-dynamic processes, which are fundamental important for the 
correct function of neuronal progenitor dynamics during cortical development (Bizzotto and 
Francis 2015). Recent data clearly highlights an important role of LIS1 in various progenitor-
depended processes like mitotic progression, altered spindle orientation and consequently 
defects in aRG cells division mode leading to incorrect timing of neurogenesis (Tsai J, Chen 
Y, Kriegstein A 2005; Yingling et al. 2008; Francis et al. 2006). 
1.4.2. LIS1-lissencephaly – a disorder displaying multiple faces 
Heterozygous deletions or mutations in the LIS1 gene are most common to cause 
lissencephaly in humans (Kato M. 2003). LIS1-lissencephaly includes isolated lissencephaly 
sequence (ILS, also known as classical or type I lissencephaly), MDS and very rarely 
subcortical band heterotopia (SBH) (Dobyns and Das 2014). This study focuses on ILS, which 
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is caused by de novo mutations in the LIS1 gen, including small intragenic deletions or 
insertions as well as point mutations. Common MRI LIS1 phenotypes include an anomalous 
thickened cortex of 12-20 mm (normal 3-4mm) and absent or abnormally broad cerebral gyri 
(Barkovich, Koch, and Carrol 1991). Those phenotypes are seen in vastly different severe 
manifestations (Figure 5). Dobyns and Truwit (Dobyns and Truwit 1995) established a grading 
system of gyral malformation including agyria (grade 1), mixed agyria-pachygyria (grades 2 
and 3) and pachygyria (grades 4 to 6) to better define several recognized subtypes according to 
their MRI phenotype (Pilz et al. 1998; Dobyns and Truwit 1995) (outlined in Figure 5). 
   
Figure 5: Scheme of the lissencephalic severity spectrum. The healthy primate brain is characterized by multiple 
folds, so called gyri and sulci. This gyrification developed evolutive by the expansion of the neocortex. One of the 
main phenotypes of lissencephalic brains is a reduction of gyrification, which occurs in different severities. The 
milder phenotypes are characterized by broader gyri. Moderate lissencephalic brains often show a gradient of 
severity from anterior to posterior with anterior pachygyria and posterior agyria. The most severe lissencephalic 
phenotypes are characterized by the complete absents of gyrification (smooth brain). 
The clinical severity generally correlates with the degree of agyria, but not with the LIS1 gene 
mutation (Saillour et al. 2009). Much of our knowledge about LIS1-lissencephaly comes from 
post-mortem analyzes of patient’s brains, which provided valuable insight into 
neuropathological condition. However, such tissue represents the final stage of disease and 
cannot be used to analyze the development of MCD or causative mechanisms. Pre- and prenatal 
imagine might provide more detailed information on disease progression, however, not permit 
functional studies. The translation into mouse models has generated fundamental insight into 
the pathological mechanisms associated to the disease phenotype (Collins et al. 2019; Uzquiano 
et al. 2019; Chevassus-Au-Louis et al. 1999; Mi Moon and Wynshaw-boris 2013). The basic 
sequence of events during corticogenesis are commonly shared across species making mouse 
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models a well-suited system to unravel neurodevelopmental disorders. Transgenic mice 
represent a powerful tool for examining genetic mechanisms. Consequently, several mouse 
models of lissencephaly were created based on LIS1 protein dosage variations, leading to the 
identification of many molecular functions of the LIS1 protein (see 1.4.1). However, many 
phenotypes observed in humans are not recapitulated in non-human models, highlighting severe 
difference in development, the structure of the brain and gene function between human and 
non-human models. One example is the healthy lissencephalic mouse brain, which is an 
imperative restriction when analyzing lissencephalic disorders, failing to recapitulate the 
severity of human-specific phenotypes. Even though these studies could show that LIS1 gene 
dosage is relevant for the phenotypic severities. However, the impact of specific mutations 
within the LIS1 gene as identified in LIS1-patients on alterations of human-specific 
processes during cortical development was so far not investigated. Therefore,  to overcome 
those structural and technical hurdles iPS cells derived cerebral organoids have emerged as 
an attractive tool to model and study human-specific aspects of MCDs recapitulating the 3D 
cytoarchitecture, cell composition and spatial organization reminiscing of early human brain 
development (M. A. Lancaster et al. 2017; Camp et al. 2015; Kanton et al. 2019). This study 
elucidates whether cerebral organoids are sensitive to recapitulate variable disease severities to 
analyze individual pathologies for personalized medicine.  
1.5. The variable phenotypic manifestations of LIS1-lissencephaly – an unsolved 
phenomenon 
To date little is known about the underlying pathologies leading to the diverse LIS1-
lissencephalic severities. Mouse models have unraveled many molecular pathologies but failed 
to capture disease severity. Therefore, studies utilizing human and patient-specific model 
systems are needed for severity cause elucidation. A more in-depth understanding is important 
as it may lead to more specific approaches to comfort and help affected children. Multiple 
clinical case studies describe that there is no correlation between disease causing LIS1 mutation 
and patients disease severity. Neither the mutation type nor the location of the mutation within 
the LIS1 gene were found to predict the severity grade of LIS1-lissencephaly (Saillour et al. 
2009; Uyanik et al. 2007; Philbert et al. 2017; Pilz et al. 1998). There are known cases were the 
same mutation leads to different disease severities (oral communication, Nadja Bahi-Buisson). 
That raises the question in how far the genetic plays into pathology. Are environmental factors 
or any by-chance effects involved or is it mainly the degree of LIS1-function disruption which 
determines disease severity. Initially, one publication suggested a putative correlation with the 
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mild lissencephaly associated missense mutations and truncating mutations localized at the 3’ 
end of the LIS1 gene (Cardoso et al. 2000). Although more recent studies did not confirm this 
relationship (Uyanik et al. 2007; Saillour et al. 2009). Saillour et al. (Saillour et al. 2009) 
analyzed a large LIS1-patient cohort including 40 patients carrying LIS1 mutations (75%) or 
small deletions (20%). They tried unsuccessfully to correlate the severity of the disease in terms 
of epileptic seizures, radiological findings, and body movement impairments with the LIS1 
mutations. Moreover, Uyanik et al. (Uyanik et al. 2007) revealed 21 intragenic mutations 
distributed over the entire LIS1 gene. Except 2 mutations in the LIS1 homology domain and 2 
in the region encoding the coiled-coil domain were all found in one of the seven WD40 repeat 
domains. But neither the type nor the position of the mutation correlated with a particular 
phenotype. Rather, they found that the clinical severity correlates only with the degree of agyria 
and cortical thickening, which supports the statement of Barkovich and colleagues already in 
1991 (Barkovich, Koch, and Carrol 1991). Due to the lack of accessibility of patient’s brain, it 
is difficult to analyze molecular pathologies in living cells. Post-mortem analyzes show the 
final stage of disease but are not suitable for functional studies or disease progression analysis 
leading to disease heterogeneity.  To date there are only a few studies analyzing LIS1-
lissencephalic severity cause in human in vitro models. Early on, in 1999, Fogli et al. (Fogli et 
al. 1999) did genotype-phenotype correlations of 7 patients with classical lissencephaly 
carrying a heterozygous LIS1 splice-site or truncation mutation. The patient harboring a splice-
site mutation suffered from more severe disease than the patients with LIS1 truncation 
mutation. Using lymphoblastoid cell lines of those patients, they found that patient cells 
containing the splice-site mutation were suggestive of partial protein synthesis from the mutated 
allele, whereas cells harboring truncation LIS1 mutation did not show detectable protein 
translation. Consequently, their data propose that the intracellular dosage of the LIS1 protein 
correlates with the severity, which was also shown by murine studies (Y. H. Youn et al. 2009; 
Gambello, Darling, Yingling, Tanaka, Gleeson, and Wynshaw-Boris 2003). Caspi et al. 
(Caspi et al. 2003) analyzed different LIS1 point mutations by examining protein stability, 
folding, intracellular localization and protein-protein interactions by utilizing in vitro 
models. Their data suggest that the mutated proteins were affected at different levels and no 
single assay could be used to predict the lissencephalic phenotype. They found that the 
cellular phenotype of cells, expressing mutant proteins that retain partial folding and 
interactions may be modified by overexpression of specific LIS1 interacting proteins. These 
findings implicate that there are probably different biochemical and cellular mechanisms 
obstructed in each patient yielding the varied lissencephaly phenotypes. Our collaboration 
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partners (Philbert et al. 2017, Camille Maillard, unpublished Data) analyzed fibroblasts of 4 
LIS1-patients including 2 patients characterized by mild disease, grade 4-5, as well as 2 patients 
suffering from severe disease, grade 1-2. The analysis of LIS1 mRNA levels in patient 
fibroblasts showed that wildtype transcript levels from those 4 patients (mild and severe) are 
reduced by approximately half compared to controls due to the heterozygous mutations. But 
only the mutant transcript levels from patients with mild disease, carrying a frameshift, are 
degraded by non-sense mediated decay (NMD), as shown by inhibition of NMD by Emetine. 
In contrast, mutant transcripts of patients with severe disease, with in-frame missense mutation, 
are not degraded, so that the missense mutation would lead to misfolded proteins in the severe 
patients, which might be degraded by the proteasome. By proteasomal inhibition they (Philbert 
et al. 2017, Camille Maillard, unpublished Data) found clusters of LIS1 in cells from patients 
with severe disease, in which mutant transcripts are not degraded. Cells from patients with mild 
disease did not show this phenomenon supporting the assumption that only cells from severe 
patients contain misfolded protein variants. They further hypothesized that the observed LIS1 
clusters in severe conditions might be stress granules (SG), which are cytosolic membrane-less 
organelles that form temporarily, allowing the cell to bear a cellular stress by stalling mRNA 
translation and enhancing the synthesis of cytoprotective proteins (J.-Y. Youn et al. 2019). This 
hypothesis was supported by fibroblast treatment with sodium arsenate, a cellular stressor, and 
co-labeling of LIS1 and G3BP1, a SG marker. Moreover, they found that LIS1 clusters are 
observed only after MG132 treatment, suggesting LIS1 mutant proteins are misfolded and then 
degraded by proteasome. These findings suggest that the wildtype transcript reduction by 50 % 
together with the 50 % of misfolded proteins are more harmful to the cell physiology than only 
the 50 % wildtype transcripts as found in cells from patients with mild disease. To further 
elucidate potential underlying pathologies leading to disease severity heterogeneity in neuronal 
progenitors and during brain development, fibroblasts (and lymphocytes) of the 4 patients 
(mild, severe) named above as well as cells from 2 additional patients suffering from moderate 
disease were send to me for reprogramming into iPS cells and 3D in vitro disease modelling. 
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1.6. Aims and research objectives  
MCDs are the consequence of alterations in the precise choreography of progenitor 
proliferation, neurogenesis and neuronal migration during corticogenesis. LIS1-lissencephaly 
is a heterogeneous MCD. To date little is known about the molecular origin for such 
lissencephalic heterogeneity and no effective treatment is available. LIS1 mouse models show 
that LIS1 gene dosage is relevant for the phenotypic severities. However, the impact of 
specific mutations within the LIS1 gene as identified in LIS1-patients on alterations of 
human-specific processes during cortical development was so far not investigated. 
Therefore, the here presented project had the main aim to shed light on the underlying 
pathology leading to different lissencephalic disease severities caused by LIS1 mutations. 
To do so 7 patients were selected from a LIS1-patient cohort comprising 63 cases who cover 
the whole spectrum of gyrification alterations of LIS1-lissencephaly ranging from Dobyns 
grade 5 (mild) to 1 (severe). Somatic cells of those patients (all harboring heterozygous 
mutation in the LIS1 gene) were reprogrammed and 2 clones for each LIS1-patient iPS cell line 
characterized. To analyze specific early human developmental aspects in the different 
lissencephalic conditions a reproducible protocol for the generation of homogenous human 
cerebral forebrain-type organoids was developed. Furthermore, to analyze the mutational 
consequences on human cortical development the ability of my 3D organoid models to 
sensitively recapitulate different disease severities of LIS1-lissencephaly should be 
explored. To that end, I also planned to develop precise quantitative assessment protocols to 
detect phenotypic differences sensitively and accurately in the developed 3D in vitro model 
systems. Moreover, I had the intention to use my 3D organoid models for unraveling molecular 
pathologies, which might be specific for the different disease severities. The last major aim was 
to identify substances, which counteract in vitro disease phenotypes as potential candidates for 
disease therapy.  
Summarized, to shed more light on lissencephalic disease heterogeneity following aims arise:  
I. To generated and characterize a large LIS1-patient iPS cell cohort which covers the 
whole spectrum of gyrification alterations of LIS1-lissencephaly. 
II. To develop an in vitro cortical forebrain-type organoid protocol to reconstruct cortical 
stem cell niche and analyze corticogenesis in health and disease. 
III. To design quantitative 3D organoid assessment protocols to precisely compare healthy 
and different disease severity conditions. 
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IV. To test the sensitivity of the established 3D organoid system to mirror different disease 
severities and reflect LIS1-lissencephaly associated phenotypes. 
V. To investigate underlying molecular pathology in the LIS1-patient derived organoids 
from different disease severities.  
VI. To identify substances, which counteract LIS1-lissencephlic associated phenotypic 
alterations. 
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2. Materials 
This study was completed at the Hector Institute of Translational Brain Research (HITBR) 
headed by Prof. Dr. Philipp Koch. All used cell lines, technical equipment, consumables as well 
as chemicals, cell culture media, enzymes, buffers, solutions, primers, antibodies and software 
are listed in this section. The entire experiments were completed in compliance with Germany’s 
legal provisions and ethical guidelines and the ‘Declaration of Helsinki – Ethical Principles for 
Medical Research Involving Human Subjects’ from the World Medical Association. The 
employment of all human cell lines was in full ethical agreement with institutional regulations. 
2.1. Cell lines 
The cell lines used in this study included fibroblasts, peripheral blood mononuclear cells 
(PBMCs) and iPS cells. Control skin fibroblasts were obtained from Coriell Biorepository 
(control 1, 2-year-old female, catalog ID GM00969; control 2, 5-month old male donor, catalog 
ID GM08680). LIS1-patient fibroblasts and lymphocytes were collected and send from Nadja 
Bahi-Buisson from the Necker Enfants Malades university hospital in France (mild LIS1-
patient 1, 8-year old male donor, c.569-10T>C LIS1 mutation; mild LIS1-patient 2, 5-years old 
male donor, c.569-10T>C LIS1 mutation; moderate LIS1-patient 1, 6-years old female donor, 
c.13del LIS1 mutation; moderate LIS1-patient 2, 13-year old female donor, delEx11 LIS1 
mutation; severe LIS1-patient 1, 4-year old female donor, c.1002+1G>A; severe LIS1-patient 
2, 18-year old female donor, c.531G>C LIS1-mutation; severe LIS1-patient 3, 3-year old 
female donor, c.445>T LIS1 mutation, see table 1). iPS cell lines were generated with patient 
consent, and this study was ethically approved. In additional 4 control iPS cell lines were 
received from Dr. Sandra Horschitz (Ethics Committee II of Medical Faculty Mannheim of 
Heidelberg University approval no. 2014-626N-MA, control 3, 21-years old female donor; 
control 4, 44-year old female donor; control 5, 25-year old female donor; control 6, 26-year old 
female donor). 
Table 1: Overview of LIS1-lissencephaly patients including age, sex, mutation and severity grade. 
 mild P1 mild P2 moderate P3 moderate P4 severe P5 severe P6 severe P7 
age 8 5 6 13 4 18 3 
sex male male female female female female female 
mutation c.569-
10T>C 
c.671-
10T>G 
c.13del delEx11 c.1002+1G>A c.531G>C c.445>T 
severity 
grade 
4-5 4-5 3 3 1-2 2 1-2 
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Table 2: Generated LIS1-patient iPS cell lines and utilized control iPS cell lines 
Cell line Source 
control C 1.1 Coriell Biorepository, catalog.ID GM00969 (2-year-old female donor) 
control C 1.2 Coriell Biorepository, catalog.ID GM00969 (2-year-old female donor) 
control C 2.1 Coriell Biorepository, catalog.ID GM08680 (5-month-old male donor) 
control C 2.2 Coriell Biorepository, catalog.ID GM08680 (5-month-old male donor) 
control C 3.1 Sandra Horschitz, HITBR Mannheim (21-year-old female donor) 
control C 3.2 Sandra Horschitz, HITBR Mannheim (21-year-old female donor) 
control C 4.1 Sandra Horschitz, HITBR Mannheim (44-year-old female donor) 
control C 4.2 Sandra Horschitz, HITBR Mannheim (44-year-old female donor) 
control C 5.1 Sandra Horschitz, HITBR Mannheim (25-year-old female donor) 
control C 5.2 Sandra Horschitz, HITBR Mannheim (25-year-old female donor) 
control C 6.1 Sandra Horschitz, HITBR Mannheim (26-year-old female donor) 
control C 6.2 Sandra Horschitz, HITBR Mannheim (26-year-old female donor) 
mild LIS1-patient P1.1 Olivia Krefft, HITBR Mannheim, Germany (8-year-old male donor) 
mild LIS1-patient P1.2 Olivia Krefft, HITBR Mannheim, Germany (8-year-old male donor) 
mild LIS1-patient P2.1 Olivia Krefft, HITBR Mannheim, Germany (5-year-old male donor) 
mild LIS1-patient P2.2 Olivia Krefft, HITBR Mannheim, Germany (5-year-old male donor) 
moderate LIS1-patient P3.1 Olivia Krefft, HITBR Mannheim, Germany (6-year-old female donor) 
moderate LIS1-patient P3.2 Olivia Krefft, HITBR Mannheim, Germany (6-year-old female donor) 
moderate LIS1-patient P4.1 Olivia Krefft, HITBR Mannheim, Germany (13-year-old female donor) 
moderate LIS1-patient P4.2 Olivia Krefft, HITBR Mannheim, Germany (13-year-old female donor) 
severe LIS1-patient P5.1 Olivia Krefft, HITBR Mannheim, Germany (4-year-old female donor) 
severe LIS1-patient P5.2 Olivia Krefft, HITBR Mannheim, Germany (4-year-old female donor) 
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severe LIS1-patient P6.1 Olivia Krefft, HITBR Mannheim, Germany (18-year-old female donor) 
severe LIS1-patient P6.2 Olivia Krefft, HITBR Mannheim, Germany (18-year-old female donor) 
severe LIS1-patient P7.1 Olivia Krefft, HITBR Mannheim, Germany (3-year-old female donor) 
severe LIS1-patient P7.2 Olivia Krefft, HITBR Mannheim, Germany (3-year-old female donor) 
2.2. Technical equipment 
All used technical equipment is listed in this section. 
Table 3: Technical equipment 
Device Manufacture 
10X Vortex Adapter 10X Genomics (San Francisco, USA) 
10X Magnetic Separator 10X Genomics (San Francisco, USA) 
2100 Bioanalyzer Laptop Bundle  Agilent (Waldbronn, Germany) 
4200 Tape station Agilent (Waldbronn, Germany) 
Analytical Balance BP121-S 
Sartorius Stedim Biotech S. A. (Aubagne 
Cedex, France) 
Centrifuge 5415D Eppendorf AG (Hamburg, Germany) 
Centrifuge Z 216 MK 
HERMLE Labortechnik GmbH (Wehingen, 
Germany) 
Chromium Controller 10X Genomics (San Francisco, USA) 
Chromium Next GEM Secondary Holder 10X Genomics (San Francisco, USA) 
CO2 Incubator HERAcell 150i 
Thermo Fisher Scientific Inc. (Waltham, 
Massachusetts, USA) 
Confocal Microscope Leica TCS SP5II 
Leica Microsystems GmbH, (Mannheim, 
Germany) 
Electrophoresis Power Supply EPS 301 
Amersham Pharmacia Biotech (Little 
Chalfont, UK) 
Extraction hood mc6® das Laborsystem Waldner GmbH & Co (Wangen, Germany) 
Fluorescence Microscope Axioskop 2 plus 
Zeiss Microscopy GmbH (Oberkochen, 
Germany) 
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Fluorescence Microscope Celldiscoverer 7 
Zeiss Microscopy GmbH (Oberkochen, 
Germany) 
Fluorescent Lamp ebq 100 
Lighting & Electronics Jena GmbH, (Jena, 
Germany) 
Fragment Analyzer Automated CE System 12, 
and 48/96 cap 
Advanced Analytical Technologies (Heidelberg, 
Germany) 
Heraeus Sorvall Four Place Swinging Bucket, 
Rotor 6445 
Thermo Fisher Scientific Inc. (Waltham, 
Massachusetts, USA) 
Heraeus® Herasafe™ 2030i Biological Safety 
Cabinet 
Thermo Fisher Scientific Inc. (Waltham, 
Massachusetts, USA) 
Heraeus® Labofuge® 400R Centrifuge 
Thermo Fisher Scientific Inc. (Waltham, 
Massachusetts, USA) 
HiSeq 4000 Sequencing system Illumina (San Diego, USA) 
Illumina Nova Seq 6000 system Illumina (Berlin, Germany) 
Inverted Leica DMIL LED Microscope 
Leica Microsystems GmbH, (Mannheim 
Germany) 
Light-Sheet-Microscope Leica Microsystems GmbH, (Mannheim 
Germany) 
LUNA™ Automated cell counter Logos Systems (Weilerswist, Germany) 
Micro Balance iso9001 
Sartorius Stedim Biotech S. A. (Aubagne 
Cedex, France) 
MilliQ Integral Water Treatment System 
Merck Millipore (Burlington, Massachusetts, 
USA) 
MJ Research PTC-200 Thermal Cycler 
Biozym Diagnostik GmbH (Oldendorf, 
Deutschland) 
Nanodrop™ ND-1000 Spectrophotometer 
Thermo Fisher Scientific Inc. (Waltham, 
Massachusetts, USA) 
Neurolog System Stimulator Module Digitimer LLC (Ft. Lauderdale, Florida, USA) 
NovaSeqTM 6000 sequencing system Illumina (San Diego, USA) 
Odyssey Imaging System 
Li-Cor Bioscience (Bad Homburg vor der Höhe, 
Germany) 
Orbital shaker KS 250 basic 
IKA Labortechnik ® GmbH, staufen 
(Germany) 
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2.3. Plastic ware 
All used plastic ware is listed in this section. 
Table 4: Plastic ware 
Product Manufacturer 
Cell Scrapper 16 cm SARSTEDT AG & Co. KG, (Nümbrecht, 
Germany) 
Coverslips 12, 15 mm Ø VWR International (Radnor, Pennsylvania, 
USA) 
CryoPure Tubes 1 ml SARSTEDT AG & Co. KG (Nümbrecht, 
Germany) 
pH-Meter Profi Lab WTW pH597 
SIGMA-ALDRICH (St. Louis, Missouri, 
USA) 
Quant Studio 7 Flex 
applied Biosystems by Thermo Fisher Scientific Inc. 
(Waltham, Massachusetts, USA) 
Qubit 4.0 Fluorometer 
Thermo Fisher Scientific Inc. (Waltham, 
Massachusetts, USA) 
Sunlab Roll Mixer SU 1400 Sustainable lab instruments (Heidelberg, Germany) 
Thermal Cycler C1000 Touch (with 96-deep well 
reaction module) 
Bio-Rad Laboratories (Essen, Germany) 
Thermal MasterCycler Pro Eppendorf AG (Hamburg, Deutschland) 
Thermal Cycler MJ Research PTC-200  
Biozym Scientific GmbH (Hessisch Oldendorf, 
Germany) 
Termal Cycler Veriti (96-well) 
Thermo Fisher Scientific Inc. (Waltham, 
Massachusetts, USA) 
Thermomixer comfort 5355 Eppendorf AG (Hamburg, Deutschland) 
UV lamp GeneFlash Syngene (Cambridge, UK) 
Vortex Reax control 
Heidolph Instruments GmbH & CO. KG, 
Schwabach (Germany) 
Warm bath ED-17 
JULABO Labortechnik GmbH (Seelbach, 
Deutschland) 
Warm bath for cell culture 
Köttermann GmbH & Co. KG 
(Uetze/Häningsen, Germany) 
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Disposable bag SARSTEDT AG & Co. KG (Nümbrecht, 
Germany) 
DNA LoBind Tubes 1,5 and 2 ml Eppendorf (Hamburg, Germany) 
Eppendorf tubes 0,1, 0,5, 1,5 and 2 ml SARSTEDT AG & Co. KG, (Nümbrecht, 
Germany) 
Falcons 15, 50 ml SARSTEDT AG & Co. KG, (Nümbrecht, 
Germany) 
Flowmi Strainer P1000 Pipette Tip, 40 uM Bel-Art SP SciencewareTM (New jersey, USA) 
Frame Star 96 well semi-skirted PCR Plate  4titude (Wotton, UK) 
Glass Pasteur pipettes Thermo Fisher Scientific Inc. (Waltham, 
Massachusetts, USA) 
Imaging 35 mm Ø dish, polymer coverslipbottom Ibidi GmbH (Martinsried, Germany) 
MicroAmp 8-Tube Strip 0,2 ml Thermo Fisher Scientific Inc. (Waltham, 
Massachusetts, USA) 
MicroAmp 8-Cap Strip, clear Thermo Fisher Scientific Inc. (Waltham, 
Massachusetts, USA) 
Micropipettes 1000, 200, 100, 20, 10, 2 µl ABIMED GmbH (Langenfeld, Deutschland) 
Microscope slides 76x26 mm Carl Roth GmbH & Co. KG (Karlsruhe, 
Deutschland) 
Nitrile Powder-Free Gloves ABENA®, Culver City (USA) 
Parafilm M Pechiney Plastic Packaging (Chicago, USA) 
Pasteur pipettes Alpha Laboratories Limited (Hampshire, UK) 
PCR Seal 4titude (Wotton, UK) 
PCR Single Cap 8-Soft Strips, 0,2 ml Biozym Scientific GmbH (Hessisch 
Oldendorf, Germany) 
PCR Tubes 0,2 ml 8-tube stripes Eppendorf (Hamburg, Germany) 
Petri-dishes 60x15 mm and 100x15mm with Nocken SARSTEDT AG & Co. KG (Nümbrecht, 
Germany) 
Pipet tips 1000, 200, 20, 10 µl SARSTEDT AG & Co. KG, (Nümbrecht, 
Germany) 
Serological Pipets, 50, 25, 10, 5 ml SARSTEDT AG & Co. KG, (Nümbrecht, 
Germany) 
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TC 6, 12, 24, 96 Well-Cell Culture Plate, Standard F SARSTEDT AG & Co. KG, (Nümbrecht, 
Germany) 
TempAssure PCR 8-tube strip USA Scientific (Ocala, USA) 
Ultralow Cluster, 96-well plate, ultra-low attachment round 
bottom with lid 
Costar® by SIGMA-ALDRICH (St. Louis, 
Missouri, USA) 
2.4. Cell culture consumables 
This section contains all information what cell culture consumables have been used within this 
study including compounds, chemicals and media compositions. 
2.4.1. Cell culture compounds and chemicals 
All used compounds and chemicals are listed in this section. 
Table 5: Cell culture compounds and chemicals 
Product Manufacturer 
A83-01 Tocris (Wiesbaden, Germany) 
B27® Supplement (50X) Gibco® Thermo Fisher Scientific Inc. 
(Waltham, Massachusetts, USA) 
BSA solution (7.5%) SIGMA-ALDRICH (St. Louis, Missouri, USA) 
BDNF Peprotech (Hamburg, Germany) 
cyclisches adenosin-monophosphat (cAMP) SIGMA-ALDRICH (St. Louis, Missouri, USA) 
CHIR99021 Cell Guidance Systems Ltd (Cambridge, UK) 
D-Glucose SIGMA-ALDRICH (St. Louis, Missouri, USA) 
DMEM (1X) + GlutaMAX™-I Gibco® Thermo Fisher Scientific Inc. 
(Waltham, Massachusetts, USA) 
DMEM/F-12 (1:1) (1X) + L-Glutamine Gibco® Thermo Fisher Scientific Inc. 
(Waltham, Massachusetts, USA) 
DMEM/F-12 (1:1) (1X) + L-Glutamine + 
HEPES 
Gibco® Thermo Fisher Scientific Inc. (Waltham, 
Massachusetts, USA) 
DMSO SIGMA-ALDRICH (St. Louis, USA) 
Dorsomorphin Stem Cell Technologies (Cologne, Germany) 
Dulbecco´s Phosphate Buffered Saline SIGMA-ALDRICH (St. Louis, Missouri, USA) 
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EDTA SIGMA-ALDRICH (St. Louis, Missouri, USA) 
Epothilone D SIGMA-ALDRICH (St. Louis, Missouri, USA) 
Fetal bovine serum (FBS) Invitrogen (Waltham, Massachusetts, USA) 
FLT3 Gibco® Thermo Fisher Scientific Inc. 
(Waltham, Massachusetts, USA) 
GDNF Cell Guidance Systems Ltd (Cambridge, UK) 
Gelantine SIGMA-ALDRICH (St. Louis, Missouri, USA) 
GelTrex™ (GT) Gibco® Thermo Fisher Scientific Inc. 
(Waltham, Massachusetts, USA) 
GlutaMAX™-I (100X) Gibco® Thermo Fisher Scientific Inc. 
(Waltham, Massachusetts, USA) 
Heparin SIGMA-ALDRICH (St. Louis, Missouri, USA) 
HEPES Carl Roth GmbH & Co. KG (Karlsruhe, Deutschland) 
Human FGF-2 (154) Cell Guidance Systems Ltd (Cambridge, UK) 
Human recombinant bFGF Invitrogen (Waltham, Massachusetts, USA) 
Human Recombinant Insulin SIGMA-ALDRICH (St. Louis, Missouri, USA) 
Human TGF-β1 Cell Guidance Systems Ltd (Cambridge, UK) 
Interleukin 3 (IL-3) Gibco® Thermo Fisher Scientific Inc. 
(Waltham, Massachusetts, USA) 
Interleukin 6 (IL-6) Gibco® Thermo Fisher Scientific Inc. 
(Waltham, Massachusetts, USA) 
Knockout™-Serum Replacement (KOSR) Gibco® Thermo Fisher Scientific Inc. 
(Waltham, Massachusetts, USA) 
L-Ascorbic Acid Cell Guidance Systems Ltd (Cambridge, UK) 
L-Ascorbic Acid 2-Phosphate (LAAP) SIGMA-ALDRICH (St. Louis, Missouri, USA) 
L-Tryptophan SIGMA-ALDRICH (St. Louis, Missouri, USA) 
Laminin Gibco® Thermo Fisher Scientific Inc. 
(Waltham, Massachusetts, USA) 
LDN-193189 StemMACSTM (Bergisch Gladbach, Germany) 
LM22A SIGMA-ALDRICH (St. Louis, Missouri, USA) 
LM22B 10 Tocirs (Wiesbaden, Germany) 
MEM Non-Essential Aminoacids (NEAA), Gibco® Thermo Fisher Scientific Inc. 
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(100X) (Waltham, Massachusetts, USA) 
2-Mercaptoethanol  Invitrogen (Waltham, Massachusetts, USA) 
Natrium chloride (NaCl) SIGMA-ALDRICH (St. Louis, Missouri, USA) 
Natrium selenite (NaSe) SIGMA-ALDRICH (St. Louis, Missouri, USA) 
Penicillin Streptomycin 10,000 units/ml Gibco® Thermo Fisher Scientific Inc. 
(Waltham, Massachusetts, USA) 
PluriPro Cell Guidance Systems Ltd (Cambridge, UK) 
Pluronic SIGMA-ALDRICH (St. Louis, Missouri, USA) 
Poly-L-ornithine SIGMA-ALDRICH (St. Louis, Missouri, USA) 
Progesterone SIGMA-ALDRICH (St. Louis, Missouri, USA) 
Purmorphamine Cell Guidance Systems Ltd (Cambridge, UK) 
Puromycin PAA (Pasching, Austria) 
Putrescine SIGMA-ALDRICH (St. Louis, Missouri, USA 
Rho-Kinase-Inhibitor  
Y-27632 (Rock Inhibitor) 
Cell Guidance Systems Ltd (Cambridge, UK) 
Stem cell factor (SCF) Gibco® Thermo Fisher Scientific Inc. 
(Waltham, Massachusetts, USA) 
Transferrin SIGMA-ALDRICH (St. Louis, Missouri, USA) 
Trypan blue Invitrogen (Waltham, Massachusetts, USA) 
TrypLE Express Gibco® Thermo Fisher Scientific Inc. 
(Waltham, Massachusetts, USA) 
Trypsin-EDTA (10X) Gibco® Thermo Fisher Scientific Inc. 
(Waltham, Massachusetts, USA) 
Trypsin inhibitor (TI) Gibco® Thermo Fisher Scientific Inc. 
(Waltham, Massachusetts, USA) 
UltraPure™ EDTA Invitrogen (Waltham, Massachusetts, USA) 
XAV 939 Enzo (Lörrach, Germany) 
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2.4.2. Cell culture media composition 
All base media were ordered from Life Technologies (Karlsruhe) and supplemented with 1X 
Penicillin/Streptomycin (Pen/Strep). The compounds and small molecules where added 
according to the listed concentrations. The complete cell culture media were stored at 4°C and 
used within 4 weeks. Directly after cell passaging all media were supplemented with 5mM 
Rock inhibitor Y-27632 (Rock inhibitor) for 1 day. 
Table 6: Cell culture media 
Medium Composition Concentration 
Freezing medium KOSR  70% 
Cytobuffer  
20% 
DMSO 
10% 
E8 base medium DMEM/F-12 (1:1) (1X) + L- Glutamine + HEPES  
LAAP 
0,64 mg/ml 
NaSe 
28 nM 
E8 complete medium E8 base medium   
Human recombinant insulin 
10 µg/ml 
FGF-2 (154) 
1 ng/ml 
H-Transferrin 
2 µg/ml 
TGF-β1 
10 ng/ml 
HBS solution (2X) NaCl 280 mM 
 HEPES 50 mM 
 Na2HPO*7H2O (pH 7,05) 1,42 mM 
 add 10 M NaOH to pH 7,05 add 
Human ES cell medium Knockout™-Serum Replacement (KOSR) 
KOSR 1:5000, 
NEEA 1X 
GlutaMax 1X 
β-Mercaptoethanol 55 µM 
bFGF 4 ng/ml 
Pen/Strep 1X 
Maturation medium Neuronal differentiation medium 
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LM22A 1µM 
LM22B 1µM 
GDNF 10 nM 
Ascorbic acid 0,2 mM 
GelTrex 1:500 
Mouse Embryonic Fibroblast 
(MEF) medium 
DMEM (1X) + GlutaMAX™-I 
FCS 10 % 
Pyruvat 1 % 
NEEA 1% 
Pen/Strep 1X 
N2/B27 base medium DMEM/F-12 (1:1) (1X) + L-Glutamine 
 N2 supplement 1X 
 B27® Supplement 1X 
 β-Mercaptoethanol 0,1 nM 
 cAMP 1,5 µg /ml 
 D-Glucose 0,4 µg/ml 
 NEEA 1X 
 GlutaMax 1X 
 Pen/Strep 1X 
N2 Supplement DMEM (1X) + GlutaMAX™-I  
H-Transferrin  2 mg/ml 
Human recombinant insulin  0,5 mg/ml 
Putrescine 1,6 µg/ml 
Progesterone 
0,6 µm/ml 
NaSe 
0,5 µg/ml 
Neuronal differentiation medium N2/B27 base medium  
KOSR  
Human recombinant insulin 
1:50 
2,5µg/ml 
Neuronal induction medium 
N2/B27 base medium  
Heparin 
10 µg/ml 
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LDN 
180 nM 
A83 
500 nM 
XAV 
10 µg/ml 
PBMC medium StemPro34 medium  
 SCF 100 ng/ml 
 FLT3 100 ng/ml 
 IL-3 20 ng/ml 
 IL-6 20 ng/ml 
PluriPro (PP) medium PluriPro 99 % 
 Pen/Strep 1% 
PP/E8 medium PP 50 % 
 E8 complete medium 50 % 
StemPro34 medium DMEM (1X) + GlutaMAX™-I  
 StemPro Supplement (50X) 1X 
 BSA (25%) 2% 
 GlutaMax 1X 
 β-Mercaptoethanol 55 µM 
 bFGF 4 ng/ml 
Wash medium DMEM (1X) + GlutaMAX 99 % 
 Pen/Strep 1 % 
2.5. Molecular biology consumables 
This section contains all information what molecular biology consumables have been used 
within this study including compounds, chemicals and solution compositions. 
2.5.1. Molecular biology compounds and chemicals 
This section provides information about molecular compounds and chemicals used within this 
study. 
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Table 7: Molecular compounds and chemicals 
Product Manufacture 
30% Acryl-bisacryl-amide SIGMA-ALDRICH (St. Louis, Missouri, USA) 
Agarose SIGMA-ALDRICH (St. Louis, Missouri, USA) 
AmmershamTM HybondTM 0,2µm  
PVDFB Blotting Membrane 
Healthcare Life Science (Freiburg, Germany) 
Ammoniumperoxodisulfat (APS) SIGMA-ALDRICH (St. Louis, Missouri, USA) 
Calcium chloride (CaCl2) SIGMA-ALDRICH (St. Louis, Missouri, USA) 
Cell staining buffer for Cell Hashing BioLegend (Koblenz, Germany) 
Chloroform SIGMA-ALDRICH (St. Louis, Missouri, USA) 
DAPI SIGMA-ALDRICH (St. Louis, Missouri, USA) 
ddH2O Merck Millipore (Burlington, Massachusetts, USA) 
DNA 100 bp ladder New England Biolabs (Ipswich, New England, USA) 
dNTPs Peqlab GmbH (Erlangen, Germany) 
Eosin G-Lösung 0,5% wässrig  Carl Roth GmbH & Co. KG (Karlsruhe, Deutschland) 
Ethanol ≥99.8 % SIGMA-ALDRICH (St. Louis, Missouri, USA) 
FCS Invitrogen (Waltham, Massachusetts, USA) 
Galantine  SIGMA-ALDRICH (St. Louis, Missouri, USA) 
U-shaped 2.5 mm glass capillaries Hilgenberg (Malsfeld, Germany) 
Glucose Carl Roth GmbH & Co. KG (Karlsruhe, Deutschland) 
Glycerol Merck (Burlington, Massachusetts, USA) 
Hämalaunlösung sauer nach Mayer Carl Roth GmbH & Co. KG (Karlsruhe, Deutschland) 
HEPES Carl Roth GmbH & Co. KG (Karlsruhe, Deutschland) 
Horse serum Thermo Fisher Scientific Inc. 
(Waltham, Massachusetts, USA) 
Human TruStain FcX Blocking Solution 
for Cell Hashing 
BioLegend (Koblenz, Germany) 
Isopropanol SIGMA-ALDRICH (St. Louis, Missouri, USA) 
Loading Dye New England Biolabs (Ipswich, New England, USA) 
Low melting agarose Cambrex Bio Science (Wiesbaden, Germany) 
Low TE Buffer (10 mM Tris-HCl pH 8,0, Thermo Fisher Scientific Inc. 
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0,1 mM EDTA) (Waltham, Massachusetts, USA) 
Mowiol SIGMA-ALDRICH (St. Louis, Missouri, USA) 
N,N,N’,N’-Tetrakis(2-
hydroxypropyl)-ethylenediamine 
TCl Chemicals (Eschborn, Germany) 
Nuclease-free H2O Thermo Fisher Scientific Inc. 
(Waltham, Massachusetts, USA) 
PeqGreen Peqlab GmbH (Erlangen, Germany) 
Paraformaldehyde (PFA) SIGMA-ALDRICH (St. Louis, Missouri, USA) 
Potasium Chloride (KCl) AppliChem GmbH (Darmstadt, Germany) 
Phosphatase inhibitor Thermo Fisher Scientific Inc. 
(Waltham, Massachusetts, USA) 
Protease inhibitor Thermo Fisher Scientific Inc. 
(Waltham, Massachusetts, USA) 
Qiagen Buffer EB Qiagen (Hilden, Germany) 
RNASE Away Molecular Bioproducts Inc. (Leicestershire, UK) 
Saponin SIGMA-ALDRICH (St. Louis, Missouri, USA) 
Sodium chloride (NaCl) SIGMA-ALDRICH (St. Louis, Missouri, USA) 
Sodium citrate (Na3C6H5O7) SIGMA-ALDRICH (St. Louis, Missouri, USA) 
Sucrose SIGMA-ALDRICH (St. Louis, Missouri, USA) 
TAE Buffer (10X) SIGMA-ALDRICH (St. Louis, Missouri, USA) 
ThermoPol® Reaction Buffer Pack New England Biolabs (Ipswich, New England, USA) 
TriFast peqGOLD Peqlab GmbH (Erlangen, Germany) 
Tris-Tricine-SDS Buffer (10X) SIGMA-ALDRICH (St. Louis, Missouri, USA) 
Triton X-100 SIGMA-ALDRICH (St. Louis, Missouri, USA) 
Tween 20 Bio-Rad Laboratories (Hercules, California, USA) 
Type F Immersion Oil Leica Microsystems GmbH, (Mannheim, Germany) 
Urea SIGMA-ALDRICH (St. Louis, Missouri, USA) 
WypAll X60 Wipes Kimberly-Clark ProfessionalTM (Koblenz, Germany) 
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2.5.2. Molecular biology buffer and solution compositions 
All used molecular buffers and solutions are listed in this section. 
Table 8: Molecular buffer and solution composition 
Buffer Composition Concentration 
3M Tris-HCl/ SDS Buffer Tris base 182 g 
 HCl to pH 8.45 add 
 dH2O to 500 ml add 
 SDS 1,5 g 
6X SDS-PAGE Sample Buffer Tris 375 mM, pH 6,8 25 ml 
 10 % SDS solution 60 ml 
 Glycerol 6% 6 ml  
β-Mercaptoethanol 9 % 9 ml  
Bromphenol-blue-solution 9 % 0,03 g  
10% APS Ammonium persulfate 1 g 
 dH2O to 10 ml add 
10X Anode buffer Tris base 1M 242 g 
 add HCl to pH 8,8 add 
 dH2O to 1000 ml add 
10X TBS NaCl (150mM) 87,6 g 
 Tris (50mM) 60,5 g 
 add HCl to pH 7,4 add 
 dH2O to 1000 ml add 
50x Tris-acetate-EDTA-buffer 
(TAE) 
Tris 242 g  
EDTA solution (0.5M; pH 8.5) 100 ml  
Water-free acetic acid (100%) 57.1 ml  
dH2O to 1000ml add 
Blotting Transfer buffer  Glycine 
2,9 g 
 Tris 
5,8 g 
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SDS 
0,37 g 
 Methanol 
200 ml 
 dH2O to 1000ml 
add 
Clearing blocking solution Horse serum 
10% 
 Gelantine 
0,2% 
 Triton X-100 
0,1% 
 PBS 
add 
Cryo-embedding medium PBS 
82,5 % 
 Sucrose 
10 % 
 Gelantine 
7,5 % 
dNTP Mix dATP 
25 mM 
 dTTP 
25 mM 
 dCTP 
25 mM 
 dGTP 
25 mM 
HBS solution (2X) NaCl 
280 mM 
 HEPES 
50 mM 
 Na2HPO*7H2O (pH 7,05) 
1,42 mM 
 add 10 M NaOH to pH 7,05 
add 
Immuno-blocking solution PBS 
89,9 % 
FCS 
1 % 
Triton X100 (only for intracellular epitopes) 
0,1 % 
Lysis buffer Tris HCl  
50 mM 
 NaCl  
50 mM 
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EDTA  1 mM 
TritonTM X-100 1% 
HCl to 7.4 add 
 
Protease inhibitor  1 tablet/ ml 
 
Phosphatase inhibitor 1 tablet/ ml 
Mounting solution Tris solution (0.2 M; pH 8.5) 12 ml  
 H2O 6 ml  
Glycerol 6 g  
Moviol 2.6 g  
DABCO 0.1 g  
PCR master mix solution 
Taq Buffer 2,5 µl 
 
MgCl2 0,75 µl 
 
dNTPs (100mM, 25mM each dNTP) 0,2 µl 
 
Primer (1:10) 1,0 µl 
 
DNA 1,0 µl 
 
GoTaq G2 Flexi DNA polymerase 0,2 µl 
 
dH2O to 25 µl add 
PFA fixation solution (4%) 
PFA 40 g 
 
dH2O 1000 ml 
Protein loading buffer 
Tris solution (0.1 M; pH 6.8) 75.75%     
 
Glycerol 20%         
SDS 4%            
 
Bromphenol blue 0.25%       
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ScaleCUBIC-1 solution N,N,N’,N’-Tetrakis(2-hydroxypropyl)-
ethylenediamine 
25% 
 Triton X-100 15% 
 Urea 25% 
 in dH2O add 
SDS-PAGE separation gel 
solution (10%) 
3M Tris-HCl/ SDS, pH 8.45 13,33 ml 
 30% acrylamide 13,33 ml 
50% glycerol 8,00 ml 
10% ammonium perlsulfat (APS) 112 µl 
TEMED 37µl 
 dH2O to 40 ml  add 
SDS-PAGE stacking gel solution 
(4%) 
3M Tris-HCl/ SDS, pH 8.45 4,96 ml 
 30% acrylamide 2,56 ml 
10% ammoniumperlsulfat (APS) 134,4 µl 
TEMED 44,8 µl 
 dH2O to 20 ml  add 
SDS-PAGE gel solution buffer Tris solution (1.5M; pH 6.8) 99.6%  
 SDS 0.4%  
TBST-buffer 10X TBS 100 ml 
 Tween 100X 1 ml 
 H2O to 1000 ml add 
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2.6. Enzymes 
All used enzymes are listed in this section. 
Table 9: Molecular enzymes 
Enzyme name Manufacturer 
Alkaline Phosphatase, Shrimp  Roche Diagnostics (Penzberg, Germany) 
Dnase I (molecular biology) Invitrogen (Karlsruhe, Germany) 
Go Taq G2 Flexi DNA polymerase Promega (Mannheim, Germany) 
Phusion High Fidelity DNA Polymerase  New England Biolabs (Frankfurt, Germany) 
T4 DNA Ligase  New England Biolabs (Frankfurt, Germany) 
Taq DNA Polymerase, recombinant  Invitrogen (Karlsruhe, Germany) 
2.7. Plasmids 
All used plasmids are listed in this section. 
Table 10: Molecular plasmids 
Plasmid name Source  
Lentiviral-TOP-dGFP-reporter Addgene plasmid #14715; Reya et al Nature. 2003 May 22. 
423(6938):409-14. 
Viral packing vector psPAX2 Addgene plasmid #12260 
Viral packing vector pMD2.G Addgene plasmid #12259 
2.8. Kits 
All used kits are listed in this section. 
Table 11: Molecular kits 
Kit Manufacturer 
CTS™ CytoTune™-iPS 2.1 Sendai 
Reprogramming Kit 
Thermo Fisher Scientific Inc. (Waltham, 
Massachusetts, USA) 
DNase I Amplification Grade SIGMA-ALDRICH (St. Louis, Missouri, USA) 
Dneasy Blood and Tissue Kit  Qiagen (Hilden, Germany) 
Go Tag G2 Flexi DNA Polymerase Kit Promega (Mannheim, Germany) 
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High Sensitivity D1000 ScreenTape Kit Agilent (Waldbronn, Germany) 
High Sensitivity D5000 ScreenTape Kit Agilent (Waldbronn, Germany) 
High Sensitivity NGS Fragment Analysis 
Kit 
 Advanced Analytical Technologies (Heidelberg, Germany) 
High Sensitivity RNA ScreenTape Kit Agilent (Waldbronn, Germany) 
iScript cDNA Synthesis Kit  Bio-Rad Laboratories (Hercules, California, USA) 
KAPA Library Quantification Kit for 
Illumina platforms 
KAPA Biosystems (Amsterdam, Netherlands) 
peqGOLD Gel Extraction Kit  Peqlab Biotechnologie (Erlangen, Germany) 
peqGOLD Plasmid Miniprep Kit I  Peqlab Biotechnologie (Erlangen, Germany) 
Pierce BCA Protein Assay Kit Thermo Fisher Scientific Inc. (Waltham, 
Massachusetts, USA) 
PureYield Plasmid Maxiprep System  Promega (Mannheim, Germany) 
Qubit ds DNA HS Assay Kit Thermo Fisher Scientific Inc. (Waltham, 
Massachusetts, USA) 
Rneasy Kit  Qiagen (Hilden, Germany) 
SPRIselct Reagent Kit Beckman Coulter (Krefeld, Germany) 
2.9. Primers 
All used primers are listed in this section. 
Table 12: Primers for LIS1-mutation validation and regional identity control 
Primer Forward Reverse 
18s attccttggaccggcgcaa gccgcatcgccggtcgg 
Emx1 agacgcaggtgaaggtgtgg caggcaggcaggctctcc 
FoxA2 ccaccaccaaccccacaaaatg tgcaacaccgtctccccaaagt 
FoxG1 ccctcccatttctgtacgttt ctggcggctcttagagat 
HoxA4 ttcagcaaaatgccctctct taggccagctccacagttct 
HoxB2 tttagccgttcgcttagagg cggatagctggagacaggag 
HoxB4 acacccgctaacaaatgagg gcacgaaagatgagggagag 
HoxB6 gaactgaggagcggactcac ctgggatcagggagtcttca  
LIS1 exon 1 gagccagttcagaagggg gtggaggagacagaggggag 
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LIS1 exon 2 
ggttaacatgattgggagtggg agaagagacctcccaaagctg 
LIS1 exon 3 
ggttgctgtcacagagccat agttcagtaccaagtagaccaca 
LIS1 exon 4+5 
attccagctgtcagcccttg tgaacccagtcagcaactcc 
LIS1 exon 6 agacagggagcggactatgt 
gcaagagaatctgggctcgt 
LIS1 exon 7 gctttgacatagtgaaacccca tcgaagtgactgcaacacca 
LIS1 exon 8 tgtctgttagcttattgttcctact tcagaattgctggatgcagat 
LIS1 exon 9 ctgagtccttcctgtgtagcat agcatctccccctcaaacac 
LIS1 exon 10 aacagaactgctgcgacagg ggcgtacatacccaaggagg 
Nkx2.1 ccggaggcagtgggaag ccctccatgcccactttctt 
Otx2 tgcaggggttcttctgtgat agggtcagagcaattgacca  
Pax5 aggatgccgctgatggagtac tggaggagtgaatcagcttgg 
TUBB3 gagcggatcagcgtctacta ggttccaggtccaccagaa 
2.10. Antibodies 
All used antibodies are listed in this section. 
Table 13: Molecular primary antibodies 
Antibody Host Dilution Manufacturer 
Acetylated α-tubulin (AC-TUB) Rabbit 1:500 Cell Signaling 
AFP  Mouse 1:200 Hölzel 
ARL13B Mouse 1:50 DSHB 
ß-ACTIN  Mouse 1:5000 Millipore 
β-Catenin Mouse 1:1000 Cell Signaling 
ß-III-TUBULIN (TUBB3)  Mouse 1:2000 Sigma-Aldrich 
TUBB 3  Rabbit 1:2000 Cell Signaling 
FOXG 1  Rabbit 1:300 TebuBio 
EMX 1 Rabbit 1:500 Sigma-Aldrich 
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LIS1 Mouse 1:500 Sigma-Aldrich 
N-CADHERIN (N-CAD) Mouse 1:500 BD 
NANOG Mouse 1:200 DSHB 
PAX 6  Rabbit 1:500 DSHB 
OCT 3/4 Rat 1:500 R&D Systems 
OTX 2  Goat 1:500 R&D Systems 
phospho-VIMENTIN (p-VIM) mouse 1:500 Novus Biologicals 
TPX 2  Rabbit 1:500 Novus Biologicals 
SMA  Rabbit 1:400 Abcam 
SSEA 3 Rabbit 1:500 Abcam 
SOX 2  Rat 1:500 Santa Cruz 
ZO-1  Rabbit 1:100 DSHB 
Table 14: Molecular secondary antibodies 
Antibody Host Anti Dilution Manufacturer 
488 Goat Rabbit 1:10,000 Invitrogen  
488 Goat Mouse 1:10,000 Invitrogen 
555 Donkey Rabbit 1:10,000 Life technologies  
555 Goat Guinea pig 1:10,000 Invitrogen  
568 Goat Mouse 1:10,000 Invitrogen 
647 Donkey Mouse 1:10,000 Invitrogen 
DyLightTM 680 
Conjugate 
Goat Mouse 1:1000 Cell Signaling 
DyLightTM 680 
Conjugate 
Goat Rabbit 1:1000 Cell Signaling 
DyLightTM 800 
Conjugate 
Goat Mouse 1:1000 Cell Signaling 
DyLightTM 800 
Conjugate 
Goat Rabbit 1:1000 Cell Signaling 
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2.11. Software 
All used software is listed in this section. 
Table 15: Computational software programs 
Software Manufacturer 
ApE v2.0.47 M. Wayne Davis 
AxioVision 40 4.5.0.0 Zeiss Microscopy GmbH (Oberkochen, Germany) 
FIJI (ImageJ) National Institutes of Health (Rockville, Maryland, USA) 
Leica Application Suite 2.3.1 Leica Microsystems GmbH (Wetzlar, Germany) 
Microsoft Excel 2010 Microsoft Corporation (Redmond, Washington, USA) 
Microsoft PowerPoint 2010 Microsoft Corporation (Redmond, Washington, USA) 
Microsoft Word 2010 Microsoft Corporation (Redmond, Washington, USA) 
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3. Methods 
To approach the in section 1.6 listed aims multiple methods were used, which are in detail 
described in this section. 
3.1. Cell culture  
The cell culture was completed at the HITBR in Mannheim. Employing the standard of the art, 
iPS cells were cultured under feeder-free condition as colonies in Essential 8 (E8) medium or 
Pluripro (PP) medium (Cell guidance) at a constant temperature of 37ºC and 5% CO2. The in 
this study incorporated gender matched control lines were received as iPS cell lines (see 2.1), 
the LIS1-patient fibroblasts and PBMCs were reprogrammed by non-integrative delivery of 
OCT 4, SOX 2, KLF 4, and c-MYC using CytoTune-iPS 2.1 Sendai Reprogramming Kit 
(Thermo Fisher) (for more information to the LIS1-patient material see table 1). 
3.1.1. Culture and maintenance of fibroblasts 
Fibroblast cells were cultured on galantine-coated cell culture plates in MEF medium with 
daily medium change at 37ºC and 5% CO2. When cell cultures reached 70-100% confluency, 
cells were dissociated and passaged. Before adding the dissociation reagent 0,05% Trypsin-
EDTA (Gibco) (500μl) for 10 min, the cells were washed with PBS. The single-cell 
suspension was transferred into a 15 ml tube containing 5 ml of DMEM (1X) + GlutaMAX™-
I and centrifugated at 800 rpm for 5 min. After the aspiration of the supernatant, the cell pellet 
was resuspended in fresh MEF medium (2 ml per well of a 6-well plate) without Rock inhibitor. 
The splitting ratio can be up to 1:5 depending on the required cell density. 
3.1.2. Culture of peripheral blood mononuclear cells 
PBMCs consist mainly of lymphocytes and monocytes and do not significantly proliferate 
in vitro (especially monocytes). The addition of mitogens can help expanding those cells, 
but the reprogramming should be performed closely after blood isolation. For this study, the 
LIS1-patient PBMCs were immediately frozen after isolation and send from the pediatric 
neurology, Necker Enfants Malades university hospital in France. Directly after arrival, the 
PBMCs were thawed in 2 ml StemPro34 medium, counted and centrifugated for 10 min at 
300g (swinging bucket rotor needed). In the following 500,000 cells/well were seeded in 1 
ml PBMC medium in one well of a 24-well plate. For the next 3 days half of the media was 
changed daily. At day 4 reprogramming was performed (see 4.1.3). 
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3.1.3. Generation of induced pluripotent stem cell cultures 
The discovery in 2007 of Shinya Yamanaka to convert human somatic cells back to stem cells 
revolutionized the research field and received 2012 the noble price. The molecular basis relays 
on the reintroduction of 4 transcription factors including human OCTAMER BINDING 
PROTEIN 3/4 (hOCT 3/4), human SEX DETERMINING REGION Y-BOX 2 (hSOX2), 
human KRÜPPEL-LIKE FACTOR 4 (hKLF 4) and cMYC. To date different protocols for the 
cellular reinstatement of pluripotency exist. In this study, the highly efficient Sendai-virus 
approach was used. It is important to mention that no matter what somatic cell type is subjected, 
it is important to use young passages to ensure good reprogramming efficiency and a normal 
karyotype. Fibroblasts and PBMCs were reprogrammed by non-integrative delivery of OCT 4, 
SOX 2, KLF 4 and cMYC using the CSTTM- iPS 2.1 Sendai reprogramming kit (Thermo 
Fisher). 
3.1.3.1. Sendai virus-based reprogramming of fibroblasts 
The reprogramming of the fibroblasts was performed according to the manufacture’s 
description (CTSTM CytoTuneTM-iPS 2.1 Sendai Reprogramming Kit User Guide). All 
fibroblast lines had a young culture passage (P) (P<10) and were tested negative for 
mycoplasmas. 1 day before transduction 2 wells with each 40% confluency were seeded on 1 
well of a 6-well plate. 1 of the 2 wells was used to count the cells to calculate the needed virus 
amounts, which are determined by the MOI (CIU/cell) times the number of PBMCs divided by 
the titer of the virus (CIU/ml) times 0,010. The viruses were thawed at 37°C for 10 to 20 seconds 
(sec), placed at room temperature (RT) for complete thawing and then immediately placed on 
ice. In the next step, the calculated virus amounts of all 3 Sendai viruses were supplemented to 
1 ml prewarmed MEF medium and added into the fibroblast well. It followed an incubation at 
37°C overnight. The next day the medium was changed to MEF medium without virus. It 
followed further culturing for 6 more days with medium change every other day. At day 7 the 
fibroblasts were spitted in a 1:3 ratio. As soon as the first iPS cells clonal colonies appeared the 
medium was changed to hES medium (approximately 3 weeks later). When the iPS cell colonies 
were clearly visible by eye without using a microscope, they were clonal expanded (see 4.1.3.3). 
3.1.3.2. Sendai virus-based reprogramming of PBMCs 
The reprogramming of the PBMCs was performed according to the manufacture’s description 
(CTSTM CytoTuneTM-iPS 2.1 Sendai Reprogramming Kit User Guide). 4 days after thawing the 
suspension PBMCs were counted to calculate the needed volumes of the viruses to reach the 
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target MOI. Virus amount calculation and virus thawing was performed as described in 3.1.3.1. 
In the next step, the calculated virus amounts of all 3 Sendai viruses were added to 1 ml PBMC 
medium. For each cell line 500,000 cells were pipetted into an 1,5 ml reaction tube and the 
virus containing PBMC medium was added. It followed a centrifugation step at 1000 xg for 30 
min at RT. Afterwards an additional 1 ml of PBMC medium was added and the whole mixture 
was plated in 1 well of a 12-well plate for incubation at 37°C overnight. The next day the cell 
suspension was transferred into a 15 ml tube and centrifugated at 200 xg for 10 min to aspire 
the supernatant and resuspend in 0,5 ml of PBMC medium per well of a 24-well plate. For the 
next 2 days no medium change was performed. At day 3 after transduction the cells were 
centrifugated at 200 xg for 10 min to aspire the supernatant and resuspended in Stempro34 
medium. 10,000, 50,000 and the rest of the cells were each plated on 1 well of a GT-coated 6-
well plate. The next day and on day 6 half of the medium was changed. On day 7 half of the 
medium was replaced by hES medium and on day 8 the medium was completely changed to 
hES medium. From this timepoint the hES media was changed daily until iPS cells clones were 
ready to be clonal expanded (approximately 1 week later). 
3.1.3.3. Clonal expansion of iPS cell lines 
To generate monoclonal iPS cell lines, appearing clones were separated and expanded. Only 
cell dense colonies with sharp borders were selected and transferred into 1 well of a 24-well 
plate using a cut 100 µl pipette tip to scratch the clonal colonies from the GT-coated wells. The 
first passage was plated on 1 well of a 12-well plate, the second passage on 1 well of a 6-well 
plate and the third passage was placed on 2 wells of a 6-well plate (see 3.1.5 for passaging 
procedure). Next, 1 well was further passaged and the second well was cryo-conserved. At least 
10 cryo-vials for each generated iPS cell line were generated. All iPS cell lines were quality 
controlled. 
3.1.4. Quality control of iPS cell lines 
Following iPS cell clonal expansion, 2 clones for each cell line were characterized using 
tripotente differentiation, immunochemical staining for pluripotency markers and whole-
genome single nucleotide polymorphism (snp) analysis for chromosomal integrity control. In 
addition, the LIS1 mutations were validated via polymerase chain reaction (PCR) and sanger 
sequencing. 
 
 
                                                       Unraveling the pathology of different disease severities  
 
 
 
71 
3.1.4.1. Whole-genome single nucleotide polymorphism genotyping 
The snp analysis was performed at the Institute of Human Genetics at the University in Bonn. 
Genomic DNA was prepared using the DNeasy Blood & Tissue Kit (Qiagen) and 50 ng/ml was 
used for whole-genome amplification. In the following, the amplified DNA was fragmented 
and hybridized to sequence specific oligomers bound to beads on an Illumina Human610-Quad 
chip or a HumanCytoSNP-12 chip. The Data was analyzed by Josef Frank from the Genetic 
Epidemiology Department headed by Prof. Rietschel using Illumina Bead Studio. 
3.1.4.2. Germ layer differentiation 
To test the pluripotent capacity of the generated iPS cell lines, cells were tested for the ability 
to spontaneously differentiate into the 3 germ layers including endoderm, mesoderm and 
ectoderm. To achieve a 3D-like dense cell population, iPS cells were dissociated into single-
cells using TrypLE Express (Gibco) and plated in a pluronic-coated U-bottom 96-well plate 
(6000 cells/well) in PP/E8 medium supplemented with 50 μM Rock inhibitor to induce 
embryoid body (EB) formation. After 2 days EBs were plated onto GelTrex (GT)-coated dishes 
in mouse embryonic fibroblast (MEF) medium and cultured for 4 weeks. In the following, 
differentiated cell cultures were fixed with 4 % PFA and then subjected to immunocytochemical 
analysis using the antibodies against α-1-fetoprotein (AFP) for endodermal cells, smooth 
muscle actin (SMA) for mesodermal lineage and bIII-tubulin (TUBB3) for ectodermal cells. 
3.1.4.3. Validation of LIS1 genotype 
The LIS1-patient iPS cell cohort is characterized by diverse LIS1 mutations in the different 
patient lines. To confirm the mutations 1 well of a 6-well plate of each LIS1-patient iPS cell 
line was harvested and used for DNA isolation using the DNeasy Blood & Tissue Kit (Qiagen). 
To amplify the mutation containing DNA regions specific primers for each iPS cell line were 
designed (see table 12) and PCR for target sequence amplification was performed (see 4.3.3). 
The PCR fragments were separated using DNA electrophoresis and extracted from the agarose 
gel using the Gel Extraction Kit (peqGOLD). The in water diluted PCR fragments were 
subjected to sanger sequencing by Microsynth-Seqlab. 
3.1.5. Maintenance of iPS cell cultures 
The iPS cell cultures can be grown in colony or monolayer formation determinant by the 
feeding medium used. For this project, the iPS cells were mainly cultured as monolayer cultures 
using the monolayer PP medium, which had a beneficial effect on the LIS1-patient cell vitality 
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especially when generating 3D cell cultures. One disadvantage of monolayer cultures is the 
need for daily medium change and a higher passaging frequency when comparing to colony 
cultures, which can lead to a faster accumulation of chromosomal abnormalities. Due to this, it 
is important to perform snp analysis on regular basis and to thaw young, snp analyzed cells. 
Colony culturing was induced by the usage of E8 medium and was implemented for the new 
reprogrammed iPS cell lines for backup generation and quality control. To transform the colony 
cultures to monolayer growth, 2 cell-dense wells of a 6-well plate were dissociated using TrpLE 
(Gibco) for 10 min, then transferred to a 15 ml tube and centrifugated at 800 xg for 4 min. The 
cell pellet was resuspended in 2 ml of half PP, half E8 (PP/E8) medium (1:1) supplemented 
with 5 μM Rock inhibitor (Cell guidance systems) and plated into 1 well of a 6-well plate. 50% 
of PP medium was sufficient to induce monolayer growth. The next day the medium was 
changed to PP medium. 
3.1.5.1. Maintenance of iPS cell colony cultures 
The iPS cell colonies were maintained on GT-coated cell culture plates in E8 medium with 
daily medium change. Colonies were passaged when reaching 70 % – 80 % confluency. First, 
cells were washed with 0,5 mM EDTA (Gibco) (1:1000 dilution in PBS) and then incubated 
with 0,5 mM EDTA (Gibco) for 4 min at RT. After EDTA aspiration cultures were gently 
dissociated into smaller fragments by gently washing them of the well with a 1000 μl pipette 
containing E8 medium supplemented with 5 μM Rock inhibitor (Cell guidance systems). The 
passaging ratio can vary between 1:4 to 1:6 depending on the cell line used. All human iPS cell 
lines were regularly checked and confirmed negative for mycoplasma. 
3.1.5.2. Maintenance of iPS cell monolayer cultures 
The iPS cell monolayers were maintained on GT-coated cell culture plates in PP medium with 
daily medium change. iPS cells were dissociated to single-cells by TrypLE Express (Gibco) 
treatment for 10 min when cultures reached 100% confluency and split in a 1:2 – 1:4 ratio 
depending on the proliferative capacity of the cell lines used. Following dissociation to single-
cells, suspension was diluted in 5 ml DMEM (1X) + GlutaMAX™-I (Gibco) and transferred to 
a 15 ml tube. Following centrifugation at 800 xg for 4 min and supernatant aspiration, the cell 
pellet was diluted in PP medium supplemented with 5 μM Rock inhibitor Y-27632 (Cell 
guidance systems) to promote single-cell survival. All human iPS cell lines were regularly 
checked and confirmed negative for mycoplasma. 
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3.1.6. Generation of WNT-GFP reporter lines 
For examining the level of WNT-signaling activation in control- (control 2.1, control 3.1) and 
LIS1-patient- (mild P1.1, mild P2.2, moderate P3.1, severe P5.1 and severe P7.1) derived 
organoids, iPS cells were transduced with a lentivirus (see 4.3.1 for virus production) 
expressing GFP under activation of WNT-signaling (lentiviral-top-dGFP reporter, Addgene 
plasmid #14715, Reya et al., 2003). Puromycin (1 μg/ml, Sigma-Aldrich) selection was initiated 
48h following transduction. The iPS cell WNT-GFP reporter lines were used for cortical 
organoid generation (3.1.9). 
3.1.7. Cryo-conservation of cells 
Fibroblasts and iPS cells were stored at -150°C or in liquid nitrogen for cryo-conservation. 
When iPS cell cultures reached 100% confluency, the cells of at least 2 wells of a 6-well plate 
were dissociated to single-cells by TrypLE Express (Gibco) treatment for 10 min and diluted in 
5 ml DMEM (1X) + GlutaMAX™-I (Gibco). Following centrifugation at 800 xg for 4 min and 
supernatant aspiration, the cell pellet (at least 1 million cells) was diluted in 1 ml of pause 
medium supplemented with 10 μM Rock inhibitor Y-27632 and then immediately transferred 
to a freezing container containing isopropanol at -80 ºC. After 24 hours (h) cells were transferred 
to minus 150°C or liquid nitrogen for long term storage. 
3.1.8. Generation of highly homogenous 2D cortical progenitor cultures 
Within the project highly homogenous 2D cortical progenitors were used for western blot 
analysis. Consequently, iPS cells were cultured in PP medium as monolayer in 1 well of a 6-
well plate until the cell culture reached 95% confluency. To initiate neural cortical induction 
the culture medium was changed to neural induction medium (see table 6). The medium 
composition was adopted from Chamber et al. 2009 and is based on the dual inhibition of 
SMAD signaling. The fate inducing small molecules were A83, a TGF signaling inhibitor, 
LDN, a BMP signaling inhibitor, and in addition XAV for WNT-signaling inhibition to avoid 
posterization to hindbrain fates. The very dense iPS cell cultures were kept on the same well 
for 10 days with daily medium change. After 10 days cells were harvested for molecular 
analysis or expanded by passaging in neural induction medium. The withdrawal of the small 
molecules after the passaging leads to the differentiation of the cortical progenitors to cortical 
neurons. 
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3.1.9. Generation of cerebral forebrain-type organoids 
Within Dr. Julia Ladewigs research group, me and my colleagues developed a protocol for 
highly homogenous cortical forebrain-type organoids (outlined in Figure 7, Krefft et al. 2018; 
Iefremova et al. 2017). Due to the rapid progress within the organoid field, the published 
protocol was constantly further advanced and brought up to standard of the art technology. It 
included EB formation, neural induction, GT embedding and organoid maturation. 
 
Figure 6: Protocol outline for cortical forebrain-type organoid generation. The organoid generation is initiated 
by embryoid body formation, which are restricted to the ectodermal fate by neural induction through dual SMAD 
and WNT inhibition. The outgrowth of neuroepithelial ventricular structures is supported by extracellular matrix 
proteins and mechanical scaffold provided by Geltrex (GT) embedding. To ensure good nutrient delivery into the 
tissue, organoids are cultured on a shaker. For further maturation growth factors including Ascorbic acid (AA), 
LM 22 A, LM 22 B and GT are added into the differentiation medium (maturation medium) from day 35 on. 
3.1.9.1. Embryoid body formation and neural induction 
Organoid generation is initiated by EB formation. The most important and crucial step during 
EB generation is the number of cells used. The optimal cell number is different for every cell 
line and needs to be tested. Most of the time less cells led to more compact EBs with clear and 
sharper borders, which led to highly homogenous organoids. Before starting EB generation, 
ultralow cluster 96-well plate ultra-low attachment round bottom with lid (Costar by Sigma-
Aldrich) were covered and incubated for 10-20 min at 37°C with pluronic solution (50 mg/ml, 
Sigma-Aldrich). To generate EBs, iPS cells were dissociated into single-cells using TrypLE 
(Gibco) for 10 min. Single cell suspension was transferred into a 15 ml tube containing DMEM 
(1X) + GlutaMAX™-I (Gibco) and counted using the automated cell counter, LUNA (Logos 
Biosystem). After centrifugation at 800 xg for 4 min cells were diluted in PP medium 
supplemented with 50 µM Rock inhibitor. In the next step 6000 cells per EB for control iPS 
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cell lines and 8000 cells per EB for LIS1-patient lines were seeded into 1 well of a pluronic-
coated 96-well plate ultra-low attachment round bottom with lid (Costar by Sigma-Aldrich). 
EBs were fed every other day for 4 days. On day 5 medium was changed to neural induction 
medium containing the dual SMAD inhibitors A83 and LDN as well as the WNT inhibitor 
XAV. For the next 5 days medium was changed every other day until the EBs developed 
translucent tissue at the edges. To promote the expansion of the neuroepithelium into cortical 
VZ structures, the EBs (now called organoids) are embedded into GT between day 8 and day 
10, depending on the iPS cell line used. 
3.1.9.2. Organoid embedding and differentiation 
The organoid GT embedding was done in 2 different ways. One technique is called the parafilm 
droplet embedding, which is more time consuming than the second embedding technique but 
ensures that every organoid is separately embedded in a GT droplet. This method should be 
preferred when single organoids are needed afterwards. The second organoid embedding 
method is named “cookie embedding”. This technique is faster and needs less GT because 
multiple organoids are embedded in the same GT droplet. The disadvantage is that organoid 
fusion happens more frequently. For both embedding procedures, GT was thawed on ice 2-3 h 
before starting organoid GT embedding. 
For the droplet embedding parafilm was cut into 4 cm x 4 cm pieces and placed over an empty 
tip tray for 100 µl tips to press dimples into the parafilm sheet, which was then sterilized with 
70% ethanol and irradiated with UV light (power: 15 watts, wavelength: 435 nm) under the 
closed sterile bench for 30 min. In the next step, each EB were transferred into 1 dimple using 
a cut 100 µl tip. The medium surrounding the EB was gently aspirated using an uncut 100 µl 
pipette tip. Then 20 µl of undiluted GT was added to each EB, which was then positioned in 
the middle of the drop using an uncut 100 µl pipette tip. The plastic parafilm sheet was carefully 
transferred using sterile forceps into a 10 cm dish, which was placed in the incubator for 20 min 
to allow GT solidification. Afterwards, the embedded organoids were transferred into a 
pluronic-covered low-attachment 6 cm dish containing 6 ml of neural induction medium. To do 
so the parafilm was gently pressed upside down onto the dish using sterile forceps, so that the 
GT was gently squeezed into the tilted 6 cm dish and then slowly lifted, so that the drops gently 
slide of the parafilm into the medium. Each 6 cm dish had a maximum of 16 EBs. The 6 cm 
dish was then placed in the incubator at 37ºC. 
For the cookie embedding the EBs of one batch (maximum 16) were all together transferred 
into a 1,5 ml Eppendorf tube. The medium was carefully aspired using an uncut 100 µl pipette 
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tip. In the following all EBs were diluted in 200 µl GT using a cut pipette tip and immediately 
transferred into a pluronic-covered low-attachment 6 cm dish, which was placed in the 
incubator for 25 min to allow GT solidification. In the following 6 ml of neural induction 
medium is added on top and then placed in the incubator at 37°C. 
At day 10 medium was changed to organoid differentiation medium and the dish was placed on 
a shaker with a tilting angle of 5º and 14 rpm for further agitation. For the next 15 days medium 
was changed every third day until the desired time point was reached. For this study organoids 
were mostly fixed at day d20 for immunochemical analysis and quantitative assessment. For 
single-cell RNA analysis organoids were cultured for 58±2 days. On day 35 the medium was 
changed to maturation medium containing Ascorbic acid (AA), LM 22 A, LM 22 B and GT to 
promote better tissue complexity. 
3.2.  Histology and immunocytochemistry 
A major part of this project was the immunocytochemical analysis of organoid cryo-sections 
and the quantitative assessment of cytoarchitectural parameters. The methodology from 
fixation, cryo-embedding, cryo-sectioning, tissue clearing and immunocytochemical- as 
well as hematoxylin-eosin staining are described in this section. 
3.2.1. PFA fixation 
For the preservation of cells and organoids after cultivation 4 % PFA fixation was used to 
reserve cell structures and crosslink proteins. Due to the toxicity of PFA the fixation was carried 
out under a chemical fume hood. First, organoids were transferred into a 24-well plate with a 
cut 1000 ul pipette and twice washed with PBS. iPS cells were directly fixed in the 3,5 cm 
culture dish and twice washed with PBS. After PBS aspiration, 4 % PFA (table 8) was added 
followed by a 10 min incubation at RT. Afterwards, 4 % PFA was carefully aspirated and 
organoids as well as iPS cells were washed 3 times with PBS. For tissue dehydration organoids 
were placed in 30 % sucrose solution and stored at 4 ºC overnight. Organoids can be stored up 
to 7 days until cryo-cutting or clearing. iPS cells can be stored for up to 4 weeks at 4 °C until 
further processing. 
3.2.2. Organoid cryo-embedding and cryo-sectioning 
To perform cryo-sectioning organoids were embedded in sucrose/galantine embedding solution 
(see table 8), which was stored at -20 °C. Before starting, the solution was liquified by warming 
to 75 ºC. The dehydrated organoids were transferred to 2 ml Eppendorf tubes. After aspirating 
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the 30 % sucrose solution, 1 ml embedding medium was added, and the tubes were placed at a 
heating plate (60 ºC). In the next step, embedding molds were covered with a layer of 
embedding solution and placed on ice to solidify. 1 to 4 organoids from the tube at the heating 
plate were placed on top and additional embedding medium was added to cover the organoids 
completely. Afterwards, the mold was hold in 100% ethanol/dry ice freezing bath (-30 to -50 
ºC) for at least 1 min to shock-freeze the tissues. The embedded organoids were stored at -80 
ºC for at least 30 min before cryo-cutting. 
The cryo-sectioning was performed at the cryostat. Sections were made with 20 µm thickness 
and sequential collected on microscope slides, so that every slide had sections from all organoid 
regions. The sections dried at RT for at least 1 h before being stored at -80 ºC or directly be 
used for immunocytochemical staining. 
3.2.3. Organoid clearing 
For whole tissue mounting organoids were fixed in 4 % PFA for 2 h at RT. Subsequently, 
organoids were washed 3 times with PBS at RT for 2 h. Optical clearing was performed 
according to Susaki et al. (Susaki et al. 2014) by immersion of samples in ScaleCUBIC-1 
solution for 48 h at 37 °C and subsequent washing in PBS 3 times for 2 h at RT. Following 
optical clearing samples were immersed in clearing blocking solution  for 24 h at 37°, followed 
by primary antibody incubation for 48 h at 37 °C, and subsequent washing in blocking solution 
3 times for 2 h at RT. Secondary antibody incubation was done for 48 h at 37°C, followed by 
washing samples 3 times for 4 h each in PBS at RT. Refractive index matching was performed 
by immersion of samples in an aqueous solution of glycerol (RI=1.457) for 48 h at RT. All 
incubations were carried out under protection of light and constant movement. Samples were 
mounted in U-shaped 2.5 mm glass capillaries by embedding in 0.1 % low melting agarose in 
ddH2O. For light sheet microscopy, glass capillaries were transferred into 35 mm glass bottom 
dishes, immobilized by agarose embedding and immersed in RI-matched glycerol solution. For 
temperature adjustment, samples were kept in the microscopy room for at least 24 h prior to 
image acquisition. Image acquisition was done using a Leica Microsystems TCS SP8 DLS, 
equipped with LAS X software, L 1.6x/0.05 DLS illumination objective, HC APO L 10x/0.30 
W DLS detection objective and 7.8 mm Glycerol DLS TwinFlect mirrors. Image stacks were 
acquired with a step size of 3.7 µm and fused with LAS X. Organoid clearing and whole tissue 
imaging was performed with the help of Elina Nürnberg. 
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3.2.4. Immunocytochemical staining 
To analyze the cytoarchitecture of cortical organoids and visualize specific proteins 
immunocytochemical staining`s were performed on 2D cells and 3D organoid sections. A 
liquid barrier pen was used to circle the sample material so that smaller amounts of antibody 
solutions were needed to cover the area of interest. After washing with PBS, an incubation 
with blocking solution (0,1 % Triton and 10% FCS) followed for 1 h at RT. For nuclear 
proteins the triton concentration was increased to 0,5% for a better nucleus 
permeabilization. Primary antibodies were diluted according to the manufacturer’s 
instructions (see table 13) and incubated over night at 4 °C. The next day samples were 
washed 3 times with PBS. The secondary antibodies were diluted according to the 
manufacturer’s instructions (see table 14) and incubated for 1 h at RT with subsequent 
washing. It followed 3 times washing with PBS and a 5 min incubation with DAPI (1X) 
staining solution (see table 14) with subsequent washing. The slides were then covered with 
mounting solution (see table 8) and enclosed with a cover slip. Immunocytochemically 
stained sections were stored at 4 °C and imaged using the Inverted Leica DMIL LED 
Microscope with Thunder imaging software (Leica), the confocal microscope TCS SP5II 
(Leica) or the Fluorescence Microscope Celldiscoverer 7 (Zeiss). 
3.2.5. Hematoxylin and eosin staining 
Hematoxylin-eosin staining was used to visualize cell morphology within the organoid cortical 
VZ structures to analyze cellular organization. Hematoxylin has a deep blue-purple color and 
stains nucleic acids while Eosin is pink and stains proteins nonspecifically resulting in blue 
nuclei and pinkish cytoplasm and extracellular matrix. In the first step organoid sections was 
placed in ddH2O for 10 sec, stained with hematoxylin solution (Carl Roth) for 10 min, shortly 
put in ddH2O and then rinsed under running tap water for 10 min. In the next step the slide was 
twice hold in 70% ethanol for 10 sec and then again rinsed in tap water for 10 min. Next, the 
slide was stained with 0,5% eosin solution (Carl Roth) for 5 min and afterwards shortly put in 
ddH2O. For dehydration and clearing, it followed an alcohol series incubation starting with 70 
%, 80 % and 90 % ethanol solution for 10 sec and then twice 100% ethanol incubation for 5 
min each. Afterwards the slide was dried and mounted with Mowiol. Slides were stored at 4 
°C and imaged using the inverted Leica DMIL LED Microscope with Thunder imaging 
software (Leica). 
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3.3. Molecular biology 
In addition to the histological investigations, molecular biological analysis played an 
important part within this project to decipher the molecular basis of observed LIS1-
associated phenotypes in 3D organoids and to understand the variable lissencephalic 
severities. 
3.3.1. Lentivirus production 
For the generation of WNT-GFP reporter iPS cell lines lentivirus was produced in 
HEK293T cells, which were received from Bettina Bohl. Prior to the virus transfection the 
medium was changed to MEF medium supplemented with chloroquine (25 µM; 0,129g in 
10 ml H20) to prevent autophagy and prevent DNA degradation. In the next step 7,9 µg of 
psPAX2 packing vector (coding for viral envelop proteins), 3,5 µg pMD2.G packing vector and 
10 µg of the transfer vector pRRL.sin-18.ppt (Addgene plasmid #14715) were mixed in 450 µl 
H2O. Additionally, 50 µl 2M CaCl2 solution was added to the vector mix. Next, 500 µl 2x HBS 
in 15 ml tube was prepared and fizzed by using a 5 ml pipette to blow air into the solution. 
During this fizzing process the DNA solution was added dropwise on the outside of the 5 ml 
plastic pipette into the HBS frizzed solution. It followed 30 min incubation at RT and then 
dropwise adding to the HEK293T cells. After 8 h fresh MEF medium was added. 2 days after 
the transduction the medium was collected and fresh medium added, which was again collected 
on day 3 after transduction. The conditioned medium from day 2 and 3 were pooled and 
centrifugated at 12,000 xg for 5 min. The supernatant (17 ml) was filtered through a 0,45 µm 
filter. It followed the addition of 4,2 ml 50% PEG-600 solution, 1,8 ml 4M NaCl and 1,9 ml 
PBS and mixing by inverting. Afterwards the solution was incubated for 1,5 h at 4 °C and 
inverted every 30 min during this incubation time. After centrifugation for 5000 xg for 20 min 
at 4 °C supernatant was discarded, and virus pellet was dissolved in 100 µl HBS/1 % BSA and 
stored at -80 °C. Virus production was performed together with Bettina Bohl. 
3.3.2. DNA isolation 
Genomic DNA was isolated from 2D iPS cells for LIS1 mutation validation using the 
Dneasy blood and tissue kit (Qiagen) to isolate high-quality DNA with great yields. The 
kit provides buffers, proteinase, collection tube and columns for isolation and provides a 
simple protocol with lysis and precipitation steps. 
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3.3.3. RNA isolation 
To analyze gene expression via PCR, RNA was isolated using peqGOLD TriFast 
(Peqlab). 3 to 4 organoids were transferred into a 2 ml Eppendorf tube and washed twice 
with PBS before adding 500 µl peqGOLD TriFast. Suspensions were resuspension until 
cell clumps were dissolved. 2D cells were washed twice with PBS and then scratched of 
the well using a cell scrapper. The cells were suspended in PBS and transferred into a 2 
ml Eppendorf tube for centrifugation at 800 xg for 4 min to pellet the cells. PBS was 
discarded and cells were resuspended in 1 ml of peqGOLD TriFast until no cell clumps 
were observable. The lysates were incubated for 10 min at RT and then 200 µl of 
chloroform was added. In the following the Eppendorf tubes were inverted for 15 sec 
and then incubated for 10 min at RT. In the next step lysates were centrifuged at 12,000 
xg for 5 min at 4 °C. The resulting pink phase containing the proteins was discarded and 
the clear phase containing the nucleic acid was transferred into a new Eppendorf tube 
and supplemented with 500 µl isopropanol (1:1 ratio). The RNA precipitation was done 
for 2-3 h on ice or overnight at -20 °C. After incubation the sample was centrifuged 15 
min at 12,000 xg at 4 °C. Supernatant was discarded and the pellet was washed twice 
with 1 ml of 75 % ethanol in DEPC water followed by a centrifugation step of 12,000 
xg for 10 min at 4 °C. In the last washing step, the 75% ethanol was thoroughly 
discarded, and the RNA pellet was left to air dry at RT for about 30 min. Once the pellet 
was dry, it was resolved in 20 µl of DEPC-H2O by 37 °C and shaking at 400 rpm in the 
heating block for 15 min. It followed DNA treatment to prevent DNA contamination 
using the DNase I Amplification Grade kit. For this the samples were supplemented with 
2,5 µl of DNase and 2,5 µl reaction buffer and incubated 15 min at RT. To stop the 
reaction 2,5 µl of STOP solution were added and another incubation for 10 min at 70 °C 
was performed. Concentration (ng/ µl) was measured with the nanodrop and RNA was 
stored at -80 °C. 
3.3.4. Reverse transcription 
To qualitatively study gene expression, the isolated RNA needed to be reversed 
transcript back to DNA to perform PCR or qPCR. Consequently, the iScript cDNA 
synthesis kit from Bio-Rad systems was used. Following the manufactures instruction 1 
µg RNA was added to 4 µl 5X iScript reaction mix and supplemented with 1 µl iScript 
reverse transcriptase enzyme. The reaction mix was added to 20 µl with nuclease free 
H2O. The reverse transcription was done using the MJ Research PTC-200 Thermal 
                                                       Unraveling the pathology of different disease severities  
 
 
 
81 
Cycler (Biozym Diagnostics) using the steps shown in table 16. Afterwards cDNA 
concentration (ng/µl) was measured using the nanodrop and diluted in H2O to 250 ng/µl. 
The samples were stored at -20 °C. 
Table 16: Steps and condition of the iScript program 
Cycle Step Temperature Time 
Priming 
Reverse Transcription 
Inactivation 
25 °C 
46 °C 
95 °C 
10 minutes 
20 minutes 
1 minute 
3.3.5. PCR and DNA electrophoresis 
The PCR was used to amplify specific gen regions of interest. For the validation of mutated 
genome sequences genomic DNA (gDNA) was isolated from the cells (see 3.3.2). To analyze 
the presence and quantity of gene expression for specific marker genes RNA was isolated, 
reverse transcription (RT) performed and cDNA generated (see 3.3.3). 1 PCR reaction mix 
contained 2,5 µl of tag polymerase buffer comprising 10mM MgCl2, 5 µl of dNTPs (100mM, 
25mM each dNTP, see table 8), 1 µl primer (see table 12), 1 µl DNA (250 ng/µl) and 0,25 µl 
tag polymerase added to 25 µl total volume with nuclease free H2O. The reaction was done 
using the MJ Research PTC-200 Thermal Cycler (Biozym Diagnostics) using the steps shown 
in table 17. 
Table 17: Reaction conditions RT PCR 
Cycle Step Temperature Time Cycles 
Initial denaturation 
Denaturation 
Annealing 
Extension 
95 °C 
95 °C 
55-65 °C 
72 °C 
30 seconds 
30 seconds 
1 minute 
30 seconds 
1 
35-45 
35-45 
35-45 
To separate the target DNA amplicons from other PCR components, electrophoresis was 
performed using a 1% Agarose gel containing 20,000X pegGreen DNA and RNA binding dye 
(Peqlab). The PCR products were mixed with 6X loading dye and pipette into the gel. To 
determine the DNA fragment size a 100 bp DNA ladder were loaded, and the gel was placed 
inside the electrophoresis chamber with 1X TAE buffer. To separate the fragments 100 V and 
400 mA were applied for 50 min. Afterwards PCR bands were revealed using the UV light lamp 
and if necessary isolated from the agarose gel using the Gel Extraction Kit (peqGOLD). 
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3.3.6. Quantitative protein assessment 
For the detection of LIS1 protein levels western blot analyzes were performed using the 
blotting system from Bio-Rad. 
3.3.6.1. Sample collection and lysis 
2D progenitors or iPS cells were washed with ice-cold PBS, scraped off into 1 ml PBS using a 
cell scrapper and collected via centrifugation at 800 xg for 4 min. The cell pellets were lysed in 
lysis buffer (50 mM Tris-HCl pH 7.4, 50 mM NaCl, 1 mM EDTA, 1% Triton X-100) containing 
pierce protease inhibitor mini tablet (1 tablet per 10 ml, Thermo Fisher) and pierce phosphatase 
inhibitor mini tablet (1 tablet per 10 ml, Thermo Fisher) for 1 h on ice. Subsequently, cell debris 
was pelleted by centrifugation at 12,000 xg for 10 min. The supernatant containing the proteins 
were transferred into a new 1,5 ml Eppendorf tube and used for protein concentration 
measurements using the Bicinchoninic acid (BCA) protein assay kit (ThermoFischer). 
3.3.6.2. BCA protein assay 
The BCA protein assay is a widely used method for protein concentration determination, which 
uses the reduction of copper (II) sulfate (Cu2+) to CU1+ by protein in an alkaline medium. The 
pierce BCA protein assay kit (Thermo Fisher) provides 2 components necessary to perform this 
reduction reaction and absorption measurements containing BCA, sodium carbonate, sodium 
bicarbonate, sodium tartrate and CU2+. The protein amount is proportional to the amount of 
reduced CU2+ and 2 molecules of BCA form with each CU1+ ion a purple colored complex that 
intensively absorbs light at a wavelength of 562nm. Concluded, can the protein concentration 
be measured by the absorption spectra. The exact steps were performed according to the 
manufacturer’s instructions (Thermo Fisher). 
3.3.6.3. SDS-PAGE 
To separate the proteins according to their mass sodium dodecyl sulfate–polyacrylamide gel 
electrophoresis (SDS-PAGE) was performed. SDS acts as a surfactant covering the proteins 
intrinsic charge properties. For immunoblotting, 30-50 μg of protein were boiled in 6x SDS 
sample buffer for 5 min at 95 °C. Lysates were put on 12 % SDS-PAGE gels (see table 8 for 
information about the buffers used) and separated using the blotting system from Bio-Rad with 
the PowerPac HC power supply for SDS PAGE (40 V the first 10 min, then 120 V until loading 
dye runs out the gel). To transfer proteins from the gel on a membrane semi-dry western blotting 
was performed. 
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3.3.6.4. Semi-Dry western blotting and band detection 
The semi-dry western blot was done using the trans-blot turbo transfer system (Bio-Rad) for 45 
min at 20 V and 10 A. In between the electrodes the “blotting sandwich” was prepared from 
down to top as follows: 6 layers of wypall-hydroknit wipes (Kimberly-Clark), 0,2 µl 
nitrocellulose membrane (GE Healthacare Life Science), SDS-PAGE gel and again 6 layers of 
wypall-hydroknit wipes. All components were socked in blotting buffer (see table 8) for 10 sec 
before assembly. Following blotting the membrane was put into a 50 ml tube containing 2,5 ml 
of 5 % purified BSA (Sigma-Aldrich) in PBS for blocking on a rolling mixer (sustainable lab 
instruments) for 1 h. In the next step the membrane was incubated over night at 4 °C with the 
primary antibody diluted according to the manufacturer’s instructions (see table 13) in TBS 
(see table 8). The next day the membrane was washed 2 times with TBST for 10 min and 1 time 
with TBS for 10 min. Then the secondary antibody (DyLightTM Conjugate antibody) was 
diluted according to the manufacturer’s instructions (see table 14) in TBS. After subsequent 
washing the protein band detection was done using the odyssey imaging system from Li-cor. 
3.4. Quantification and statistics 
To have persuasive data and make conclusive assumptions it is necessary to put observed 
phenotypes in numbers and deliver trustworthy statistics. The organoid technology is a very 
young research field and reliable quantitative assessment protocols did not exist when I 
started my PhD project in 2017. Due to this, I developed complex quantification protocols 
for different organoid VZ structure parameters to precisely assess cortical development in 
a dish (published in Iefremova et al. 2017, see results 4.1). 
3.4.1. Plane of cell division analysis 
The orientation of the plane of cell division plays a crucial role during corticogenesis. 
Consequently, the mitotic planes were analyzed by marking dividing cells 
immunocytochemically for p-VIMENTIN (p-VIM) and the mitotic spindle with TPX2 in 20 
μm thick organoid sections. The orientation of the mitotic spindle of aRG cells were 
investigated in at least 5 different VZ structures per organoid in relation to the prospective VZ 
surface. This quantification method was established by Vira Iefremova and George Manikakis. 
3.4.2. Statistical analysis 
Quantitative data was generated in at least triplicates and tested for gaussian distribution using 
the Kolmogorov-Smirnov-Test. The Levene-test was applied to test for homogeneity of 
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variances. If the data was characterized by gaussian distribution one-way-Anova was used to 
determine whether a significant difference exists between groups and can be termed significant 
(*p < 0.05, **p < 0.01, ***p < 0.001). If the Kolmogorov-Smirnov-Test or the Levene-Test 
were significant, the assumption of homogeneity of variances and gaussian distribution was 
hurt and the significance was determined using Kruskal-Wallis-Test and Post-Hoc-Test (see 
appendix statistics). Means and standard deviation (s.d.) were computed. All results presented 
as bar graphs show mean +/- s.d.. 
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4. Results 
To decipher the consequences of the diverse LIS1 mutations on human corticogenesis and test 
the sensitivity of our 3D organoid in vitro cell culture system to mirror disease severities a 
LIS1-lissencephaly patient iPS cell cohort was established, a forebrain-type organoid protocol 
was developed and quantitative assessment protocols were designed to sensitively detect fine 
differences. Furthermore, molecular explorations were conducted to analyze severity-specific 
pathology and specific substances were identified to rescue observed phenotypic alterations. 
Moreover, the consequences of the particular mutations on LIS1 folding and stability were 
elucidated. To decipher pathological gene expression alterations at later developmental stages 
transcriptional profiling was performed. The results are presented within this section. 
4.1. Generation of a LIS1-lissencephaly patient iPS cell cohort covering the complete 
lissencephalic severity spectrum  
The LIS1-patient iPS cell cohort was established by Sendai virus-based reprogramming of 
fibroblasts and PBMCs (see 3.1). The cohort comprised female and male patients between the 
age of 3 and 18 years with different severe brain alterations ranging from Dobyns grade 5 to 1  
(Dobyns W.B., 1999) (see 2.1 and table 1). To quality control the generated iPS cell lines 
pluripotency stainings, snp-analysis and mutational validation by sequencing were performed. 
4.1.1. Generated iPS cell lines express pluripotency transcription factors 
In 2007 Takashi et al. (Takahashi et al. 2007) opened a completely new perspective for patient- 
and disease specific research by introducing the induction of pluripotent cells from adult human 
fibroblasts. The ability to manipulate and reverse cell fate to generate iPS cells relies on the 
defined mix of 4 transcription factors including OCT 3/4, SOX 2, KLF 4 and CMYC. Following 
the introduction of those 4 factors into the LIS1-patient PBMCs and Fibroblasts, the generated 
iPS cell lines were quality controlled for the expression of pluripotency factors by 
immunocytochemical analysis including SOX 2 and OCT 3/4, which are important 
transcription factors for the promotion of self-renewal of undifferentiated stem cells, NANOG 
(HOMEOBOX PROTEIN) a transcription factor important for the suppression of the 
expression of cell fate determining factors and STAGE-SPECIFIC EMBRYONIC ANTIGEN 
3 (SSEA3), a cell surface glycosphingolipid, which is important for cell signaling and specific 
for mammalian pluripotent stem cells. All generated iPS cell lines showed a positive 
immunofluorescence signal for SOX 2, OCT 3/4, NANOG and SSEA 3 (Figure 7). 
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Figure 7: Immunocytochemical analysis of iPS cell pluripotency. All generated iPS cell lines (2 clones per 
line) were quality controlled for pluripotency including immunocytochemical staining`s for the pluripotency 
markers SOX 2 and OCT 3/4, which a transcription factors crucial for self-renewal of undifferentiated stem cells, 
NANOG, a transcription factor important for the maintenance of pluripotency through the suppression of cell 
determination factors, and SSEA 3, a glycosphingolipid, which is specifically on the cell surface of pluripotent 
stem cells. Scale bars, 50 µm. 
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4.1.2. Generated iPS cell lines have tripotente differentiation capacity 
Pluripotency is defined by the ability of a cell to give rise to all cell types that make up the 
living body. To test the differentiation potential of the iPS cell lines in vitro into the 3 germ 
layers, EBs were generated and plated for spontaneous differentiation for 4 weeks without any 
fate determining signaling molecules. Figure 8 shows that the differentiation led to 
heterogenous cell populations containing a variety of cell identities. To identify the cell lineages 
immunocytochemical staining`s were performed for SMA, which is exclusively expressed by 
mesodermal lineage cells, AFP, a marker for endodermal cells and TUBB3 for the identification 
of ectodermal lineage cells. All generate iPS cell lines showed tripotente differentiation 
capacity (Figure 8 A-F). 
 
Figure 8: Assessment of tripotente differentiation capacity into the 3 germ layers endoderm, mesoderm and 
ectoderm. (A-C) Representative brightfield recordings of 4 weeks differentiated iPS cells without morphogenic 
cues from 1 mild LIS1-patient patient line (P2.1) (A), 1 moderate LIS1-patient patient line (P4.2) (B) as well as 
from 1 severe LIS1-patient line (P5.2) (C). (D-F) Representative immunocytochemical recordings for the 
mesoderm marker smooth muscle actin (SMA) (D), the endoderm marker α-fetoprotein (AFP) (E) and the 
ectoderm marker ß-III-tubulin (TUBB3) (F). Scale bars 20 µm. 
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4.1.3. Generated iPS cell lines have a normal karyotype 
Since the reprogramming of somatic cells became a wide used tool to study development and 
disease, multiple studies have concentrated on the analysis of chromosomal stability during 
reprogramming and iPS in vitro cell culture using high-resolution genome-wide approaches 
(Chia et al. 2017; Taapken et al. 2011). Due to the high-frequent accumulation of genomic 
alterations in iPS cells, it is particularly important to continuously monitor the genomic integrity 
of generated and cultured iPS cells. Such genomic alterations may influence the developmental 
potential and can lead to non-disease-associated phenotypes as well to malignant capacity of 
the cell lines. Within this project high density snp analysis were performed to monitor the 
genomic status of the LIS1-patient iPS cell lines and detect possible chromosomal copy number 
variations (CNV) (Figure 9). Figure 9 shows for all generated iPS line the B allele frequents 
(BAF) and the Log R ratio (LRT) graph for every chromosome. To generate such graphs the 
allele-specific signal intensities from genotyping arrays were integrated with information on 
SNP spacing and SNP allele frequencies by a hidden Markov model (HMM) algorithm. BAF 
is a measurement of the allelic intensity ratio, the value should be around 0,5. The LRR is a 
normalized measurement of total signal intensity. All generated iPS cell lines showed BAF and 
LRR values in non-concerning ranges (Figure 9). The chromosomal integrity was given. When 
a deletion CNV would have occurred, the values would cluster around 0 or 1. In case of a 
duplication the values would have been around 0, 0,33, 0,67 and 1. The mathematical data 
integration and graph visualization was performed by Josef Frank from the Department of 
Genetic Epidemiology headed by Prof. Rietschel.  
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Figure 9: Validation of karyotypic integrity. All generated iPS cell lines were high resolution single-nucleotide 
polymorphism (snp) analyzed for chromosomal integrity. The graphs illustrate the B allele frequents (BAF) and 
the Log R ratio (LRT) for every chromosome. BAF is an allelic intensity ratio, the value should be around 0,5. 
When a deletion chromosomal copy number variation (CNV) occurred the value clusters around 0 or 1. When a 
duplication is present the values are around 0, 0,33, 0,67 and 1. The LRR is a normalized measurement of total 
signal intensity. When a deletion CNV happened the LRR values for snp markers in this region decreased and 
when a duplication is present the values increased. 
4.1.4. Generated iPS cell lines harbor the respective patient-specific LIS1 mutations  
One major goal of this project is to elucidate the consequences of patient-specific LIS1 
mutations. Consequently, it was mandatory to validate the different LIS1 mutations in the 
generated iPS cell lines. To do so, the gene regions of interest were amplified by PCR, purified 
by DNA electrophorese and Gel extraction and then sanger sequenced. Each LIS1-patient line 
harbored the respective patient-specific LIS1 mutation (Figure 10 A-G). The 2 mild LIS1-
patient lines (mild LIS1-patient P1 and P2) had a base exchange from cytosine to thymine 
(T>C) on position 569-10 in the coding sequence (c.569-10T>C) (Figure 11 A, B). The 
moderate line P3 had a deletion of nucleotide 13 in the coding sequence (c.13del) (Figure 10 
C) and the moderate line P4 was characterized by a deletion of exon 11 (del Ex11) (Figure 10 
D). Due to this deletion the validation of del Ex11 was done by whole exome sequencing. The 
3 severe LIS1-patient lines (severe LIS1-patient) had different point mutations in the coding 
sequence. The severe LIS1-patient line P5 had a base exchange from guanine to adenine at 
position 1002+1 in the coding sequence (c.1002+1G>A) (Figure 10 E). The second severe 
LIS1-patient line P6 had a base exchange at position 531 from guanine to cytosine in the coding 
sequence (c.531G>C) (Figure 10 F) and the third severe LIS1-patient line P7 had a base 
exchange at 445 from cytosine to thymine in the coding sequence (c.445C>T) (Figure 10 G). 
The sequencing of the 2 mild LIS1-patient lines and the 2 moderate LIS1-patient lines were 
performed at the pediatric neurology, Necker Enfants Malades university hospital/ institute 
imagine (INSERM) by Camille Maillard. 
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Figure 10: Validation of the respective patient-specific LIS1 mutation in the generated iPS cell lines. (A-G) 
Electropherograms generated by sanger sequencing. The mild LIS1-patient lines P1 and P2 carry a point mutation 
at c.569-10 T>C (A,B), the moderate LIS1-patient P3 have a deletion at position 13 in the coding sequencing 
causing a frameshift in the following sequence (C), the moderate LIS1-patient P4 has a deletion of exon 11 (D), 
the severe LIS1-patient P5 a point mutation at c.1002+1G>A (E), the severe LIS1-patient P6 a point mutation at 
c.531 G>C (F) and severe LIS1-patient P7 a point mutation at c.445 C>T (G). The sequencing for mild 1, 2 and 
moderate 1, 2 was done by Camille Maillard at the hospital Neckar Enfants Malades in France explaining the 
different illustration when comparing A-D with E-G (Sanger sequencing method was performed in the same way, 
except the exon 11 deletion of 732 was validated by whole exome sequencing). 
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4.2. Development of a 3D cerebral forebrain-type organoid protocol for the analyzes of 
early aspects of human brain development  
In order to test the capacity of cortical organoids to recapitulate disease severities a standardized 
organoid protocol was developed (outlined in Figure 11 A, puplished in Krefft et al. 2018 and 
Iefremova et al. 2017), which leads to highly homogenous cortical forebrain-type organoid 
cultures. During the time course of the protocol there were several opportunities to quality 
control the generated organoid batches, defined as 'go' (continue the differentiation process) 
and 'no-go' (suboptimal cultures, it is recommended to terminate the batch) criteria (Figure 11 
A-K). The first critical step in generating forebrain-type organoids was to start with high-quality 
monolayer iPS cell cultures without differentiated cells (Figures 11 B, C). In the second step, it 
was crucial to use the right cell number for EB formation (see 3.1.9), which was dependent on 
the cell line used. In general, a smaller cell number led to more vital organoids. The first detailed 
inspection of the iPS cells aggregates was performed on day 2. At this stage, the aggregates had 
formed compact cell buds with smooth edges ('go') whereas irregular appearing aggregates or 
aggregates with cavities were discarded ('no-go') (Figures 11 D, E). The next quality control 
step was performed at day 10 of the protocol. At this time point, the cell aggregates had smooth 
and optically translucent tissue on the outer surface representing induction of neuroectoderm 
('go') whereas the absence of such tissue indicates suboptimal neural induction ('no-go') 
(Figures 11 F, G). Only those aggregates that exhibit a translucent surface (Figure 11 F) were 
embedded into GT. Once embedded, the cortical organoids developed continuous 
neuroepithelial VZ structures, which expanded quickly over time Figure 11 H, J ('go'). In case 
the organoids did not develop polarized neural ectoderm ('no-go' as illustrated in Figure 11 K) 
3D cultures were discarded. Due to constant advances in the field of 3D cell culture the 
published protocol was in the following years further improved by adding specific substances 
for cell type maturation from day 35 on (see 3.1.9). 
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Figure 11: Schematic overview of the organoid protocol and illustration of 'go' and 'no-go' criteria. (A) 
Schematic overview of the protocol. CI medium: cortical induction medium; CD: cortical differentiation medium. 
(B-C) Image of an optimal 90% confluent iPS cells monolayer culture (B) and a non-suitable iPS cell culture 
exhibiting differentiation (C). (D-E) An iPS cells aggregate optimal in size, cell density, and surface appearance 
(D) and two 'no-go' cell aggregates, which exhibited either cell spares cavities (E, upper aggregate) or irregular 
edges (E, lower aggregate) 2 days following cell aggregation. (F-G) Cell aggregates exhibited translucent and 
smooth edges (F) and cell aggregates, which lacked optical clearing (G). The yellow line visualizes the area of 
interest. (H-K) An optimal organoid with continuous neuroepithelial ventricular zone structures (H, J) and an 
organoid that failed to develop radially organized neuroectoderm (I, K) imaged at day 15 and day 20, respectively. 
Scale bars, (B-C) 500 μm; (D-K) 200 μm. Figure published in JoVE (Krefft et al., 2018). 
The established protocol led to highly homogenous organoid batches (Figures 12 A-C), with ≥ 
90% homogeneity in polarized neural ectoderm formation within and across batches (Figure 12 
C). 
                                                       Unraveling the pathology of different disease severities  
 
 
 
95 
 
Figure 12: Homogeneity and reproducibility of the forebrain-type organoid protocol. (A-B) Representative 
bright-field images of organoids from 1 batch at day 15 (A) and day 26 (B). (C) Quantitative analyzes of organoids 
at day 20. Organoids which display at the outer surface a neuroepithelium, recognizable in bright-field as optically 
clear superficial tissue with a clear border and evidence of radial cellular architecture were quantified (n = 3 per 
iPS cell line with at least 16 organoids per experiment). Scale bars, A, B 500 μm. Error bars ± SD. Figure published 
in JoVE (Krefft et al., 2018). 
To validate the telencephalic identity of the organoids immunofluorescence and PCR analysis 
were performed at day 20. Figure 13 shows that organoid neuroepithelial VZ structures 
expressed the neural stem cell marker SOX 2 (Figure 13 B, D), the forebrain markers PAX 6 
and OTX 2 (Figure 13 C, E) and the dorsal cortical marker EMX 1 (Figure 13 F). Cell death 
was present in the inside of the organoids, which was normal and did not affect the development 
of cortical tissue. In addition, 3 organoids were used to assess the homogeneity of the protocol 
by gene expression analyzes using RT-PCR (performed by Ammar Jabali). The forebrain-type 
organoids showed expression of the dorsal forebrain markers (FOXG 1, OTX 2, EMX 1), while 
expression of midbrain marker (FOX 2, PAX 5) and hindbrain marker (HOXB2, HOXA4, 
HOXB4 and HOXB6) were not detectable (Figure 13 K). 
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Figure 13: Validation of forebrain-type organoids at day 20. (A-F) Immunocytochemical characterization of 
organoids. Organoids organize in multiple neuroepithelial ventricular zone structures (A, counterstained with 
DAPI). Stratified organized cells within the neuroepithelial ventricular zone structures expressed the neural stem 
cell marker SOX 2 (B, D), the forebrain markers PAX6 (C, D) and Otx2 (E), as well as the dorsal forebrain marker 
Emx1 (F). (K) RT-PCR analysis for the region-specific transcription factors at day 20 of 2 independent sets of 
organoids derived from 2 different iPS cell lines, performed by Ammar Jabali. FB: fetal brain control; AB: adult 
brain control. Scale bars, A-D 200 μm; E-I 10 μm. Figure published in JoVE (Krefft et al., 2018). 
Taken together the established organoid protocol led to highly homogenous forebrain-type 
organoid cultures, which could be used to test the utility of 3D system to model different disease 
severities. To be able to sensitivity detect severity-dependent phenotypic differences 
quantitative assessment protocols were designed. 
4.3. Development of quantitative assessment protocols for 3D cerebral organoids 
To have persuasive data and make conclusive assumptions it is necessary to put observed 
phenotypes in numbers and deliver trustworthy statistics. The organoid technology is a 
young research field and reliable quantitative assessment protocols were not published 
when I started my PhD project in 2016. Due to this, I developed complex quantification 
protocols for different organoid VZ structure parameters to precisely assess cortical 
development in a dish and to compare organoids derived from different disease severities, 
patients and batches (published in Iefremova et al. 2017). 
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4.3.1. Analyzing ventricular zone structure dimensions 
Each organoid consists of many cortical VZ structures and each of those VZ structure is a model 
for cortical development mimicking neural tube-like morphology. Consequently, it can be said 
that each organoid VZ structure is a technical repeat when it comes to the quantitative 
assessment of cortical organoids and provides valuable information when analyzing 
corticogenesis in health and disease. To assess the structures in detail, I determined multiple 
parameters, which enabled thorough comparison of VZ dimensions between disease severities, 
patient iPS cell lines and organoid batches. The parameters included the VZ structure diameter 
(A), the length of apical (B) and basal membrane (C), the ventricle-like area (D), the VZ 
structure tissue area (E) and the total VZ structure area (F) (Figure 14 A-E). To perform the 
quantifications, organoid slices were stained with DAPI to visualize VZ structure dimensions. 
Images were acquired with the inverted Leica DMIL LED Microscope with the Thunder 
imaging software (Leica) and analyzed using FIJI. For the quantification of the VZ structure 
diameter 3 length measurements forming a right-angle fan area pointing to the nearest pial 
surface, at 0, 45 and 90 degree were pooled (Figure 14 A). The VZ structure tissue area was 
defined as the ratio of the total VZ structure minus the ventricle-like area (Figure 14 E). 
Calculations and data tablets were done in Microsoft Excel. 
 
                                                       Unraveling the pathology of different disease severities  
 
 
 
98 
 
Figure 14: Schematic illustration of ventricular zone structure parameters. (A-F) Each ventricular zone (VZ) 
structure contained important information about the cytoarchitectural development of each neural tube-like 
structure. The VZ structure diameter was determinant by 3 length measurements (µm) forming a right-angle fan 
area pointing to the nearest pial surface, at 0, 45 and 90 degree (A). The apical (B) and basal (C) membrane length 
were determined by the diameter of VZ structure and ventricle-like structure. The other 3 parameters were area 
measurements (µm2) for the VZ structures including the ventricle-like area (D), the VZ structure tissue area (E) 
and the total VZ structure (F). All parameters taken together enabled a reliable assessment of VZ structure 
dimensions and consequently a detailed comparison between organoid batches, patients and severities. 
4.3.2. Quantification of astral tubulin strand densities 
For the determination of stabilizing astral α-tubulin density, organoid slides were stained with 
acetylated ALPHA-TUBULIN (AC-TUB). Images were acquired with the inverted Leica 
DMIL LED Microscope with the Thunder imaging software (Leica). To determine the signal 
to noise ratio a plot profile line (Figure 15 A, yellow lines) was drawn into the AC-TUB 
recordings into the apical (3third percentile, apical side) and basal (66th percentile, basal side) 
region of the VZ structure using FIJI (Figure 15 A-B). The plot profile was pasted into a self-
designed Excel file, which contained mathematical formulas to calculate the mean strand 
density. In the first step, the measurements of every second pixel were considered, because 
every strand was about 2 pixels wide. Then the background signal was determined, and the file 
automatically counted the signal peaks above the background signal (Figure 15 B, peaks above 
the red line). The number was normalized against the total length of the plot profile line 
resulting in a mean density of strands crossing the line (*100 = %). 
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Figure 15: Quantification protocol of acetylated -TUBULIN strand density. Organoid slices were stained 
for ACETYLATED -TUBULIN (AC-TUB) and the signal plot profile was drawn into the apical and basal 
ventricular zone (VZ) region using FIJI. The Plot profile was pasted into a self-designed Excel file, which 
contained mathematical formulas to calculate the mean strand density. In the first step the measurements of every 
second pixel were considered, because every strand was about 2 pixels wide. Then the background signal was 
determined, and the file automatically gave the number of signals on the plot profile line, which were above the 
background signal. The number was normalized by the total length of the plot profile resulting in a mean density 
of strands crossing the line (*100=%). Scale bar, 20 μm. 
4.3.3. Determination of apical membrane alignment diameter 
Each VZ structure is surrounded by the apical membrane, which contains many important 
proteins and is important for organoid niche integrity for correct morphogenic signaling. 
Consequently, a quantification protocol for the assessment of apical membrane disruption was 
established by measuring the membrane thickness at 90°, 180°, 270° and 360° to the VZ 
structure center using FIJI (Figure 16). The mean value of those 4 measurements were analyzed 
as the mean disruption diameter of apical membrane alignment. The membrane alignment was 
visualized by N-CAD staining. The data was analyzed using Microsoft Excel. 
 
Figure 16: Apical membrane diameter quantification. Organoid slices were stained for DAPI for ventricular 
zone structure tissue visualization and N-CADHERIN (N-CAD) to analyze the apical membrane. The membrane 
thickness was measured at 90°, 180°, 270° and 360° to the ventricular zone structure center using FIJI. Scale bar, 
20 μm. 
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4.4. Cerebral organoids derived from LIS1-patients reflect disease severity in the 
degree of alterations in cytoarchitecture and neurogenesis 
The alteration of gyrification is one hallmark of lissencephalic brains. In terms of LIS1-
lissenephaly this hallmark is differentially pronounced without known cause. For this study 7 
patients were selected from a LIS1-patient cohort comprising 63 cases, which cover the whole 
spectrum of gyrification alterations of LIS1-lissencephaly ranging from Dobyns grade 5 (mild) 
to 1 (severe) (Barkovich et al. 2012a). Each patient harbors a different molecular characterized 
heterozygous mutation in the LIS1 gene (Table 1). One example magnetic resonance image 
(MRI) for control and each severity class (mild, moderate and severe) is depicted in Figure 17 
A. Health human brains are characterized by manifold gyri and sulci. Whereas mild LIS1- 
patients often have a reduced number of gyri and sulci (Figure 17 A, mild LIS1-patient patient 
P1). In contrast, moderate LIS1-patients often show a gradient of severity with anterior 
pachygyria and posterior agyria (Figure 17 A, moderate LIS1-patient patient P3) and LIS1-
patients suffering from severe disease are characterized by complete agyria (Figure 17 A, severe 
LIS1-patient P7). One major question which should be deciphered within this project was, 
whether the organoid system is sensitive enough to reflect those disease severities. To approach 
this question the generated LIS1-patient iPS cell cohort and 6 age and gender matched controls 
were subjected to the developed 3D cerebral organoid protocol and 3D tissues were analyzed 
with the designed quantitative assessment methods. The organoid morphology was specific for 
the LIS1-patients severity (Figure 17 B). While organoids from control and LIS1-patients with 
mild disease gradually developed smooth neuroepithelial loop-like structures which expanded 
over time, organoids from patients with moderate disease appeared to be generally smaller in 
size (Figure 17 B). In contrast, organoids from severe LIS1-patients did not seem to be smaller 
compared to control derived organoids but developed irregular edges with single cells growing 
out of the structures (Figure 17 B, magnification on the right). Following whole-tissue clearance 
and immunohistochemical staining I found that the organoids derived from patients with severe 
disease were covered by a large belt of neurons, which was less abundant in mild and moderate 
conditions and nearly absent in control derived organoids (Figure 17 C). This phenomenon was 
also apparent following cry-sectioning and immunohistochemical staining (Figure 17 D). Next, 
I analyzed the architecture of the neuroepithelial VZ structures within the organoids in detail. 
Organoids derived from healthy individuals exhibited multiple large cortical VZ structures at 
day 20. Whereas the LIS1-patient organoids displayed a size reduction of VZ structures (Figure 
17 E).  
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Figure 17: Organoid morphology is specific for LIS1-patient`s severity. (A) LIS1-patient MRI recordings 
provided from Dr. Nadja Bahi-Buisson from the hospital Neckar Enfants Malades (mild LIS1-patient patient 1, 
moderate LIS1-patient patient 1 and severe LIS1-patient 3). (B) Representative brightfield field (BF) recordings 
of control C1.2, mild LIS1-patient P1.1, moderate LIS1-patient P3.1 and severe LIS1-patient P5.1 patient derived 
organoids at day 20. (C) Representative light sheet microcopy (LSM) recordings of whole-tissue cleared control 
2.1, mild LIS1-patient P1.1, moderate LIS1-patient P3.2 and severe LIS1-patient P5.1 derived organoids at day 20 
stained for ß-III Tubulin (TUBB3). (D) Representative TUBB3 recordings of control C4.1, mild LIS1-patient P2.1, 
moderate LIS1-patient P4.1 and severe LIS1-patient P5.2 patient derived organoids at day 20. (E) Representative 
DAPI recordings of ventricular zone structures of control C1.2, mild LIS1-patient P1.1, moderate LIS1-patient 
P3.1 and severe LIS1-patient P5.1 patient derived organoids at day 20. Scale bars, (A) 5 cm, (B, C) 200 µm (D, 
E) 50 µm. 
To that end, the VZ diameter, ventricle area, length of the apical and basal membrane, total VZ 
area and VZ tissue area were quantified (Figure 18 A-F). Here I found a significant reduction 
of all parameters in organoids derived from patients with moderate and severe lissencephaly as 
well as a significant reduction in 3 out of the 6 parameters analyzed in organoids derived from 
patients with mild lissencephaly compared to controls (Figure 18 E).  
                                                       Unraveling the pathology of different disease severities  
 
 
 
103 
 
Figure 18: Ventricular zone parameter quantification reveals a gradually decrease of tissue dimensions with 
increasing LIS1-patient severity. (A-F) Quantification of ventricular zone (VZ) structure diameter, ventricle 
area, length of apical membrane, length of basal membrane, VZ structure tissue and total VZ structure area in 
control- and LIS1-patient derived organoids at day 20. control C1.2 N=38, control C4.2 N=33, mild P1.1 N=33, 
mild P1.2 N=19, mild P2.1 N=13, mild P2.2 N=17, moderate P3.1 N=20, moderate P3.2 N=19, moderate P4.1 
N=20, moderate P4.2 N=18, severe P5.1 N=61, severe P5.2 N=49, severe P6.1 N=23, severe P6.2 N=48, severe 
P7.1 N=58. Error bars, ±SD. *p < 0.05, **p < 0.01, ***p < 0.001.  
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4.5. Molecular structure analyzes reveal a gradual breakdown of stabilizing astral 
tubulin and cellular organization 
To assess the direct consequences of the patient-specific LIS1 mutations on LIS1 microtubule 
stabilizing function, the stability of the cytoskeleton of aRG cells within the VZ was analyzed 
by acetylated ALPHA-TUBULIN (AC-TUB) staining. Microtubules are a highly dynamic 
system. The acetylation stabilizes the tubulin strands, making them more prone to remodeling. 
Analyzes were performed in cryo-cut and whole-tissue cleared organoids to carefully detect 
cutting artefacts (Figure 19 A-D). The cleared organoids show an overall reduction of AC-TUB 
positive labeled structures with increased disease severity (Figure 19 A). The AC-TUB staining 
in moderate and severe condition could barely be detected in basal regions of the VZ structures, 
whereas in control conditions the staining was sufficient to visualize apical and basal regions 
of cortical structures. When investigating the individual VZ-structures in more detail I found, 
that in control conditions the astral tubulin strands span aligned and in close proximity from the 
apical- (visualized by ARL13b, Figure 19 C) to the basal side (Figure 19 B-D). In organoids 
derived from patients with mild lissencephaly I found a small percentage (around 10 %) of 
tubulin strands not reaching the basal side of the VZ structure (Figure 19 E), whereas in 
organoids derived from patients with moderate disease the tubulin density at the basal side was 
reduced by more than 20% and in organoids derived from severe patients the reduction was 
even more drastic (up to over 50%; Figure 19 E). This collapse of stabilizing cytoskeleton was 
supported by western blot analysis of AC-TUB protein level, which was with increasing patient 
severity progressively reduced in LIS1-patient-derived progenitors. The most drastic reduction 
of AC-TUB protein level was observed in cells derived from severe LIS1-patients compared to 
controls (Figure 19 F). 
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Figure 19: Gradually breakdown of cell stabilizing astral tubulin with increasing LIS1-patient severity. (A, 
B) Representative recordings of cleared and cryo-sectioned organoids from control C4.1, mild P1.1, moderate P3.2 
and severe P5.2 LIS1-patient derived organoids stained for acetylated-α tubulin (AC-TUB) at day 20. (C) 
Representative recordings of ARl13b, a cilia marker, in control C4.1, mild P1.1, moderate P3.2 and severe P5.2 
LIS1-patient derived organoids at day 20. (D) High magnification recordings of AC-TUB stained VZ structures 
in control C4.1, mild P1.1, moderate P3.2 and severe P5.2 LIS1-patient derived organoids at day 20. (E) 
Quantification of apical and basal AC-TUB strand density in control, mild-, moderate- and severe LIS1-patient 
derived organoids. control C1.2 N=12, control C2.1 N=12, control C4.2 N=20, mild P1.1 N=13, mild P1.2 N=13, 
mild P2.1 N=13, mild P2.2 N=15, moderate P3.1 N=13, moderate P3.2 N=12, moderate P4.1 N=12, moderate 
P4.2 N=14, severe P5.1 N=22, severe P5.2 N=20, severe P6.1 N=13, severe P6.2 N=13, severe P7.1 N=12). (F) 
Western blot analyzes of AC-TUB protein level in controls (C1.2, C2.1, C4.1, C4.2 and C5.2), mild- (P1.1, P2.1, 
and P2.2), moderate- (P3.1) and severe (P5.1, P5.2 and P7.1) LIS1-patient derived cortical progenitor cells. Scale 
bars, (A) 200 µm, (B) 20 µm. Error bars, ±SD. *p < 0.05, **p < 0.01, ***p < 0.001. 
As a consequence of VZ destabilization, there was also a cellular disorganization observable 
by performing a hematoxylin-eosin (HE) staining of cryo-cut organoid slices at day 20 (Figure 
20 A). Especially the organoids derived from moderate and even more drastic in severe disease 
displayed random arranged cell bodies with gaps in between cells, whereas in control conditions 
aRG cells arrange well organized, stringed and densely packed within the VZ. In LIS1-patient 
derived organoids derived from mild disease the cellular orientation was predominantly 
comparable to control conditions (Figure 20 A). Together with this gradient of declining 
cellular organization with increasing LIS1-patient severity I also found a disturbed apical 
membrane alignment by performing immunohistochemical staining for N-CAD (Figure 20 B). 
Whereas control organoids exhibit a fine adherent junction belt at the most apical side of 1-3 
µm (measured by the accumulation of N-CAD), this organization was significantly altered in 
organoids derived from patients with severe lissencephaly (more than 10 times increased; 
Figure 20 C). A significant disturbed distribution of N-cadherin was also found in the moderate 
condition (around 20 µm) while in the mild condition a disruption could be detected although 
without significance (around 10 µm). 
                                                       Unraveling the pathology of different disease severities  
 
 
 
107 
 
 
                                                       Unraveling the pathology of different disease severities  
 
 
 
108 
Figure 20: Progressive disruption of cellular organization with LIS1-patient severity. (A) Representative 
recordings of hematoxylin-eosin (HE) recordings of control C4.1, mild LIS1-patient P1.2, moderate LIS1-patient 
P3.1 and severe LIS1-patient P5.1 derived organoids. (B) Representative recordings of cryo-cut organoids from 
control 3.1, mild LIS1-patient P2.1, moderate LIS1-patient P3.2 and severe LIS1-patient P5.1 derived organoids 
stained for N-CADHERIN (N-CAD) at day 20. (C) Quantification of apical disruption diameter in control, mild, 
moderate and severe LIS1-patient derived organoids at day 20. Schematic illustration of how the disruption 
diameter was quantified is illustrated on the right side of the diagram. control C1.2 N=12, control 2.1 N=12, control 
4.2 N=20, mild P1.1 N=13, mild P1.2 N=13, mild P2.1 N=13, mild P2.2 N=15, moderate P3.1 N=13, moderate 
P3.2 N=12, moderate P4.1 N=12, moderate P4.2 N=14, severe P5.1 N=22, severe P5.2 N=20, severe P6.1 N=13, 
severe P6.2 N=13, severe P7.1 N=12. Scale bars 20 µm. Error bars, ±SD. *p < 0.05, **p < 0.01, ***p < 0.001. 
Taken together, the analysis of molecular structures revealed a progressive breakdown of VZ 
structure stabilizing astral tubulin and with that a gradual disruption of cellular organization. 
To determine whether the patient-specific LIS1 mutations impair the microtubule stabilizing 
function of LIS1 protein and by that directedly course the observed phenotypic changes I tested 
whether a microtubule stabilizing agent rescues observed alterations.  
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4.6. Microtubule array stabilization can in part rescue phenotypic alterations 
One major aim of in vitro models is to closely recapitulate in vivo development and associated 
malformations to identify molecular pathomechanisms. Such knowledge about malformation 
and disease-causing mechanisms can help to identify drugs, which counteract developmental 
mistakes. Within this project EpothiloneD, a food and drug administration (FDA)-approved 
macrolide binding to a common binding site on beta-tubulin for strand stabilization was tested 
(Fumoleau et al. 2007; Bollag et al. 1995; Giannakakou et al. 2000). Depending on the applied 
concentration there are 2 main objectives for EpothiloneD treatment. In high concentrations 
EpothiloneD binds in high doses to microtubules, completely stabilizing dynamic processes 
and preventing cell divisions. This utilization finds its relevance predominantly in cancer 
research, where malign cells divide abnormally, to stop harmful cell proliferation. The other 
objective acquires the usage of EpothiloneD in low dosage, to stabilize microtubules without 
affecting cell divisions. Based on LIS1 essentiality for microtubule stability I tested a low 
concentration of Epothilone D (1 nM). To determine whether the patient-specific LIS1 
mutations impair the microtubule stabilizing function of the LIS1 protein and by that directedly 
course the observed phenotypic changes I applied EpothiloneD to LIS1-patient and control 
derived organoids from the start of differentiation (d10) for 5 days. The exposer of patient 
derived organoids to EpothiloneD resulted a significant increase in AC-TUB strand density at 
the basal side of the VZ structures only in LIS1-patient derived organoids, most significant in 
moderate and severe conditions (Figure 21 A, B). In contrast, control organoids were not 
significantly affected by the drug treatment (Figure 21 A, B). This stabilization of VZ structure 
stabilizing astral tubulin also had a positively impact, at least in part, on the cellular organization 
and apical membrane alignment of the LIS1-patient derived cultures (Figure 21 C, D). All LIS1-
patient lines exhibited an alignment recovery of more than 10 % after 5 days of EpothiloneD 
treatment (Figure 21 D).  
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Figure 21: Epothilone D treatment in part rescues LIS1-associated microtubule instabilities stabilizing 
ventricular zone structure architecture. (A) Representative acetylated ALPHA-TUBULIN (AC-TUB) 
recordings of control C3.1, mild- P1.1, moderate- P1.2 and severe P5.1 patient derived organoids treated with 
DMSO or 1nM EpothiloneD. (B) Quantification of apical and basal AC-TUB strand density in DMSO and 
EpothiloneD treated control C3.1 (N=9), control C4.1 (N=9), mild P1.1 (N=9), mild P2.2 (N=9), moderate P3.2 
(N=9), severe P5.1 (N=9), severe P6.1 (N=9) and severe P7.1 (N=9) LIS1-patient derived organoids at day 15. (C) 
Representative N-CADHERIN (N-CAD) recordings of control C3.1, mild P1.1, moderate P3.2 and severe P5.1 
LIS1-patient derived organoids treated with DMSO or 1nM EpothiloneD. (D) Quantification of N-CAD diameter 
expansion in DMSO and EpothiloneD treated control C3.1 (N=10), control C4.1 (N=10), mild LIS1-patient P1.1 
(N=10), mild LIS1-patient P2.2 (N=10), moderate LIS1-patient P3.2 (n=6), severe LIS1-patient P5.1 (N=6), severe 
LIS1-patient P6.1 (N=6) and severe LIS1-patient P7.1 (N=6) patient derived organoids at day 15. Scale bars (A) 
200 µm, (A, C) 20 µm. Error bars, ±SD. *p < 0.05, **p < 0.01, ***p < 0.001.  
Moreover, the recue effect on VZ structure cellular organization resulted in a much more clear 
and homogeneous generation of neuroepithelial loop structures and a marked decrease neuronal 
belt surrounding the structures (Figure 22 A). When quantitatively assessing the neuroepithelial 
structures following EpothiloneD treatment with the developed VZ structure dimension 
quantification protocol, an increase of nearly all VZ parameters in organoids from LIS1-patients 
was observed (Figure 22 B). Organoids from patients with severe disease exhibited a most 
significant enlargement of VZ structures in nearly all parameters most drastic for the VZ 
diameter. Organoids derived from mild and moderate disease show significant differences to 
the DMSO control in individual parameters while none of the parameters were significantly 
altered in control-derived organoids (Figure 22 B). Nonetheless, Epothilone D treatment was 
not sufficient to fully diminish the observed phenotypic alterations in LIS1-patient derived 
organoids, especially not in those derived from patients with severe disease. Consequently, I 
hypothesized that additional pathomechanisms had to play into disease pathology.  
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Figure 22: Microtubule array stabilization by Epothilone D partially rescues ventricular zone structure 
dimensions in LIS1-pateint derived organoids. (A) Representative DAPI recordings of control C3.1, mild- P1.1, 
moderate- P1.2 and severe- P1.1 LIS1-patient derived organoids treated with 1nM Epothilone D (EpothiloneD) 
and DMSO control. (B) Ventricular structure (VZ) parameter quantification of EpothiloneD and DMSO control 
treated control- C3.1, control- C4.1, mild- P1.1, mild- P2.2, moderate- P3.2, severe- P5.1, severe- P6.1 and severe- 
P7.1 LIS1-patient- derived organoids at day 15. control C3.1 DMSO N=16, control C3.1 CHIR N=21, control 
C4.1 DMSO N=10, control C4.1 CHIR N=18, mild P1.1 DMSO N=16, mild P1.1 CHIR N=24, mild P2.2 DMSO 
N=12, mild P2.2 CHIR N=11, moderate P3.2 DMSO N=14, moderate P3.2 CHIR N=12, severe P5.1 DMSO N=14, 
severe P5.1 CHIR N=11, severe P5.2 DMSO N=16, severe LIS1-patient P5.2 CHIR N=11, severe P6.1 DMSO 
N=10, severe P6.1 CHIR N=10, severe P7.1 DMSO N=11, severe P7.1 CHIR N=11. Scale bars (A) 200 µm. Error 
bars, ±SD. *p < 0.05, **p < 0.01, ***p < 0.001. 
My colleagues and me recently reported for MDS that alterations of the cortical cytoarchitecture 
can lead to non-cell-autonomous disturbance of WNT-signaling (Iefremova et al. 2017). Thus, 
I next questioned whether WNT-signaling might be also impacted in the LIS1-patient derived 
organoids. 
4.7. Only Organoids derived from LIS1-patients with severe disease display a non-
random aRG cell division switch due to niche-dependent WNT-signaling alterations 
WNT-signaling is a major choirmaster during corticogenesis. During forebrain development 
WNT-signaling from the cortical hem is important for the regulation of the expansion and cell-
type specification of aRG cells. My colleagues and me recently reported for MDS that 
alterations of the cortical cytoarchitecture can lead to a non-cell-autonomous disturbance of 
WNT-signaling (Iefremova et al. 2017). I thus wondered whether WNT-signaling might be also 
impacted in my LIS1 patient derived organoids. To monitor the onset and localization of WNT-
target gene activity in patient and control derived organoids WNT-GFP iPS cell reporter lines 
were generated (pRRL.sin-18.ppt, Addgene plasmid #14715, Reya et al. 203; for virus 
generation see 3.3.1; for virus transduction see 3.1.6). The reporter lines expressed GFP under 
activation of WNT-signaling. The GFP was cloned downstream of a LEF-1/ TCF responsive 
promotor containing 3 LEF-1/ TCF binding motifs and a TATA box. When WNT-signaling 
was active in aRG cells LEF-1/ TCF were expressed and activated the expressions of GFP in 
correlation with WNT-signaling activity. Organoids derived from controls exhibited VZ 
structures with a strong GFP signal along the apical lining (Figure 23 A). In contrast, the apical 
lining of VZ-structures from LIS1-lissencephaly patients showed a gradual decrease in WNT-
target gene activity with increased disease severity, most significant in organoids derived from 
severe patients (Figure 23 A, B). These WNT-signaling alterations were only observable within 
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the VZ structures, close to the apical membrane in patient derived organoids, but not in cells 
with neuronal morphology outside the VZ structures (Figure 23 A). I further speculated whether 
the perturbed niche-dependent WNT-signaling results in a premature non-random switch of 
aRG cell division from progenitor cell expansion to neurogenesis, as previously observed in 
organoids derived from MDS patients (Iefremova et al. 2017). Co-staining for p-VIM 
(phosphorylated by CDK 1 during mitosis and located in the nucleus marking all nuclei in the 
mitotic phase) and TPX 2 (microtubule associated protein that can visualize the mitotic spindle) 
were performed to analyze aRG cell division (Figure 23 C). When quantifying at least 3 
organoid batches, with at least 3 organoids per batch and at least 6-8 VZ structures per 
organoids, I found a non-random aRG cell switch only in organoids derived from severe 
disease. Whereas mild and moderate patient organoids exhibited predominantly random 
arranged mitotic spindles leading to an increase in oblique division planes (Figure 23 D) most 
likely related to LIS1 and its important role in mitotic spindle orientation (Pawlisz et al. 2008; 
N. E. Faulkner et al. 2000; Tsai J, Chen Y, Kriegstein A 2005; Yingling et al. 2008). 
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Figure 23: Organoids derived from LIS1-patients display niche-dependent WNT-signaling disruption 
leading to altered aRG cell division specific for the disease condition. (A) Representative WNT-GFP 
recordings of WNT-GFP reporter control C3.1, P1.1 mild- and P5.1 severe LIS1-patient derived organoids at day 
20. (B) Quantification of mean grey value of WNT-GFP signal in VZ structures (control C3.1 N=10, control C4.1 
N=10, mild P1.1 N=10, mild P2.2 N=10, moderate P3.2 N=10, severe P5.1 N=10). (C) Representative recordings 
of vertical-, horizontal and oblique division planes by marking dividing cells with p-VIMENTIN (p-VIMENTIN) 
and the mitotic spindle by TPX 2 in control- (C4.1) and severe LIS1-patient (P1.1) patient-derived organoids. (D) 
Quantification of orientation of plane of cell division in control and mild LIS1-patient, moderate LIS1-patient and 
LIS1- severe patient-derived organoids. (control C1.1 N=20, control C2.2 N=20, control C4.2 N=14, mild P1.1 
N=15, mild P1.2 N=15, mild P2.1 N=15, mild P2.2 N=11, moderate P1.1 N=11, moderate P1.2 N=9, moderate 
P2.1 N=10, moderate P2.2 N=13, severe P1.1 N=17, severe P1.2 N=14, severe P2.1 N=9, severe P2.2 N=10, severe 
P3.1 N=11). Scale bars (A) 50 µm, (B) 10 µm, (C) 20 µm. Error bars, ±SD. *p < 0.05, **p < 0.01, ***p < 0.001.   
4.8. GSK3ß inhibition rescues apical radial glia cell division in LIS1-patients with 
severe disease leading to improved ventricular zone structure dimensions 
To test to which extend perturbed niche-dependent WNT-signaling contributes to the observed 
non-random aRG cell division switch and to the observed phenotypic alterations, control and 
patient derived organoids were exposed to the GSK3ß inhibitor CHIR99021 (CHIR). CHIR is 
an aminopyrimidine derivative, which promotes self-renewal of stem cells by promoting 
symmetric cell divisions by inhibiting GSK-3ß activity and potentiating the upregulation of ß-
catenin. In addition, CHIR promotes self-renewal by modulating TGF-ß and upregulating the 
expression of CYCLIN A. The exposer to CHIR led to a significant rescue of non-random aRG 
cell division back to proliferative horizontal aRG cell division in severe disease conditions 
(Figure 24). While the impact of CHIR on control, mild and moderate LIS1-patient aRG cell 
divisions was insignificant, supporting the assumption of a greater impairment of canonical 
WNT-signaling in severe conditions. 
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Figure 24: WNT activation changes aRG cell division pattern in iPS cell derived organoids from severe 
disease. Quantification of vertical, horizontal and oblique division planes of dividing aRG cells in control C3.1 
(N=9), mild P1.1 (N=9), moderate P1.2 (N=9) and severe P1.1 (N=9) patient derived organoids in the absence 
(DMSO) and presence of GSK 3ß inhibitor CHIR at day 15. 
The rescue of proliferative aRG cell division led to much more clear and homogeneous 
generation of VZ-structures compared to the DMSO control (Figure 25 A) with an increase of 
VZ structure dimensions in all LIS1-patient organoids (Figure 25 B), most likely due to the 
proliferation enhancing effect of CHIR on aRG cells (C. Li et al. 2013; Pachenari, Kiani, and 
Javan 2017).  In addition, organoids from severe patients exposed to CHIR also exhibited a 
clearly reduced neuronal belt surrounding the VZ structures (Figure 25 A, indicated by errors).  
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Figure 25: CHIR treatment-related rescue of aRG cell division orientation improves organoid ventricular 
zone structure dimensions. (A, B) Representative DAPI recordings of control C3.1, mild P1.1, moderate P4.2 
and severe P6.1 LIS1-patient derived organoids treated with DMSO or 1 µM CHIR. (C-H) Loop parameter 
quantification of CHIR and DMSO control treated organoids (control C3.1 DMSO N=16, control C3.1 CHIR 
N=21, control C4.1 DMSO N=10,control C4.1 CHIR N=18, mild P1.1 DMSO N=16, mild P1.1 CHIR N=24, mild  
2.2 DMSO N=12, mild P2.2 CHIR N=11, moderate P3.2 DMSO N=14, moderate P3.2 CHIR N=12, severe P5.1 
DMSO N=14, severe P5.1 CHIR N=11, severe P5.2 DMSO N=16,severe P5.2 CHIR N=11, severe  2.1 DMSO 
N=10, severe P6.1 CHIR N=10, severe P7.1 DMSO N=11, severe P7.1 CHIR N=11. Scale bars 200 µm. Error 
bars, ±SD. *p < 0.05, **p < 0.01, ***p < 0.001. 
The aRG cell pool enlargement by CHIR did not lead to an improvement of AC-TUB strand 
spanning to basal VZ regions (Data not shown), distinctly separating phenotypic alterations 
directly caused by the disruption of LIS1 microtubule stabilizing function and those alterations, 
which are indirectly caused by the collapse of cellular organization. The hypothesis is that the 
different patient-specific mutations in the LIS1 gene have divergent direct impact on 
microtubule stability, which directly and/or indirectly (WNT-signaling impairments) lead to 
perturbed human corticogenesis providing the missing link between the patient-specific LIS1 
mutation and the clinical severity grade. 
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5. Discussion 
The application of the generated LIS1-lissencephaly iPS cell cohort to the established 
reproducible forebrain-type organoid protocol (Krefft et al. 2018; Iefremova et al. 2017) and 
the utilization of the founded quantitative organoid assessment protocols revealed the capability 
of our organoid system to sensitively reflect different disease severities, a so far not addressed 
major challenge of the system. In this context, organoids reproduced in correlation with the 
patient’s severity, alterations in organoid cytoarchitecture and premature neurogenesis. 
Moreover, I showed that the patient-specific mutations have divergent direct impact on LIS1 
microtubule stabilizing function, which in turn directly or indirectly leads to perturbed human 
corticogenesis providing the missing link between the patient-specific LIS1 mutation and the 
clinical severity grade. The breakdown of cytoarchitectural stability led directly to a progressive 
cellular disorganization with increasing patient severity, which could in part be rescued by 
microtubule array stabilization by EpothiloneD. In addition, also indirectly caused niche-
depended WNT-signaling alterations played into pathology, most prominent in severe 
conditions leading to a non-random aRG cell division switch from proliferative to neurogenic 
cell division. This premature neurogenic division switch explains the observed large belt of 
neurons around the severe organoids, which was less abundant in milder conditions and mostly 
absent in controls. Organoid exposer to GSK3ß inhibitor CHIR99021 led to a significant rescue 
of non-random aRG cell division in severe organoids and to enlarged VZ diameters as well as 
reduced neurogenesis in all patient derived organoids.  
In the following I will discuss how the iPS cell technology opened the doors for in vitro disease 
modeling. The invention of cell reprogramming was a giant milestone for in vitro research.  The 
generation of a large LIS1-patient iPS cell cohort reflecting the lissencephalic severity spectrum 
formed the base for my study and enabled human 3D disease modeling. In the next section, I 
will discuss in how far my study complemented to the current understanding of LIS1-
lissencephly from in vivo functional mouse models and human in vitro cell culture models. 
Furthermore, I will discuss potential underlying pathologies for the diverse lissencephalic 
disease severities and point out to what extend this study contributed to the understanding of 
disease heterogeneity. In the last sections, I want to reflect whether future application of 
sensitive patient-specific organoid models can help to identify personalized therapy approaches 
and also discuss future considerations to improve organoid technology in terms of maturity, 
complexity as well as functional microenvironments. 
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5.1. The iPS cell technology – a tremendous milestone for stem cell research 
Stem cells have the unique hallmark property of pluripotency facilitating them to self-renewal 
and differentiate into any body cell (Weissman 2000). In 2007, a tremendous milestone within 
the field of stem cell research was reached by Takashi and Yamanaka by discovering the 
reprogramming potential of already differentiated somatic mouse cells by transferring 4 
transcription factors (OCT3/4, SOX 2, c-MYC and KLF 4) (Takahashi K, Okita K, Nakagawa 
M 2007). The translation to human cells in 2008 opened completely new perspectives for 
regenerative medicine and personalized disease modeling (Takahashi et al. 2007; Yu et al. 
2007). The high degree of similarity of iPS and ES cells, significantly diminished the need of 
ethic-controversial ES cells (Takahashi K, Okita K, Nakagawa M 2007). Moreover, with the 
advent of defined protocols for the guided differentiation of iPS cells into specific somatic cell 
types, it became more and more possible to study cell type specific disease progressions. 
Studies like the one from Rudolf Jaenisch`s labs (Hanna et al. 2007), where sickle cell anemia 
mice were rescued by treatment with hematopoietic progenitors obtained in vitro from 
autologous iPS cells demonstrate the potential of iPS technology for regenerative medicine 
approaches. Another example is the progress due to iPS cell approaches to treat Parkinson’s 
disease (Kriks et al. 2012), platelet deficiency (Tsujia et al. 2010) as well as macular 
degeneration (Okamoto and Takahashi 2011). Due to the advent of iPS cells, we now can 
generate patient-specific cells and generated diverse target organ-like tissues giving us the 
potential to unravel human-specific disease mechanisms as well as to identify potential new 
drug candidates. In the context of my study, the opportunity to model patient-specific disease 
progression helped to understand individual pathology leading to different disease severities 
and by that provided the missing link between clinical severity and disease severity.  
5.2. Unraveling LIS1-lissencephaly - in vivo functional mouse models and in vitro 
human stem cell models 
Lissencephaly is most caused by mutation in the LIS1 gene, which was correspondingly the 
first gene identified to trigger the disorder. With 1,2 cases per 100.000 birth it can be 
categorized as rare disease. Nonetheless, it is the best studied MCD. Before the emergence of 
the iPS technology and 3D organoid cell cultures many studies analyzing LIS1-lissencephaly 
were utilizing murine systems. The basic sequence of events during corticogenesis are 
commonly shared across species making mouse models a well-suited system to unravel 
neurodevelopmental disorders. In general, mice can be easily genetically manipulated, making 
them a powerful tool for examining genetic mechanisms. Consequently, several mouse models 
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of lissencephaly were created based on LIS1 protein dosage variations leading to the 
identification of many molecular functions of the LIS1 protein. Even though the observed 
LIS1-deficiency associated phenotypes appeared milder in murine systems compared to 
humans most likely due to the low proportion of bRG cells and the related lissencephalic nature 
of the mouse brain, these murine studies suggest that LIS1 gene dosage is relevant for the 
phenotypic severities (Y. H. Youn et al. 2009; Gambello, Darling, Yingling, Tanaka, 
Gleeson, and Wynshaw-Boris 2003). Nonetheless, even so the basic sequence of events during 
corticogenesis is commonly shared across species, there are existing species differences 
including developmental timing distinctions of events as well as cell populational variances, 
which make the translation to human brains challenging. Moreover, why a specific mutation 
within the LIS1 gene as identified in LIS1-lissencephalic patients leads to different disease 
severities and whether human-specific processes during cortical development are 
differentially affected by the specific mutations could not be investigated. Consequently, 
animal models alone cannot be sufficient to fully understand disease mechanisms and patient-
specific disease causing mutations explaining the hysteria when early human brain 
developmental aspects could be analyzed for the first time in vitro (M. Lancaster et al. 2013; 
Kadoshima et al. 2013). The advent of 3D human cell culture models revolutionized the study 
of human organ development and disease, it became possible to study human brain 
development in vitro. The development of defined protocols to differentiate iPS cells made it 
possible to study all human cell types outside the body without harming the living individuum. 
Within this project I, together with my colleagues, developed a reproductible 3D differentiation 
protocol leading to highly homogenous forebrain-type brain organoids (Krefft et al. 2018; 
Iefremova et al. 2017). To implant this protocol for the analysis of patient-specific LIS1-
lissencephaly causing mutations I established a LIS1-lissencephalic iPS cell patient cohort by 
Sendai virus-based reprogramming of fibroblasts and lymphocytes comprising 2 mild, 2 
moderate and 3 severe LIS1-patients reflecting the complete lissencephalic severity spectrum. 
By that I was able to study lissencephalic patient-specific genic backgrounds of living 
individuals in a dish and approach the question why a specific mutation within the LIS1 gene 
as identified in LIS1-lissencephalic patients leads to different disease severities and whether 
human-specific processes during cortical development are differentially affected by the 
specific mutations. When comparing the generated forebrain-type cerebral organoids from 
LIS1-patients and 6 age and gender match control iPS cell lines, it became clear that organoids 
from controls and patients with mild disease gradually develop smooth neuroepithelial loop-
like structures which expand over time, whereas organoids from patients with moderate and 
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severe disease appeared to be generally smaller in size. This observation of size reduction was 
also made by other studies utilizing 3D brain organoids and modeling the most severe form of 
lissencephaly, MDS, which is caused by a heterozygous deletion of chromosome 17p13.3 
involving LIS1 and YWHAE (coding for 14.3.3 epsilon, a LIS1 interaction partner). Bershteyn 
and colleagues (Bershteyn et al. 2016) and a former study of my colleagues and me (Iefremova 
et al. 2017) showed, that organoids derived from MDS patients are drastically smaller in size 
compared to controls. Interestingly, my organoids from severe LIS1-lissencephaly patients did 
show a drastic VZ size reduction, but not an overall organoid size decrease. Instead, these 
organoids were covered by a large belt of neurons, which was drastically less abundant in mild 
and moderate conditions and nearly absent in control derived organoids. Premature 
neurogenesis and defective neuronal migration have been described in many different studies 
analyzing lissencephaly in mouse and human model systems in the past. In mice did the 
reduction of LIS1 dosage lead to migration defects causing dosage-depended cellular 
disorganization of cortical layers, hippocampus, cerebellum and olfactory bulb (Hirotsune et 
al. 1998; Gambello, Darling, Yingling, Tanaka, Gleeson, and Wynshaw-boris 2003; Tanaka et 
al. 2004). Furthermore, was the necessity of LIS1 for correct neuronal migration also shown by 
direct examination of neuronal migration in mouse embryonic brain slice cultures, which were 
in utero transfected with green fluorescent protein to label migrating neurons (Shu et al. 2004). 
Using RNAi knockdown of LIS1 also undoubtfully demonstrated that LIS1 is required of 
neuronal migration and that LIS1 deficiency leads to neuronal migration defects associated with 
lissencephaly (Shu et al. 2004; Tsai J, Chen Y, Kriegstein A 2005; Y. H. Youn et al. 2009). 
With the development of the iPS cell technology the neuronal migration problem could also be 
shown in human cells. During 2D neural differentiation iPS cells undergo morphogenic changes 
characterized by the formation of so-called neural rosettes, which reflect every early neural 
tube-like formation by radially organized epithelial cells with apical-basal polarity (Elkabetz et 
al. 2008; S. Zhang et al. 2001). Bamba et al. (Bamba et al. 2016) utilized 2D neuronal cultures 
and demonstrated that lissencephaly patient derived neurons display abnormal neurite 
extensions, impaired migration and deficient neurite formation. Nonetheless, 2D systems have 
the disadvantage in contrast to 3D systems, that the capacity of cells to differentiate and self-
organize into epithelia reminiscing of the embryo is not given. Nonetheless, due to this variety 
of studies revealing migration defects, LIS1-lissencephaly was long time considered to be an 
isolated neuronal migration disorder. However, extended mouse studies showed that the 
underlying disease triggers are characterized by a broader spectrum of disease-causing 
pathology also including progenitor abnormalities like mitotic spindle formation as well as 
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perturbed radial glial cell proliferation (Tsai J, Chen Y, Kriegstein A 2005; Tanaka et al. 2004; 
N. E. Faulkner et al. 2000; Yingling et al. 2008). To assess the direct consequences of the 
patient-specific LIS1 mutations on LIS1 microtubule stabilizing function I applied my 3D 
organoid models to my LIS1-patient cohort and investigated the stability of the cytoskeleton of 
aRG cells within the 3D VZ cortical loop-like structures by AC-TUB staining. To avoid cutting 
artifacts, I analyzed cleared and sliced organoids and found an overall reduction of AC-TUB 
positive labeled tubulin strands with increased disease severity. The more drastic the disease 
severity was, the more extreme was the cytoskeleton malformed. In addition, in correlation with 
the degree of astral tubulin disruption, I also observed a cellular disorganization. Especially the 
organoids derived from moderate and severe disease displayed random arranged cell bodies 
with gaps in between cells, whereas in control conditions aRG cells arranged well organized, 
stringed and densely packed within the VZ. Together with this cellular disorganization I 
identified a disturbed apical membrane alignment. Similar observations of cellular 
disorganization Bershteyn et al. (Bershteyn et al. 2016) and our laboratory (Iefremova et al. 
2017) observed in organoids derived from MDS patients.  Furthermore, my colleagues and me 
found that the apical membrane disruption leads to non-cell-autonomous WNT-signaling 
disruption leading to a premature, non-random switch from vertical to horizontal cleavage 
planes of aRG cells, which leads to premature neurogenesis (Iefremova et al. 2017). These 
findings support the proposed model by Yingling et al. (Yingling et al. 2008) of spindle 
disorientation due to LIS1 deficiency in RG cells. As underling mechanisms, they found a 
perturbed DYNEIN localization due to LIS1 deficiency. Comparable to our study, additionally 
supporting Yingling et al. (Yingling et al. 2008) proposal, Bershteyn et al. (Bershteyn et al. 
2016) also described an increase in horizontal cell division associated with a premature shift to 
neurogenesis in MDS derived cerebral organoids. Interestingly, when investigating aRG cell 
division modes in my LIS1-patient derived organoids, I found a clear increase in horizontal 
division patterns only in cultures derived from severe patients compared to controls, explaining 
the large neuronal belt around organoids from severe disease. Whereas mild and moderate 
patient organoids exhibited predominantly random arranged mitotic spindles leading to an 
increase in oblique division planes most likely related to LIS1 and its important role in mitotic 
spindle orientation (Pawlisz et al. 2008; N. E. Faulkner et al. 2000; Tsai J, Chen Y, Kriegstein 
A 2005; Yingling et al. 2008).  In this context, further investigations analyzing DYNEIN 
dynamics in the LIS1- patient derived organoids need to be done. To test to what extend 
perturbed niche-dependent WNT-signaling contributes to the observed phenotypic changes in 
LIS1-patient derived organoids I exposed control and patient derived organoids to the GSK3ß 
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inhibitor CHIR99021, which led to much more clear and homogeneous generation of VZ-
structures compared to the DMSO control with a significant increase in VZ diameter in 
organoids derived from moderate and severe patients. In addition, organoids from severe 
patients exposed to CHIR also exhibit a clearly reduced neuronal belt surrounding the VZ 
structures and a significant rescue of the perturbed division mode. Concluded, it can be assumed 
that LIS1-disfunction leads directly to cytoskeleton breakdown, which in turn promotes cellular 
disorganization associated with apical membrane disruption leading to niche disintegration, 
which in turn might cause indirectly WNT-signaling alterations. This interplay of LIS1-
function-associated direct and indirect pathologies might explain why CHIR only partially 
rescues observed phenotypes. In addition to add is, that the utilization of MDS-organoids also 
revealed a mitotic delay of the human-specific bRG cells at later stages (Bershteyn et al. 2016). 
This human-specific cell type disease phenotype could be shown for the first time, due to the 
application of human model systems adding to the already unraveled knowledge about LIS1-
lissencephaly in murine systems. In my LIS1-patient derived organoids I observed a specific 
increase in the abundance of cells positive for human-specific bRG marker genes at day 58+/-
2 of organoid differentiation, which was most prominent in organoids derived from patients 
with moderate and severe disease. In addition, I also identified a decrease of cells positive for 
deep cortical layer marker and an increase of upper cortical layer marker with increase patient 
severity. Together, these data suggest a premature development of bRG cells accompanied by 
an accelerated generation of upper cortical layer neurons with increased LIS1-patient severity 
leading to the hypothesis that LIS1 might be involved in the development of human-specific 
bRG cell development. One more study is to mention in terms of analyzing human-specific 
disease parameters of LIS1-lissendephaly facilitating human in vitro 3D organoids. Orly and 
her laboratory (Karzbrun et al. 2018) were able to evaluate human explicit gyrification-like 
processes unraveling that decreased brain folding observed in LIS1-patients might partially 
result from differences in the physical properties of progenitor cells. To do so, they generated 
LIS1 mutant iPS cell lines and defined physical forces that regulate cortical fording. LIS1 
mutant organoids display reduced folding properties and a longer distance between folds when 
compared to wildtype organoid wrinkles. Moreover, they identified a reduction in the speed of 
nuclear migration from the outer to the inner fold surface, which could be endorsed to the 
cytoplasmic DYNEIN function. In addition, they found that the LIS1 mutant nuclei do not 
expand that drastically in the outer fold regions as wildtype nuclei do, resulting in a reduced 
differential expansion, coherent with the decreased wrinkles. Atomic force microscopy 
suggested that the LIS1 mutant cells display reduced elasticity. This study also shows the 
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capability of human in vitro systems to complement to the existing knowledge gained by animal 
models. Moreover, my work clearly demonstrate that organoids are applicable for the analyzes 
of different disease severities also including mild conditions, a so far not addressed challenge 
of the system. Former studies modeled most severe lissencephalic conditions (Iefremova et al. 
2017; Bershteyn et al. 2016). Furthermore, this study could, for the first time show that 
lissencephalic conditions can be in part rescued by microtubule-array stabilization, thereby 
identifying a potential drug to counteract disease progression (see 5.4).  
In summary, human brain organoid studies reproduced findings observed in murine systems 
and in addition strongly suggest, that the pathophysiology of lissencephaly is more complex 
than previously thought. It might be assumed that the smooth mouse brain without the high 
number of proliferative bRG cells misses human-specific features to reflect full disease 
severity. Nonetheless, transgenic mice serve as powerful tool to unravel disease mechanisms 
caused by the dysfunction of single genes. However, to analyze specific mutation within the 
LIS1 gene as identified in LIS1-lissencephalic patients human in vitro model systems are 
needed. Cerebral organoids opened up the possibility to study human organ developmental 
aspects outside the human body, which holds massive potential for the understanding of human-
specific disease pathology. This project aimed to shed light on the question why specific 
mutations within the LIS1 gene as identified in LIS1-lissencephalic patients leads to 
different disease severities and whether human-specific processes during cortical 
development are differentially affected by the specific mutations. 
5.3. Elucidating underlying pathology of the diverse LIS1-severities – LIS1 function, 
genetics, environmental factors and by-chance effects 
In the previous sections I specified and discussed how this project could complement to the 
current understanding of LIS1-lissencephaly by putting the findings in the context of former 
studies utilizing mouse and human model systems. This chapter focuses on how far this project 
could complement to the understanding of the underlying pathology of the different LIS1-
severities. Multiple publications describe that there is no correlation between mutation and 
severity. Neither the mutation type nor the location of the mutation were found to predict the 
severity grade of LIS1-lissencephaly (Saillour et al. 2009; Uyanik et al. 2007; Philbert et al. 
2017; Pilz et al. 1998). There are known cases, were the same mutation leads to different disease 
severities (oral communication, Nadja Bahi-Buisson). That raises the question in how far the 
genetic plays into pathology. Are environmental factors or any by-chance effects involved or 
is it mainly the degree of LIS1-function disruption which determines severity? My data clearly 
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points out a direct relationship between LIS1-lissencephalic severity and LIS1-function-
associated cellular disruption. The more severe the disease the more drastic the LIS1-associated 
phenotypes like cytoskeleton breakdown, cellular disorganization, and apical membrane 
disruption in LIS1-patient derived organoids. Also, the WNT signaling impairment seems to be 
indirectly correlated with LIS1-function-associated apical membrane disruption caused by 
cellular disorganization triggered by cytoskeleton breakdown. The fact, that the severity can be 
mirrored with brain organoids excludes environmental factors playing into disease diversity as 
those are not present in my organoid models. Here, I only had access to 2 patients harboring 
the same mutation and suffering from the same disease severity. It would be interesting to 
generate organoids from patient cells with the same mutation and different disease severities to 
shed even more light on disease heterogeneity. Initially, one publication suggested a putative 
correlation with the mild lissencephaly associated missense mutations and truncating mutations 
localized at the 3’ end of the LIS1 gene (Cardoso et al. 2000). Although more recent studies did 
not confirm this relationship (Uyanik et al. 2007; Saillour et al. 2009). Saillour et al. (Saillour 
et al. 2009) analyzed a large LIS1-patient cohort including 40 patients carrying LIS1 mutations 
(75%) or small deletions (20%). They tried unsuccessfully to correlate the severity of the 
disease in terms of epileptic seizures, radiological findings, and body movement impairments 
with the LIS1 mutations. Moreover, Uyanik et al. (Uyanik et al. 2007) revealed 21 intragenic 
mutations distributed over the entire LIS1 gene. Except 2 mutations in the LIS1 homology 
domain and 2 in the region encoding the coiled-coil domain all were found in one of the seven 
WD40 repeat domains. Similar, also the mutations of the patients included in my study are 
localized within this WD40 repeat regions. But neither the type nor the position of the mutation 
correlated with a particular phenotype. Rather, they found that the clinical severity correlates 
only with the degree of agyria and cortical thickening, which supports the statement of 
Barkovich and colleagues already in 1991 (Barkovich, Koch, and Carrol 1991). In addition, 
also my study supports this observation. The more severe the brain folding’s alterations of the 
LIS1-patients, the more severe the clinical severity was of the here included patients. In 
addition, my study shows a strong correlation between clinical severity with the LIS1-function 
associated phenotypic alterations found in my LIS1-lissencepahly organoid models. My data 
hints towards the hypothesis that the degree of impairment of LIS1 function directly or 
indirectly (WNT-signaling) determines disease severity. The next logical question in line would 
be what determines the degree of impairment of LIS1 function? In line with the studies 
discussed above (Uyanik et al. 2007; Saillour et al. 2009) I also did not see a correlation to the 
mutations. The patients characterized by mild disease, grade 4-5, carry the same recurrent 
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mutation affecting a splice site (c.569-10T>C; LIS1-mild P1 und P2) leading to exon 7 skipping 
with an induced frameshift. The patients with moderate disease display either a small deletion 
(c.11delC, LIS1-moderate P3) leading to frameshift or a deletion of exon 11. The mutations 
leading to severe phenotypes, grade 1-2, have either a mutation leading to skipping of exon 9 
which is in-frame (c.1002+1G>T, LIS1-severe P5), or missense mutations (c.531G>C, LIS1-
severe P6; c.445C>T, LIS1-severe P7 ;). Concluded, the less severe mutation lead to severe 
disease, whereas the milder mutation lead to mild disease progressions. Our collaboration 
partners analyzed the impact of 4 specific mutations on LIS1 protein synthesis (Philbert et al. 
2017). They examined LIS1 mRNA levels of fibroblasts from mild LIS1-patient P1 and P2 
(c.569-10T>C) as well as from severe LIS1-patient P5 (c.1002+1G>T) and P7 (c.445C>T). 
Quantitative real-time qPCR showed that WT transcript levels from those 4 patients (mild and 
severe) are reduced by approximately half compared to controls due to the heterozygous 
mutation. But only the mutant transcripts levels from patients with mild disease (P1 and P2) 
carrying a frameshift are degraded by NMD, as shown by inhibition of NMD by Emetine. In 
contrast, mutant transcripts of patients with severe disease (P5 and P7), with in-frame missense 
mutation, are not degraded. Inhibition of the proteasome led to LIS1 clusters only in cells from 
patients P5 and P7 with severe disease severe. Cells from patients P1 and P2 did not show this 
phenomenon supporting the assumption that only cells from severe patients contain misfolded 
protein variants. Due to co-labeling of LIS1 and G3BP1, an SG marker, and fibroblast treatment 
with sodium arsenate, a cellular stressor, they found that LIS1 clusters are observed only after 
MG132 treatment, suggesting LIS1 mutant proteins are misfolded and then degraded by 
proteasome. These findings suggest that the wildtype transcript reduction by 50 % together with 
the 50 % of misfolded proteins are more harmful to the cell physiology than only the 50 % 
wildtype transcripts as found in cells from patients with mild disease, which might be associated 
with SG formation. The degradation by the proteasome seems to lead to more severe clinical 
symptoms, although by-chance effects are not ruled out. It would be interesting to further 
analyze SG formation in human 3D cortical organoids. One hypothesis could be, that the 
misfolded LIS1 proteins, which according to Philbert et al. (Philbert et al. 2017, Camille 
Maillard unpublished data) only appear in cells from patients with severe disease might 
negatively influence the complex interaction network of LIS1, explaining the direct correlation 
of disease severity and LIS1-disfunction-associated cellular disruption as observed in my LIS1-
organoid models.  
My data could show that different patient-specific mutations in the LIS1 gene have divergent 
direct impact on microtubule stability, which directly and/or indirectly lead to perturb human 
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corticogenesis providing the missing link between the patient-specific LIS1 mutation and the 
clinical severity grade. The application of this sensitive model allows the analyzes of disease 
severity specific pathomechanisms. In the next section it is discussed in how far the application 
of those sensitive in vitro models can elevate personalized medicine and may lead to a better 
understanding of individual disease progression for effective therapy. 
5.4. Patient derived organoids – unraveling individual disease progressions for the 
identification of personalized drug treatments 
This chapter discusses whether patient-specific organoid approaches can lead to an 
understanding of patient-specific disease progression as well as to the identification of 
personalized drug interventions.  Even though 3D organoid cultures are young scientific tools, 
they already have been used to identify possible drug targets (Nowakowski, et al. 2017) and 
therapeutic application against ZIKA virus infection (Li et al., 2017). Nonetheless, there are no 
published studies, which test the sensitivity of 3D systems to recapitulate different disease 
severities and understand individual’s disease progressions. My pioneer work raises hope that 
organoids can really unravel patient-specific disease progression and support personalized 
medicine approaches. The observed phenotypic differences correlated with patient disease 
severity. Moreover, the patient-specific disease severity modeling led to the identification of 
dissimilar degree of impact of specific pathways involved. In the mild and moderate LIS1-
patient derived organoids aRG cells displayed dominantly a non-planar random disorientation 
of mitotic spindle, which might be explained by LIS1-deficiency associated with DYNEIN 
delocalization (Yingling et al. 2008). Whereas, in the severe LIS1-patient organoids a planar 
switch from vertical to horizontal aRG cell division was most prominent, which might be 
associated with N-CAD disruption and disturbance of ß-CAT/WNT-signaling (Iefremova et al. 
2017). Adherents junctions have been associated with self-renewal control of aRG cells 
(Marthiens et al. 2010; Stocker and Chenn 2009). Moreover, data from mouse studies indicate 
that WNT/ß-CAT signaling is crucial for aRG cell proliferation (Chenn and Walsh 2008; 
Zechner et al. 2003) and that N-CAD is involved in WNT activity by controlling AKT 
phosphorylation, which in turn leads to phosphorylation and stabilization of ß-CAT (J. Zhang 
et al. 2010, 2013). Consequently, the protein level of important signaling proteins within the 
WNT-signaling cascade as well as their phosphorylated forms were analyzed in the different 
LIS1-patient lines (Data not shown). Despite a potential reduction of LRP 5/6 receptor in the 
severe LIS1-patient derived cells were no specific abnormalities detected. Nonetheless, based 
on the observed N-CAD/ WNT-signaling disruption the GSK 3b inhibitor CHIR was tested to 
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counteract observed phenotypes and indeed, the treatment rescued aRG vertical cell division 
planes in LIS1-patient derived organoids and consequently significantly decreased premature 
neurogenesis and increased cortical-like ventricular structure size. These findings go in line 
with former studies (Iefremova et al. 2017; Zechner et al. 2003; J. Zhang et al. 2013). The 
rescue effect specific for severe conditions confirmed the greater impact of LIS1-assocaited 
spindle disorientation rather than WNT-signaling disruption in the milder conditions. To 
counteract those LIS1-associated microtubule-destabilization triggered phenotypes, a second 
drug screen was performed testing the microtubule-stabilizing drug EpothiloneD, which is a 
macrolide compound binding to a common binding site on ß-tubulin (Giannakakou et al. 2000). 
Based on the applied concentration EpothiloneD can stabilize microtubes (low dosages) or 
block cell division by completely preventing microtubule depolymerization (high dosage) 
(Bollag et al. 1995). Applying higher dosages, EpothiloneD has been successful tested for 
hindering malign cell division and is currently subjected to clinical trials. For detailed 
information of EpothiloneD in cancer treatment see Fumoleau et al. (Fumoleau et al. 2007). In 
very low concentrations EpothiloneD has been applied to studies focusing on tauopathy-
associated disorders utilizing mouse models (B. Zhang et al. 2012; Cartelli et al. 2013; Penazzi 
et al. 2016). EpothiloneD treatment in aged tau transgenic mice with Alzheimer-like tau 
pathology and related behavioral deficits reduced axonal dystrophy and increased axonal 
microtubule density, which led to improved fast axonal transport and cognitive performance 
(B. Zhang et al. 2012). Also, Cartelli et al. (Cartelli et al. 2013) described the neuroprotective 
effect of EpothiloneD on mice mimicking experimental parkinsonism induced by 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine (MPTP). Consequently, low-dosage EpothiloneD treatment 
was also tested on the LIS1-patient derived organoids. The experiments confirmed the 
microtubule-stabilizing properties of EpothiloneD displaying significant improvement in 
cytoarchitectural stability by astral tubulin strands spanning in VZ basal regions. This rescue 
of VZ architectural stability led to improved cellular organization. In summary, the discovery 
of severity-specific pathologies as well as the identification of specific drugs differential 
rescuing phenotypic alterations in mild, moderate and severe LIS1-patient derived organoids 
underlines the capacity of iPS cell derived 3D model systems to understand individual disease 
progressions. Consequently, brain organoids are a very promising tool for personalized disease 
understanding as well as patient-specific therapeutically intervention approaches. Nonetheless, 
the field remains young and there is capacity for further enhancement before it reliably can 
serve as robust model for therapy and regenerative medicine. The following chapter discusses 
possible improvements, which could enhance in vivo similarity and reduce system limitations.  
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5.5. Brain organoids – future advances of complexity, maturity and functionality  
The here presented work displays that the organoid system serves as promising model to 
analyze human and severity-specific aspects of LIS1-associated MCD as well as related 
disorders and contributes to the identification of new therapeutic drugs. There are multiple 
studies verifying the capability of organoids to develop specific and discrete brain regions 
closely mimicking in vivo cell type compositions with gene expression profiles and epigenetic 
signatures reminiscing of human fetal corticogenesis (Kanton et al. 2019; Velasco et al. 2019; 
Quadrato et al. 2017; Camp et al. 2015). Nonetheless, they remain immature in nature only 
reflecting developmental processes of the first and second gestation semester. To make the 
organoid system mature, there are significant challenges and limitations to overcome especially 
in terms of complexity and maturity. It is undeniable that brain organoid systems have 
progressed substantially due to the development of diverse generation protocols closely 
mimicking in vivo development (M. a Lancaster et al. 2013; M. A. Lancaster et al. 2017; 
Kadoshima et al. 2013; Birey et al. 2017; X. Qian et al. 2016; Krefft et al. 2018). Depending 
on the differentiation protocol organoids differentiate spontaneously (without external 
morphogen supplementation) in an unpredictable fashion into brain regions of different identity 
(M. Lancaster et al. 2013) or with growth factor manipulation into regional specified 
homogenous brain tissue (Birey et al. 2017; Xuyu Qian et al. 2016; Kadoshima et al. 2013)(for 
review see Marsoner, Koch, and Ladewig 2018). Both differentiation approaches generate 
organoids, which face the limitation of missing tissue polarity without topographic organization 
illustrating that organoids are still a very reductionist model without body axes and morphogen 
signaling centers leading to the absence of morphogen gradients within the tissue. This 
limitation has been tackled by multiple studies with different approaches.  One approach is 
based on the guided differentiation of organoids into specific brain identities with subsequent 
fusion of those different regions (Bagley et al. 2017; Xiang et al. 2017). This approach does, 
however, not recapitulate the continuum of regional diversity found in the human brain (Krefft, 
Koch, Ladewig, in press by SDCB). Cederquist and colleagues (Cederquist et al. 2019) 
attempted to overcome the weakness of missing topographic organization by the 
implementation of morphogen-secreting cells, mimicking organizing centers, into the organoid 
tissue. Similar, also Orly Reiners laboratory (Karzbrun et al. 2018) tried to establish morphogen 
gradients by external selective morphogen exposure by microfluidic systems. All studies helped 
to direct organoid technologies into an advanced future, but still did not manage to develop 
topographic organized in vitro tissue. Another big limitation of organoids is the missing non-
neuroectodermal structures including blood vessel, meninges as well as cerebrospinal fluid. 
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Meninges have not only a brain protective role, but also establish unique microsystem for 
cellular waste disposal of the brain. In addition, they provide entry for blood vessel into the 
brain tissue. The in organoid present lumen do not contain physiological equivalent to blood 
(Wimmer et al. 2019) or cerebrospinal fluid (Kadoshima et al. 2013) limiting the nutritive 
supply of cells deep insight the tissue as well as the presence of signaling molecules for tissue 
polarity. Finally, to mention is the limitation of immune and glia cells. Studies coculturing 
organoids with microglia have started to approach this limitation (Ormel et al. 2018; Song et 
al. 2019) but further studies are needed to investigate the contribution of microglia in organoid 
tissue with respect to their role in developmental processes like synaptic pruning. Also, 
astrocytes and oligodendrocytes, which are important for synaptogenesis as well as 
myelination, are underrepresented in organoid cultures (Quadrato et al. 2017), probably due to 
the limited culture time of 3D organoids. Despite cell populational deficits, cytoarchitectural 
aspects of organoids also need to be critically reflected. The in human significantly enlarged 
and in inner and outer separated SVZ can be found in organoids, although in a limited extend 
(Watanabe et al. 2016). The same does account for the 6 cortical layers. Layer-related cell types 
can be detected in organoids, but only fragmentary without the distinct layer-specific 
orientation (Bhaduri et al. 2020). The folding of the outer cortical layers leads to the primate-
specific gyrification of the neocortex. Although organoids display wrinkles, it cannot be 
equated with gyri and sulci in human brains. The reported folding due to physical forces 
(Karzbrun et al. 2018) or genetic manipulation (Y. Li et al. 2019) mainly involves the inner 
germinal zone and not the outer layers of the cortex as it is true for gyrification (Lewitus, 
Kelava, and Huttner 2013). 
It remains elusive to what extent mature aspects of brain development can be achieved in 
organoid cultures. It is likely that there is a natural limitation of in vitro cultures to reproduce 
the incredible complexity of the human brain in a dish. Consequently, organoid data needs to 
be carefully evaluated with respect to the impact of the systems limitations. 
  
                                                       Unraveling the pathology of different disease severities  
 
 
 
133 
6. Conclusion 
The here presented work demonstrates the great potential of recent technology advances 
including iPS cell- as well as organoid tools to revolutionize stem cell research and medicine.  
Impressively, human organ development can be analyzed outside the human body with healthy 
and patient-specific disease backgrounds. These advents open completely new perceptive for 
personalized medicine. The here demonstrated research underlines the capability of cerebral 
organoids to sensitively model individual disease severities, a so far not addressed major 
challenge of the system. My data show that different patient-specific mutations in the LIS1 gene 
have divergent direct impact on microtubule stability, which directly and/or indirectly lead to 
perturbed human corticogenesis providing the missing link between the patient-specific LIS1 
mutation and the clinical severity grade. Future applications analyzing individual diseases have 
the potential to advance personalized medicine and improve the understanding of individual 
pathology for personalized therapy. Nonetheless, intensive research still needs to overcome 
hurdles focusing on organoid complexity, maturity as well as functional microenvironments to 
faithfully model in vivo development. By accomplishing following aims this thesis 
demonstrated for the first time that 3D organoids already serve as promising tool to reflect 
different disease severities and to elucidate individual disease pathology: 
1. A large LIS1-patient iPS cell cohort reflecting the complete severity spectrum of LIS1-
lissencephaly was generated and fully characterized. 
2. An in vitro system to reconstruct cortical stem cell niche and analyze corticogenesis in 
healthy and patient-specific disease backgrounds was established. 
3. The sensitivity of organoid systems to model patient-specific disease progressions was 
shown. 
4. LIS1-associated phenotypes reflecting the individual LIS1-patient’s severity were 
unraveled. 
5. Potential severity-specific disease mechanisms were found, which are directly or 
indirectly caused by the impairment of LIS1 microtubule stabilizing functions.  
6. 2 potential drugs were identified, which counteracted specific mechanisms involved in 
LIS1-lissencephaly pathology.   
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Appendix 1, Overview of iPS cell lines included in this study and validation steps 
Table 18: Overview and validation steps of iPS cell lines included in this study.  
 Pluripotency maker 
expression 
Karyotyping 
Tripotente 
differentiation 
Validation of 
LIS1 mutation 
Control 1.1 yes yes yes no 
Control 1.2 yes yes yes no 
Control 2.1 yes yes yes no 
Control 2.2 yes yes yes no 
Control 3.1 yes yes yes no 
Control 4.1 yes yes yes no 
Control 4.2 yes yes yes no 
Control 5.1 yes yes yes no 
Control 6.1 yes yes yes no 
mild 1.1 yes yes yes yes 
mild 1.2 yes yes yes yes 
mild 2.1 yes yes yes yes 
mild 2.2 yes yes yes yes 
moderate 1.1 yes yes yes yes 
moderate 1.2 yes yes yes yes 
moderate 2.1 yes yes yes yes 
moderate 2.2 yes yes yes yes 
severe 1.1 yes yes yes yes 
severe 1.2 yes yes yes yes 
severe 2.1 yes yes yes yes 
severe 2.2 yes yes yes yes 
severe 3.1 yes yes yes yes 
severe 3.2 yes yes yes yes 
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Appendix 2, Statistics 
Table 19: Post-Hoc group comparison of Kruskal-Wallis-Test of VZ diameter analyzes for control- and LIS1-
patient derived organoids at day 20.  
Sample 1-Sample 2 sig. adj. sig.a 
control mild ,000 ,000 
control moderate ,000 ,000 
control severe ,000 ,000 
a. Significance values have been adjusted by the Bonferroni correction for multiple tests 
Table 20: Post-Hoc group comparison of Kruskal-Wallis-Test of apical membrane length for analyzes for control- 
and LIS1-patient derived organoids at day 20.  
Sample 1-Sample 2 sig. adj. sig.a 
control mild ,066 ,393 
control moderate ,000 ,002 
control severe ,000 ,000 
a. Significance values have been adjusted by the Bonferroni correction for multiple tests 
Table 21: Post-Hoc group comparison of Kruskal-Wallis-Test of total VZ area analyzes for control- and LIS1-
patient derived organoids at day 20.  
Sample 1-Sample 2 sig. adj. sig.a 
control mild ,441 1,000 
control moderate ,000 ,001 
control severe ,000 ,000 
a. Significance values have been adjusted by the Bonferroni correction for multiple tests 
Table 22: Post-Hoc group comparison of Kruskal-Wallis-Test of ventricle-like area analyzes for control- and LIS1-
patient derived organoids at day 20. 
Sample 1-Sample 2 sig. adj. sig.a 
control mild ,066 ,393 
control moderate ,000 ,002 
control severe ,000 ,000 
a. Significance values have been adjusted by the Bonferroni correction for multiple tests 
Table 23: Post-Hoc group comparison of Kruskal-Wallis-Test of basal membrane length analyzes for control- and 
LIS1-patient derived organoids at day 20.  
Sample 1-Sample 2 sig. adj. sig.a 
control mild ,003 ,019 
control moderate ,000 ,000 
control severe ,000 ,000 
a. Significance values have been adjusted by the Bonferroni correction for multiple tests 
Table 24: Post-Hoc group comparison of Kruskal-Wallis-Test of VZ tissue area analyzes for control- and LIS1-
patient derived organoids at day 20.  
Sample 1-Sample 2 sig. adj. sig.a 
control mild ,671 1,000 
control moderate ,000 ,001 
control severe ,000 ,000 
a. Significance values have been adjusted by the Bonferroni correction for multiple tests 
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Table 25: Post-Hoc group comparison of Kruskal-Wallis-Test for AC-TUB strand density in basal regions 
quantification in control- and LIS1-patient derived organoids at day 20.  
Sample 1-Sample 2 sig. adj. sig.a 
control C 1.2-mild P1.1 ,413 1,000 
control C 1.2-mild P1.2 ,055 1,000 
control C 1.2-mild P2.1 ,057 1,000 
control C 1.2-mild P2.2 ,251 1,000 
control C 1.2-moderate P3.1 ,057 1,000 
control C 1.2-moderate P3.2 ,000 ,000 
control C 1.2-moderate P4.1 ,000 ,002 
control C 1.2-moderate P4.2 ,003 ,335 
control C 1.2-severe P5.1 ,000 ,001 
control C 1.2-severe P5.2 ,000 ,000 
control C 1.2-severe P6.2 ,000 ,000 
control C 1.2-severe P6.2 ,000 ,000 
control C 1.2-severe P7.1 ,000 ,000 
control C 1.2-severe P7.2 ,000 ,000 
control C 4.2-control C 1.2 ,407 1,000 
control C 4.2-mild P1.1 ,870 1,000 
control C 4.2-mild P1.2 ,340 1,000 
control C 4.2-mild P2.1 ,348 1,000 
control C 4.2-mild P2.2 ,822 1,000 
control C 4.2-moderate P3.1 ,362 1,000 
control C 4.2-moderate P3.2 ,000 ,030 
control C 4.2-moderate P4.1 ,001 ,144 
control C 4.2-moderate P4.2 ,047 1,000 
control C 4.2-severe P5.1 ,001 ,086 
control C 4.2-severe P5.2 ,000 ,000 
control C 4.2-severe P6.1 ,000 ,002 
control C 4.2-severe P6.2 ,000 ,011 
control C 4.2-severe P7.1 ,000 ,009 
control C 4.2-severe P7.2 ,000 ,010 
 
Table 26: Post-Hoc group comparison of Kruskal-Wallis-Test for N-CAD disruption diameter quantification for 
control- and LIS1-patient derived organoids at day 20.  
Sample 1-Sample 2 sig. adj. sig.a 
control C 2.1-mild P1.1 ,522 1,000 
control C 2.1-mild P2.1 ,087 1,000 
control C 2.1-mild P2.2 ,022 1,000 
control C 2.1-mild P1.2 ,002 ,296 
control C 2.1-moderate P3.1 ,035 1,000 
control C 2.1-moderate P4.1 ,000 ,005 
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control C 2.1-moderate P4.2 ,000 ,011 
control C 2.1-severe P5.1 ,000 ,004 
control C 2.1-severe P5.2 ,000 ,000 
control C 2.1-severe P6.1 ,000 ,000 
control C 2.1-severe P6.2 ,000 ,000 
control C 2.1-severe P7.1 ,000 ,000 
control C 4.2-mild P1.1 ,691 1,000 
control C 4.2-mild P1.2 ,011 1,000 
control C 4.2-mild P2.1 ,170 1,000 
control C 4.2-mild P2.2 ,057 1,000 
control C 4.2-moderate P3.1 ,084 1,000 
control C 4.2-moderate P3.2 ,000 ,029 
control C 4.2-moderate P4.1 ,000 ,053 
control C 4.2-moderate P4.2 ,001 ,106 
control C 4.2-severe P5.1 ,000 ,056 
control C 4.2-severe P5.2 ,000 ,000 
control C 4.2-severe P6.1 ,000 ,000 
control C 4.2-severe P6.2 ,000 ,001 
control C 4.2-severe P7.1 ,000 ,000 
a. Significance values have been adjusted by the Bonferroni correction for multiple tests. 
 
Table 27: Kruskal-Wallis-Test for independent samples without Gaussian distribution for AC-TUB strand         
density quantification in basal VZ regions for EpothiloneD vs. DMSO control treated control- and LIS1-patient 
derived organoids at day 15.  
 control 
C 4.1 
control 
C 3.1 
mild 
P1.1 
mild 
2.2 
moderate 
P3.2 
severe 
P5.1 
severe 
P6.1 
severe 
P7.1 
asymptotic sig. 
(2-sided test) 
,892 0,743 0,003 0,003 ,771 0,008 0,004 ,012 
a. the test statistic is adjusted for ties. 
Table 28: Kruskal-Wallis-Tests for independent samples without Gaussian distribution for N-CAD disruption 
diameter quantification of EpothiloneD and DMSO control treated control- and LIS1-patient-organoids at day 20.  
 control C 
4.1 
control C 
3.1 
mild 
P1.1 
mild 
P2.1 
moderate P3.2 severe P5.1 severe P7.1 
asymptotic sig. 
(2-sided test) 
0,518 0,287 ,037 0,623 0,336 0,109 0,055 
a. the test statistic is adjusted for ties. 
 
 
Table 29: Kruskal-Wallis-Test for independent samples without Gaussian distribution for VZ diameter 
quantification of CHIR and EpothiloneD treated control- and LIS1-patient derived organoids at day 15.  
Asymptotic sig. (2-sided test) sig. DMSO vs EpoD 
control C4.1 ,398 
control C3.1 ,735 
mild P1.1 ,149 
mild P2.2 ,061 
moderate P3.2 ,010 
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severe P5.1 ,005 
severe P6.1 ,001 
severe P7.1 ,013 
a. The test statistic is adjusted for ties.  
Table 30: Kruskal-Wallis-Test for independent samples without Gaussian distribution for WNT-GFP 
quantification of control- and LIS1-patient derived organoids at day 20.  
Asymptotic sig. (2-sided test) sig. to C3.1 
control C4.1 0,182 
mild P1.1 0,449 
mild P2.2 0,4889 
moderate P3.2 0,009 
severe P5.1 0,000 
a. The test statistic is adjusted for ties.  
Table 31: Post-Hoc group comparison of Kruskal-Wallis-Test of horizontal aRG cell division percentage of 
control- and LIS1-patient derived organoids at day 20.  
Sample 1-Sample 2 sig. adj. sig.a 
vertical 
control C 4.2-mild P1.1 ,136 1,000 
control C 4.2-mild P1.2 ,788 1,000 
control C 4.2-mild P2.1 ,283 1,000 
control C 4.2-mild P2.2 ,587 1,000 
control C 4.2-moderate P3.1 ,106 1,000 
control C 4.2-moderate P3.2 ,067 1,000 
control C 4.2-moderate P4.1 ,039 1,000 
control C 4.2-moderate P4.2 ,137 1,000 
control C 4.2-severe P5.1 ,000 ,006 
control C 4.2-severe P5.2 ,039 ,054 
control C 4.2-severe P6.1 ,002 ,150 
control C 4.2-severe P6.2 ,000 ,020 
control C 4.2-severe P7.1 ,000 ,007 
horizontal 
control C 4.2-mild P1.1 ,030 1,000 
control C 4.2-mild P1.2 ,573 1,000 
control C 4.2-mild P2.1 ,196 1,000 
control C 4.2-mild P2.2 ,141 1,000 
control C 4.2-moderate P3.1 ,001 ,067 
control C 4.2-moderate P3.2 ,002 ,197 
control C 4.2-moderate P4.1 ,001 ,088 
control C 4.2-moderate P4.2 ,001 ,023 
control C 4.2-severe P5.1 ,000 ,003 
control C 4.2-severe P5.2 ,001 ,047 
control C 4.2-severe P6.1 ,000 ,020 
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control C 4.2-severe P6.2 ,002 ,015 
control C 4.2-severe P7.1 ,000 ,007 
oblique 
control C 4.2-mild P1.1 ,042 1,000 
control C 4.2-mild P1.2 ,295 1,000 
control C 4.2-mild P2.1 ,687 1,000 
control C 4.2-mild P2.2 ,148 1,000 
control C 4.2-moderate P3.1 ,037 1,000 
control C 4.2-moderate P3.2 ,036 1,000 
control C 4.2-moderate P4.1 ,033 1,000 
control C 4.2-moderate P4.2 ,043 1,000 
control C 4.2-severe P5.1 ,259 1,000 
control C 4.2-severe P5.2 ,013 1,000 
control C 4.2-severe P6.1 ,072 1,000 
control C 4.2-severe P6.2 ,358 1,000 
control C 4.2-severe P7.1 ,031 1,000 
a. Significance values have been adjusted by the Bonferroni correction for multiple tests 
Table 32: Post-Hoc group comparison of Kruskal-Wallis-Test for plane of cell division quantification in CHIR 
and DMSO control treated control- and LIS1-patient derived organoids at day 15.  
DMSO-EpoD sig. adj. sig.a 
horizontal 
control C 3.1 ,687 1,000 
mild P1.1 ,639 1,000 
moderate P3.2 ,791 1,000 
severe P5.1 ,011 ,031 
vertical 
control C 3.1 ,958 1,000 
mild P1.1 ,892 1,000 
moderate P3.2 ,098 1,000 
severe P5.1 ,012 ,032 
a. Significance values have been adjusted by the Bonferroni correction for multiple tests 
Table 33: Post-Hoc group comparison of Kruskal-Wallis-Test for VZ diameter quantification of CHIR and 
EpothiloneD treated control- and LIS1-patient derived organoids at day 15.  
condition sig. DMSO vs. CHIR 
control C4.1 ,722 
control C3.1 1,000 
mild P1.1 ,185 
mild P2.2 ,061 
moderate 3.2 ,011 
severe P5.1 ,000 
severe P6.1 ,001 
severe P7.1 ,054 
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